










The handle http://hdl.handle.net/1887/29585 holds various files of this Leiden University 
dissertation. 
 
Author: Niesters, Marieke 
Title: Evolution of endogenous analgesia 
Issue Date: 2014-10-30 
Evolution of Endogenous Analgesia
Marieke Niesters

Evolution of Endogenous Analgesia
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus C.J.J.M. Stolker,
volgens besluit van het College voor Promoties




geboren te Wijk bij Duurstede
in 1984
Promotiecommissie
Promotor     Prof. dr. A. Dahan
Co-promotor     Dr. E.Y. Sarton
Overige leden     Prof. dr. L.P.H.J. Aarts
      Prof. dr. R. Baron (University of Kiel, Germany)
      Prof. dr. A.M. Drewes (University of Aalborg, Denmark)
      Prof. dr. M. van Kleef (MUMC, Maastricht, the Netherlands)
      Prof. dr. S.A.R.B. Rombouts
      Prof. dr. R.J. Stolker (EMC, Rotterdam, the Netherlands)
      Prof. dr. D. Yarnitsky (Rambam MC, Haifa, Israel)
Printed by Puntgaaf drukwerk, Leiden, The Netherlands
Cover design by David Kozlowski
ISBN: 978-90-9028397-5















Effect of ketamine on endogenous pain modulation in healthy 
volunteers
Offset analgesia in neuropathic pain patients and effect of 
treatment with morphine and ketamine
Influence of ketamine and morphine on descending pain mod-
ulation in chronic pain patients: A randomized placebo-con-
trolled proof-of-concept study
Tapentadol potentiates descending pain modulation in chronic 
pain patients with diabetic polyneuropathy
Resting-state fMRI studies
Effect of subanesthetic ketamine on intrinsic functional brain 
connectivity: A placebo-controlled functional magnetic reso-
nance imaging study in healthy male volunteers
Effect of deafferentation from spinal anesthesia on pain sensi-



























Pain is a complex sensation influenced by biological, emotional, cognitive and 
behavioral factors. Early important evidence for this is described in a study by 
Beecher in 1946.1 Beecher was an surgeon who worked for the US Army during 
World War II and during this time treated many wounded soldiers suffering from 
acute and severe pain. He observed that only a quarter of severely injured sol-
diers with penetrating traumas and long bone fractures (while mentally healthy) 
reported severe pain and requested analgesics. This indicated that strong emo-
tions as experienced in the battlefield could block pain perception. Another inter-
esting observation made by Beecher was the effect of placebo in severely injured 
soldiers. Due to shortages of medical supplies including strong analgesics like 
morphine, Beecher was forced to treat his patients with placebo substances. In 
several studies he performed, involving over 1,000 patients, he observed an av-
erage analgesic effect of placebo of about 35%.2 These studies indicated that the 
human body is capable of modifying painful sensations and underlie the devel-
opment of theories regarding endogenous control of pain.
The first clearly articulated concept of a pain modulatory system was described 
in 1965 by Melzack and Wall in the gate control theory.3 In this theory a gating 
mechanism within the dorsal horn of the spinal cord of rodents was proposed 
which determined whether signals were sent to the brain based on the type of 
activated nerve fibers. Supraspinal influences on this system were suggested, 
although no clear evidence was present at that time for descending pathways 
(from the brain to the spinal cord) that could influence pain perception. Evidence 
for this concept was provided by Wall in 1967 who demonstrated that the block-
ade of descending impulses from the brain stem by spinal cord lesions sponta-
neously activated dorsal horn neurons.4 This indicated that projections from the 
brain stem were able to inhibit neurons at the level of the dorsal horn in the spi-
nal cord which was the basis for the current understanding of descending control 
of pain. In the beginning of the 1970s several regions of the brain stem in animals 
such as the periaquaductal gray (PAG) and rostral ventromedial medulla (RVM) 
were shown to be involved in the initiation of descending inhibitory pathways 
as electrical stimulation of these regions induced analgesia, inhibition of with-
drawal reflexes and inhibition of dorsal horn neurons sensitive to noxious stim-
ulation. The administration of morphine in these regions provided similar ob-
servations and currently we know that these pain modulatory pathways are the 
central substrate for the analgesic actions of opioids and endorphins.5,6 In 1979 
Le Bars et al. demonstrated in rats that afferent noxious information from var-
ious parts of the body was able to inhibit activity of nociceptive neurons in the 
dorsal horn which simultaneously received afferent noxious information from a 
different part of the body. This phenomenon was called diffuse noxious inhibi-
tory controls (DNIC). In animals DNIC involves a spinal-bulbo-spinal feedback 
loop where afferent noxious pathways are able to activate descending inhibitory 
pathways originating in the brain stem to inhibit nociceptive neuronal activity at 




be present in humans.9 However, 
imaging studies demonstrate that 
in humans descending control of 
pain also involves higher cortical 
areas, such as the amygdala, the 
thalamus, the insula and the an-
terior cingulate cortex (ACC).10,11 
The current understanding of no-
ciceptive modulatory pathways 
in humans involves an afferent 
pathway for nociceptive input 
to several areas of the cortex and 
brain stem for pain perception 
and interpretation. Descending 
pathways, either facilitatory or 
inhibitory, can modulate this af-
ferent noxious information at the 
level of the dorsal horn of the spi-
nal cord as illustrated in figure 1.
Conditioned pain modulation
The biology of the DNIC-like effect in humans is more complex compared to 
rodents, for instance due to the involvement of higher cortical centers. Therefore, 
new terminology has been proposed to refer to the DNIC-like effect in humans 
to discriminate between the brain stem mediated inhibitory effect in rodents and 
the complex facilitatory and inhibitory pain modulatory properties present in 
humans. Two noxious stimuli are required during psychophysical research to 
explore descending control of pain in humans, which are referred to as the test 
stimulus and the conditioning stimulus. The test stimulus is the stimulus on 
which the conditioning effect is evaluated; the conditioning stimulus is the stim-
ulus that induces the change in pain perception. The effect of the conditioning 
stimulus on the test stimulus is called “Conditioned Pain Modulation” (CPM) 
Figure 1. Schematic illustration of the 
pain modulatory pathways. Nociceptive 
input reaches the brain via an afferent 
pathway (red). Next, the descending pain 
modulatory pathway is activated by sev-
eral higher cortical sites that project to the 
brainstem to modulate nociceptive input 
at the level of the dorsal horn. This de-
scending pathway can be either facilitato-
ry or inhibitory. (adapted from: Dahan A, 
Niesters M, Sarton E. Endogenous mod-
ulation of pain is visible in the brain. Clin 
Neurophysiol. 2012; 123: 642-3).
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Chapter 1
1 which is the net effect of the facilitatory and inhibitory mechanisms of pain pro-cessing.12
In the current thesis CPM was evaluated using heat pain as test stimulus and 
cold pain as conditioning stimulus (Fig. 2A). Heat pain was administered on the 
lower part of the dominant arm using a 30-second stimulus during which the 
test subject continuously rated pain intensity. The test stimulus was applied with 
and without the conditioning stimulus, which was administered on the lower leg 
During effective descending inhibitory control of pain, as observed in healthy 
volunteers, the conditioning stimulus will decrease the pain intensity of the test 
stimulus (Fig. 2B).9
Offset analgesia
More recently, a novel model of endogenous inhibitory control of pain has been 
proposed that produces temporal alterations in pain processing named offset 
analgesia (OA).13 OA is the perception of profound analgesia during a slight 
decrease of a noxious heat stimulus, which is more pronounced than would be 
predicted by the rate of the temperature decrease. Although a peripheral origin 
of OA is not excluded (e.g. related to primary afferent neurons within the dorsal 
horn), OA is generally considered an example of central inhibitory modulation 
of pain probably induced by neuronal circuits similar to CPM. A schematic illus-
tration of a normal OA response as observed in healthy volunteers is shown in 
figure 3.
Figure 2. A. Schematic presentation of the experimental set-up to evaluate conditioned pain modu-
lation (CPM). Heat pain (test stimulus) was applied using a 3 x 3 cm peltier element on the lower 
part of the dominant arm while the subject rated pain intensity using a slide on a potentiometer 
using the other arm. Cold pain (conditioning stimulus) was applied using a cold water bath (6-12 
°C) in which the lower leg and foot was immersed. B. Schematic illustration of CPM as observed in 
healthy volunteers. The dotted lines represent the pain intensity scores during the 30-second heat 
stimulus (straight black line) on the lower part of the arm without (blue line) and with (orange 
line) the conditioning stimulus. The difference between the two dotted lines represents the CPM 
effect. CS: conditioning stimulus; VAS: visual analogue scale.
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Introduction
1Outline of this thesis
The aim of the current thesis was 
to evaluate the effect of central-act-
ing drugs on endogenous control 
of pain in healthy volunteers and 
patients with chronic neuropath-
ic pain using psychophysical re-
search and functional magnetic 
resonance imaging (fMRI). 
In chapter 2 the effect of short-
term treatment with the analge-
sic ketamine on CPM and OA is 
evaluated in healthy volunteers 
in a placebo-controlled cross-over 
study.
Chapter 3 describes the presence 
of OA in a large group of healthy 
volunteers in the age range 6-80 
years and a group of chronic 
neuropathic pain patients. Fur-
thermore, the effect of short-term 
treatment with the analgesics ketamine, morphine and placebo on OA responses 
in neuropathic pain patients is evaluated.
In chapter 4 the effect of short-term treatment with ketamine, morphine and pla-
cebo on CPM responses in chronic neuropathic pain patients using a cross-over 
study is described.
Chapter 5 describes the effect of a 4-week treatment with the new analgesic 
tapentadol on CPM and OA in patients with painful diabetic neuropathy in a 
double-blind, placebo-controlled study. 
In chapter 6 the effect of ketamine and pain perception during ketamine infusion 
on large-scale network interaction in the brain measured by resting-state fMRI 
is evaluated. We aimed to identify changes in brain connectivity for (1) brain 
areas involved in ketamine’s pharmacodynamic profile with respect to intended 
(analgesia) and side effects (most importantly psychedelic effects) and (2) areas 
involved in pain processing.
Chapter 7 describes the effect of deafferentation induced by spinal anesthesia 
on intrinsic brain connectivity measured by resting-state fMRI and on the pain 
perception of non-deafferented skin. Our aim was to investigate whether (1) pain 
perception above the level of the anesthetic was altered and (2) whether this co-
Figure 3. Schematic illustration of offset analgesia 
(OA) as observed in healthy volunteers. The dotted 
line represents the pain intensity scores during a 
30-second dynamic heat stimulus applied on the skin. 
Heat stimulation consists of 3 phases: 1) a ramp to 
the target temperature that is kept constant for 5 sec-
onds; 2) a 1 °C temperature increase that is also kept 
constant for 5 seconds; 3) a 1 °C temperature decrease 
(back to the target temperature) that is kept constant 
for 20 seconds followed by a quick return towards the 
baseline temperature. OA is seen in response to the 1 




1 incided with changes in functional neuroimaging markers of cortical and tha-lamic networks in healthy volunteers.
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The number of patients affected by chronic pain is growing. Various mechanisms 
may underlie the process of chronification of pain. Important mechanisms in-
clude NMDAR activation and up-regulation and inflammatory responses in the 
spinal cord;1-3 both cause central sensitization and are related to repeated affer-
ent excitation.1 Another mechanism involved in pain chronification is dysfunc-
tion of inhibitory pathways or a shift in the balance between pain inhibition and 
pain facilitation. In the last decades the role of central pain modulation in the 
control of nociception been investigated intensively.4,5 Inhibitory and facilitatory 
descending pathways, originating at higher central nervous system sites, such 
as the cerebral cortex, nucleus raphe magnus, periaquaductal grey (PAG), locus 
coeruleus and rostraventral medulla (RVM), modulate activity of dorsal horn 
nociceptive neurons.4,6 Alterations in endogenous pain modulation have been 
observed in chronic pain diseases like irritable bowel syndrome, fibromyalgia, 
chronic tension headache, temporomandibular disorder and complex regional 
pain syndrome type 1 (CRPS-1).5,7-9 Seifert et al. showed a shift from inhibition 
towards facilitation of nociceptive input in CRPS patients.9
Recent studies indicate that treatment of chronic pain patients with the NMDAR 
antagonist ketamine has a prolonged beneficial effect on spontaneous pain re-
porting and is effective when used in combinations with opioids in the treatment 
of acute postoperative pain and cancer pain management.10-15 Ketamine may pro-
duce prolonged analgesia through multiple mechanisms. Most important and 
most frequently studied is its desensitizing effect on sensitized nociceptive neu-
rons in the spinal cord by blocking the NMDAR.1 As a result, ketamine blocks 
the enhanced signal transmission in the pain circuitry. The effect of ketamine 
on endogenous inhibitory pain control remains unknown. Since ketamine ame-
liorates chronic pain (such as occurs in CRPS patients) an effect on endogenous 
pain modulation is plausible. In the current study we address this issue by ex-
amining the effect of low-dose ketamine (40 mg/h) on two expressions of endog-
enous control of pain: Diffuse Noxious Inhibitory Controls (DNIC) and Offset 
Analgesia (OA).5,7,16-20
DNIC has been investigated in both animals and humans, showing central inhi-
bition of a focal pain stimulus by administering a noxious stimulus at a remote 
area, thereby reducing the perception of the focal pain stimulus.5,21 OA has re-
cently been proposed as a second endogenous analgesia mechanism. This mech-
anism demonstrates profound analgesia during slight incremental decreases of 
a noxious heat stimulus, which is more rapid than would be predicted by the 
rate of temperature decrease.16,19,20 Recent studies indicate that OA coincides with 
activation of the PAG, RVM and locus coeruleus, areas with substantial roles in 
descending inhibition of pain.19
The main aim of the present study is to explore whether ketamine interacts with 
pathways involved in endogenous pain modulation and whether it enhances 
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inhibitory control. To that end we studied the effect of low-dose ketamine on 
DNIC and OA in healthy volunteers. We hypothesize that ketamine enhances 
both DNIC and OA and by that contributes to the prolonged analgesic effect of 
ketamine in chronic pain patients. 
Methods
Subjects
Ten healthy volunteers (4 men/6 women) were recruited for participation in the 
study, after approval of the protocol by the local medical ethics committee (Com-
missie Medische Ethiek LUMC). Informed written consent was obtained accord-
ing to the Declaration of Helsinki from all participants. The study was registered 
in the Dutch trial register (www.trialregister.nl) under number NTR2005. Before 
participation all subjects received a physical examination and their medical his-
tory was taken. Exclusion criteria were: age < 18 years or > 75; presence or histo-
ry of a medical disease such as renal, liver, cardiac, vascular (incl. hypertension) 
or infectious disease; presence or history of a neurological and psychiatric dis-
ease (e.g. increased cranial pressure, epilepsy, psychosis); glaucoma; pregnancy; 
obesity (BMI > 30) and any use of pain medication.
Pain assessment, DNIC and offset analgesia
Heat pain was induced using the Pathway Neurosensory Analyzer (Medoc Ltd, 
Ramat Yishai, Israel). Using a 3 x 3 cm thermal probe, the skin on the volar side 
of the arm was stimulated with a preset and computer controlled temperature 
scheme. Baseline temperature was set at 32 ℃. During heat pain stimulation, 
subjects quantified the pain intensity of the noxious stimulus using the slider on 
an electrical potentiometer connected to a computer, allowing continuous mon-
itoring of the Visual Analogue Scale (eVAS), that ranged from 0 (no pain) to 100 
(worst pain imaginable). To overcome adaptation, the volar side of the arm was 
divided into three zones. The thermode was moved from zone to zone between 
stimuli. Prior to the study, the test temperature was determined by applying a 
series of heat stimuli, ranging from 42 ℃ to 49 ℃ with increments of 1 ℃; each 
stimulus was applied for 10 seconds, with 5-10 min intervals between stimuli. 
The temperature evoking an eVAS of at least 50 mm was used during the remain-
der of the study (this is the test temperature).
Cold pain was induced by cold water immersion of the subject’s foot and lower 
leg into a reservoir with cold water. Water with a predetermined temperature 
was produced by a rapid water-cooling system (IcyDip, IcySolutions BV, Delft, 
The Netherlands). The cold water temperature could be set at any value ranging 
from 6 ℃ to 18 ℃. Prior to the study various water temperatures were tested. 
The temperature that produced an eVAS of at least 30 mm was used in the re-
mainder of the study. After each exposure to cold water, the subject’s foot was 




DNIC was determined according to the protocol described by King et al.7 In 
short, for the experimental stimulus focal heat pain was applied to the subject’s 
volar side of the left arm as follows: the temperature gradually increased from 
baseline (32 ℃) to the test temperature (at 1.5 ℃/s) and was held constant for 
30 seconds. Next, the temperature decreased rapidly (at 6 ℃/s) to baseline. Each 
heat stimulus was repeated for a total of three times, after which the same stimu-
lus was applied for another three times but now in combination with the condi-
tioned stimulus (immersion of foot and lower leg in cold water). The conditioned 
stimulus was applied 25 seconds before the start of the experimental stimulus 
and ending simultaneously with the end of the experimental stimulus. Between 
each heat stimulus there was a 3 minute rest period. During the heat stimulation 
the subjects rated pain intensity using the eVAS slider.
Offset analgesia was determined as described by Yelle et al.20 In short, a focal heat 
stimulus was applied to the subject’s volar side of the arm. The thermode posi-
tioned on the arm was ramped (1.5 ℃/s) from baseline temperature to the indi-
vidual’s test temperature. The test temperature was kept constant for 5 seconds 
after which it was raised by 1 ℃ for 5 seconds and next decreased by 1 ℃ to the 
test temperature and kept constant for 20 seconds. Next, the temperature quickly 
returned (6 ℃/s) to baseline. Subjects rated the intensity of the heat stimulus us-
ing the eVAS slider. Offset analgesia was determined three times with a 3 minute 
rest period between tests.
Figure 1. A. Schematic diagram of the study 
protocol. Initially the subjects performed a 
training session; these data were discarded. 
After receiving treatment (ketamine or pla-
cebo) and a 20-minute rest period, the test 
phase started with DNIC (diffuse noxious 
inhibitory control) and OA (offset analge-
sia) experiments. Each subject received the 
2 treatments on separate occasions. OA and 
DNIC studies were randomized. B. Calcula-
tion of offset analgesia. The visual analogue 
scale (eVAS) response, ranging from 0 (no 
pain) to 100 (worst pain imaginable), to a 
heat pain stimulus (black line) is given. The decrease in eVAS from peak eVAS value to its nadir 
following the 1 ℃ decrease of the heat pain stimulus (at t = 20 seconds) is calculated (ΔeVAS). To 
correct for the value of the peak eVAS, the ΔeVAS is divided by the peak eVAS giving the ‘corrected’ 
ΔeVAS or ΔeVASc (= ΔeVAS/[peak eVAS]).
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Study design
The study had a single-blinded, cross-over design. Subjects were randomized for 
treatments (intravenous S(+)-ketamine (Ketanest-S, Pfizer BV, Capelle a/d IJssel, 
The Netherlands) or placebo (NaCl 0.9%)) and pain test order (offset analgesia or 
DNIC, experiment with and without conditioning stimulus). Randomization for 
studies with and without water immersion was performed to avoid a distraction 
or learning effect.22 There were at least two weeks in between the placebo and 
ketamine sessions. On both experiment days, individual test temperatures for 
the experimental and conditioned stimulus were determined first. Next, the sub-
jects were trained by performing DNIC and offset analgesia studies, as described 
above. Subsequently, the subjects received a 1-h infusion of either S(+)-ketamine 
(40 mg per 70 kg) or placebo. After a 20-minute wash-out period the test phase 
began with studies to determine DNIC and offset analgesia after placebo or ket-
amine treatment (with a 30-minute interval between studies). See also figure 1A.
Side effects
During ketamine and placebo treatment the occurrence of nausea and vomit-
ing was recorded (yes/no), and drug high and drowsiness were scored using an 
11-point numerical rating scale ranging from 0 (= no effect) to 10 (= most severe 
effect). 
Data and statistical analyses
The DNIC and offset analgesia data collected during training were discarded. 
The eVAS data were averaged over 1-second periods. To quantify the DNIC data, 
the area-under-the-curve (AUC) of each eVAS response curve was calculated. 
A linear mixed model was used to compare the AUCs without and with condi-
tioning stimulus after ketamine and placebo infusions. Group differences were 
tested by a chi-square test. To quantify offset analgesia the decrease in eVAS from 
peak eVAS value to the eVAS nadir following the 1 ℃ decrease of the test stim-
ulus was measured (ΔeVAS; Fig. 1B) corrected for the value of the peak eVAS 
(ΔeVASc = ΔeVAS/[peak eVAS]). ΔeVASc values observed after ketamine and 
placebo treatment were compared using a linear mixed model. p-values < 0.05 




All subjects completed the protocol without unexpected or major side effects. 
Baseline subject characteristics are listed in table 1. Between treatment days no 
significant differences were observed in test temperatures of the conditioning 
and experimental stimuli. Mean testing temperatures were 46.1 ± 2.5 ℃ (mean ± 
SD) and 45.9 ± 2.9 ℃ for placebo and ketamine study days, respectively (t-test: 
p = 0.908). The corresponding mean baseline eVAS scores were 52.1 ± 9.8 mm 




ditioning stimulus were 10.3 ± 3.9 ℃ (placebo) and 10.7 ± 3.8 ℃ (ketamine; p = 
0.838) with mean baseline eVAS scores of 29.9 ± 16.7 mm (placebo) and 32.6 ± 
20.6 mm (ketamine; p = 0.764). The baseline or training eVAS responses to the 
two heat stimuli paradigms, DNIC and OA obtained prior to placebo and ket-
amine treatment, are given in figure 2 (the DNIC response is given without con-
ditioning stimulus). It shows that the baseline eVAS responses were similar for 
the two treatment sessions.
Ketamine-induced analgesia and side effects
Despite an average 1-hour interval between the end of the ketamine infusion 
and the eVAS responses, ketamine analgesia persisted: eVAS (obtained at iden-
tical temperatures) were significantly lower after ketamine treatment compared 
to placebo treatment by 10 to 12 mm (p < 0.01). In order to get an indication 
of the analgesic effect of ketamine, we plotted the first 13 seconds of the eVAS 
responses following ketamine and placebo treatment for the 2 heat stimuli par-
adigms in figure 3. We present only the initial part of the response in relation to 
Table 1. Subject characteristics
Number of subjects (M/F) 10 (4/6)
Age (year) 24.1 ± 3.7
Weight (kg) 76.5 ± 13.8
Baseline heat temperature in placebo/ketamine studies (℃) 46.1 ± 2.5/45.9 ± 2.9 (ns)
Baseline water temperature in placebo/ketamine studies (℃) 10.3 ± 3.9/10.7 ± 3.8 (ns)
Values are mean ± SD; ns = not significantly different.
Figure 2. Baseline eVAS (visual analogue scale ranging from 0 (no pain) to 100 (worst imaginable 
pain)) responses (obtained during training): A. responses obtained during the 30-second continu-
ous heat stimulus and B. the varying heat stimulus used to induce offset analgesia. Orange circles 
are the eVAS response prior to placebo treatment; blue circles prior to ketamine treatment. Values 
are mean ± SEM. No differences in baseline responses were obtained between treatment sessions.
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ketamine analgesia as it may be argued that other phenomena (e.g. adaptation, 
endogenous analgesic effects) influence the remainder of the response. Conse-
quently, DNIC and OA eVAS responses (and their respective AUCs) in studies 
following ketamine treatment were smaller compared to responses obtained fol-
lowing placebo treatment. Ketamine produced nausea in six subjects and vomit-
ing in three. Numerical rating scores for drug high were 6.0 ± 1.2 versus 1.2 ± 0.8 
(p < 0.05) and for drowsiness 4.7 ± 0.8 versus 0.8 ± 0.6 (p < 0.05) during ketamine 
versus placebo treatment.
Diffuse noxious inhibitory control
eVAS responses (DNIC and OA) without conditioning stimulus were obtained 
59 minutes (95% confidence interval 44 – 79 minutes) following the end of the 
ketamine or placebo infusion. eVAS responses (DNIC) with conditioning stim-
ulus were obtained 56 minutes (41 – 76 minutes) following ketamine infusion. 
Mean DNIC responses are presented in figure 4. Heat pain stimulation for a peri-
od of 30 seconds gave an eVAS response with rapid temporal sensitization (0-10 
seconds) followed by a phase of adaptation (10-30 seconds). After placebo and 
ketamine infusions, significant effects of the conditioning stimuli were observed 
(p < 0.0001). After placebo infusion significant inhibitory control (i.e. DNIC) was 
activated in all subjects. Experimental heat pain applied simultaneously with the 
conditioned stimulus resulted in eVAS values below those observed during test-
ing just experimental heat pain (AUCs 764.3 ± 139.9 versus 1008.9 ± 178.2; p < 
0.001). In contrast, after ketamine infusion, no DNIC was observed, but rather 
a significant facilitatory pain response occurred when heat pain was combined 
with the conditioning stimulus (AUCs 889.8 ± 201.5 versus 708.4 ± 155.9; p < 0.01).
Figure 3. Ketamine’s analgesic effect. First 13 seconds of the eVAS (visual analogue scale ranging 
from 0 (no pain) to 100 (worst pain imaginable)) responses without conditioning stimulus after 
placebo (orange circles) and ketamine treatment (blue circles) for studies performed in the A. DNIC 
paradigm and B. offset analgesia paradigm. Ketamine produced a significant analgesic effect with a 




In figure 5 the individual magnitudes of the eVAS responses without condition-
ing stimulus versus responses with stimulus are presented in a scatter plot. It 
shows that while the mean AUC without conditioning stimulus (x-axis) after 
ketamine treatment is reduced compared to placebo the individual data over-
lap. The plot further shows that magnitude of the eVAS response without con-
Figure 4. Effect of A. placebo and B. ketamine treatment on endogenous pain modulation as deter-
mined by a diffuse noxious inhibitory control paradigm, that is, a heat pain stimulus (black line) 
applied without and with a conditioning stimulus (leg immersion in cold water). After placebo 
treatment the eVAS (visual analogue scale ranging from 0 (no pain) to 100 (worst pain imagin-
able)) response to experimental heat pain with the conditioning stimulus was significantly in-
hibited compared to the response without the conditioning stimulus (p < 0.001). After ketamine 
treatment the eVAS response to the noxious heat stimulus was increased when the conditioning 
stimulus was applied (p < 0.01). The data are the population mean of the subjects’ mean eVAS 
values (SEM).
Figure 5. Scatter plot of the effect of the 
conditioning stimulus on eVAS (visual 
analogue scale ranging from 0 (no pain) 
to 100 (worst pain imaginable)) responses 
after placebo treatment (orange circles) 
and ketamine treatment (blue circles). 
The dashed lines are lines of identity. 
On the x-axis the areas-under-the curve 
(AUC) of the eVAS responses without 
conditioning stimulus; on the y-axis the 
AUCs of the eVAS responses with condi-
tioning stimulus.
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ditioning stimulus had just limited effect on the magnitude of the response with 
stimulus (slope of linear regression on the ketamine data = 1.19; on the placebo 
data 0.75).
Offset analgesia
Mean OA responses are shown in figure 6. The response after ketamine treatment 
was smaller than after placebo treatment; a sign of persistent analgesic effect of 
ketamine in the hours following treatment. Offset analgesia was observed in all 
subjects after both placebo and ketamine infusion. The placebo ΔeVASc (0.91 ± 
0.03) did not differ significantly from the ketamine ΔeVASc (0.86 ± 0.06), indicat-
ing no effect of ketamine on OA. No correlation was observed between placebo 
ΔeVASc and DNIC responses (inhibition determined by subtracting AUCs) (p > 
0.05, correlation coefficient = 0.11).
Absence of sex differences
No sex differences in the response of ketamine relative to placebo were observed 
in the effects of ketamine on analgesia, DNIC and OA responses.
Discussion
Descending control of nociceptive spinal responses has both inhibitory and facil-
itatory components.6 Diffuse noxious inhibitory control and offset analgesia are 
examples of dynamic inhibitory processes. DNIC is a spinal-medullary-spinal 
feedback loop that is activated when two painful stimuli are applied simulta-
neously.5,17,18 A heterotopic noxious stimulus modifies the perception of another 
noxious stimulus, and, in case of DNIC, inhibits the perception of the primary 
(i.e. test) stimulus. It has been suggested that DNIC serves as a filter that helps 
to extract nociceptive signals from the background noise by inhibiting basal so-
matosensory activity of the population nociceptive neurons (i.e. increasing the 
signal-to-noise ratio).17 In our current study we generated inhibition of a heat 
pain stimulus applied to the arm, by immersion of the foot and lower leg in cold 
Figure 6. Effect of placebo and ket-
amine treatment on endogenous pain 
modulation as determined by the off-
set analgesia paradigm. The ΔeVAS 
values (decrease in eVAS (visual an-
alogue scale ranging from 0 (no pain) 
to 100 (worst pain imaginable)) from 
peak eVAS value to its nadir follow-
ing the 1 ℃ decrease of the heat pain 
stimulus (at t = 20 seconds)) correct-
ed for the difference in peak ΔeVAS 
did not differ between treatments. The 
data are the population mean of the 




water (placebo data; Fig. 4A). An infusion with ketamine resulted in a blocked 
inhibitory pain response with more pain when a conditioning stimulus was com-
bined with the test stimulus rather than an increase in DNIC (Fig. 4B; i.e. the 
null-hypothesis was rejected). Our data indicate that the balance between pain 
inhibition and pain facilitation (that normally has predominance for pain inhibi-
tion) was shifted by ketamine towards blocking DNIC, resulting in some form of 
pain facilitation. Similar alterations in endogenous pain modulation have been 
observed with acute and chronic morphine treatment.23,24 
Ketamine analgesia versus anti-analgesia
The effect of ketamine on DNIC was not expected and is, at present, difficult 
to explain. Ketamine is usually associated with analgesia in chronic pain and 
in combination with opioids in cancer pain and perioperative pain.10-15,25,26 Pain 
relief occurs due to blockade of excitatory NMDARs, which results in a reduced 
or even blocked signal transmission in the pain circuitry towards the thalamus 
and cerebral cortex. Still, there are several multiple, converging lines of evidence 
showing that ketamine and other NMDAR antagonists are associated with pain 
facilitation and antagonism of opioid-induced pain relief. We recently showed 
in healthy volunteers that while ketamine had a dose-dependent antinocicep-
tive effect on static nociceptive pain (repetitive noxious heat pain stimuli), pain 
responses following infusion were perceived as more painful (by about 1 cm 
VAS) for more than 3 hours compared to pre-drug pain responses.26,27 In agree-
ment with these findings, Mitchell described a cancer patient that developed se-
vere hyperalgesia and allodynia directly following treatment with ketamine.28 
During treatment, the noncompetitive NMDA receptor antagonist MK801 can 
cause an anti-analgesic effect in mice, where it significantly reduced morphine 
and stress-induced analgesia (an effect which displayed sex-dependency).29-32 In 
another study, MK801 induced hyperalgesia in an acute pain model in the rat.33 
Interestingly, in the anesthetized rat, the NMDAR has been implicated in inhibi-
tion of chronic inflammatory pain. High dose (but not low dose) NMDA micro-
injected into the RVM inhibited primary hyperalgesia 3 hours following injection 
of complete Freund’s adjuvant into a hind paw.34 In total, these data indicate that 
apart from a potent analgesic effect, NMDAR antagonists, including ketamine, 
may, under specific circumstances, produce anti-analgesic and pain facilitatory 
effects. 
Mechanisms of ketamine effect on DNIC
Multiple, non-exclusive mechanisms may cause anti-analgesic or pain facil-
itatory responses during and/or following ketamine treatment. (i) It has been 
argued that excitatory amino acids accumulate at spinal and supraspinal sites 
during effective blockade of the NMDAR.30,33 These amino acids may activate 
non-NMDA excitatory receptors (metabotropic or non-NMDA ionotropic glu-
tamate receptors) and consequently produce anti-analgesia and increased pain 
responses. (ii) Ketamine may recruit different nociceptive mechanisms (compare 
the mechanism proposed for the block of DNIC by morphine)23 or additional-
ly activate non-NMDA receptor systems, such as the opioid system causing a 
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net inhibitory effect on DNIC.35 (iii) DNIC may require supraspinal processing, 
which is effectively disrupted by ketamine (e.g. a dissociative effect of ketamine 
between the limbic system and cerebral cortex).1 And (iv), because we performed 
our experiments following ketamine infusion, a direct effect at the NMDAR is 
not excluded, for example by actions of accumulated excitatory amino acids (see 
“i”), which during the loss of NMDAR blockade from the decrease in ketamine 
concentration causes a rebound increase in NMDAR activity and consequently 
enhanced transmission of afferent nociceptive stimuli (i.e. pain facilitation).26 
Because the link of excitatory receptor systems and the process of endogenous 
pain inhibition/facilitation (and its neurotransmitters such as serotonin and nor-
epinephrine) remains understudied, further studies are needed to investigate the 
specific role of the excitatory receptors in the balance between pain inhibition 
and facilitation under physiological and chronic pain conditions.
Offset analgesia
Apart from DNIC, we tested the effect of ketamine on offset analgesia. OA is con-
sidered an inhibitory mechanism that increases the temporal contrast between 
stimuli (i.e. a temporal sharpening filter).16,19,20 OA is defined as the decrease in 
pain intensity following a decrease in stimulus temperature that is dispropor-
tionate compared to a similar increase in temperature. After placebo infusion, we 
observed an increment in eVAS of 6 mm going from 46 to 47 ℃ while a subse-
quent similar decrease in temperature caused a drop in eVAS of 33 mm (a ratio 
of 5.5; Fig. 3). A similar ratio was observed after ketamine infusion. Furthermore, 
the drop in eVAS was twice as fast (average 6 mm/s) in OA experiments com-
pared with the adaptation seen in DNIC experiments (3 mm/s). Ketamine had 
no effect on OA development, i.e. the enhanced and robust analgesia following 
the 1 ℃ decrease in noxious stimulus intensity remained unaffected by ketamine 
(drop in eVAS relative to peak eVAS = 0.91 ± 0.03 after placebo versus 0.86 ± 0.06 
after ketamine treatment). These data contrast the observations in the DNIC ex-
periments. As previously discussed, both in their generation and probably also 
in their neuroanatomic pathways the inhibitory processes OA and DNIC are dis-
tinct: OA relates inhibition to the offset of a noxious stimulus, while DNIC is 
related to the onset of a heterotopic stimulus.16,19,20 In agreement with this is the 
observation that there was no correlation between ΔeVASc and DNIC. We fur-
ther show that OA and DNIC are dissimilar in their interaction with the glutama-
tergic receptor system.
Critique of methods
We tested the effect of ketamine and placebo using a single-blind study design as 
we expected to become unblinded during the treatment of the subjects. Also the 
subjects noted more severe side effects during ketamine treatment but were not 
made aware that this was specific to the test treatment.  We cannot exclude that 
specific a priori expectations may have influenced the study outcome at some 
level. For example, it was shown that the subject’s expectation of hyperalgesia 




ciceptive reflexes.36 To our advantage is that our subjects remained uninformed 
regarding a possible effect of ketamine on DNIC or OA and the a priori expecta-
tions of the investigators were towards an increase in inhibitory control. Further-
more, we observed that treatment sequence had no effect on outcome parameters 
(DNIC and OA, experiment with and without water immersion) and therefore 
we do not think that our approach influenced the study outcome significantly. 
Finally, it may be argued that the ketamine effect on DNIC is related to the small-
er magnitude of the eVAS responses following ketamine treatment and that, for 
example, the increase in eVAS responses during water immersion is due to a 
drift towards pre-ketamine baseline values (due to the loss of ketamine analge-
sic effect). There are several arguments opposing this assumption. DNIC eVAS 
responses without and with conditioning stimulus were randomized and on av-
erage occurred both about 60 min following the end of the ketamine infusion. 
Hence ketamine’s analgesic effect was of similar magnitude in the 2 experiments. 
Furthermore, the magnitude of the eVAS responses with conditioning stimulus 
is minimally related to the magnitude of the responses without stimulus (Fig. 
5). A small effect (ranging from 0 to 20%) cannot be excluded with larger eVAS 
responses with conditioning stimulus associated with larger responses without 
water stimulation. The reverse would be expected when the response would 
have drifted back to pre-ketamine baseline values. 
Conclusions
In conclusion, our data suggest that ketamine treatment effects endogenous 
modulation of nociceptive stimuli as examined by the DNIC paradigm. DNIC 
responses following a 1-hour low-dose ketamine treatment displayed a modu-
lated (blocked or even facilitated) DNIC. These findings suggest a modulatory 
involvement of the NMDA and/or other glutamatergic receptors at some level 
within the endogenous pain system. No effect of ketamine treatment was ob-
served on the inhibitory effects of subsequent OA responses. This suggests that 
OA and DNIC differ in their susceptibility for glutamatergic influences. The en-
during pain relief of chronic pain during and following ketamine treatment10-15 
cannot be explained by our current findings and suggests the absence between 
DNIC alterations and relief of spontaneous chronic pain from ketamine. How-
ever, it may well be that the effect of ketamine on descending pain modulation 
is different in chronic pain patients and cannot be addressed by performing ket-
amine studies in volunteers.
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Offset Analgesia in Neuropathic Pain 
Patients and Effect of Treatment
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Offset analgesia (OA) is the perception of profound analgesia during a slight 
incremental decrease of a noxious heat stimulus, which is more pronounced than 
would be predicted by the rate of the temperature decrease.1-4 In 2002, Grill and 
Coghill were the first to describe this analgesic phenomenon and argued that 
OA “may serve as a temporal contrast enhancement mechanism”.1 Although a 
peripheral origin of OA is not excluded (e.g. related to primary afferent neurons 
within the dorsal horn), OA is generally considered an example of central inhib-
itory modulation of pain probably induced by neuronal circuits within the peri-
aqueductal gray, rostral ventromedial medulla and locus coeruleus, areas with 
substantial roles in descending inhibition of pain.5,6 Other examples of central (in-
hibitory) modulation of pain include diffuse noxious inhibitory controls (DNIC), 
stress-induced analgesia and placebo analgesia, all of which share pain-related 
supraspinal and spinal pathways.4,7,8 There are indication that central inhibitory 
modulation of pain is affected in various chronic pain states such as fibromyal-
gia, irritable bowel syndrome, and complex regional pain syndrome.8-11 Thus far, 
OA has not been evaluated in chronic pain. 
In the current study we measured OA responses in a population of patients with 
neuropathic pain (NP) due to small-fiber neuropathy (SFN) and compared their 
responses with an age- and sex-matched control group and a large group of 
healthy volunteers with an age range of 6 to 80 years of either sex. The descrip-
tion of OA in a large population allows a clear discrimination between OA in 
health and disease (NP); we studied volunteers of either sex from age 6 years on, 
which will give an indication of the developmental aspects of OA and possible 
sex differences. In addition, we assessed the effect of analgesic treatment on OA 
in NP patients. The effect of morphine and ketamine was tested using a random-
ized placebo-controlled design. Although morphine and ketamine are consid-
ered strong analgesics and frequently used to relief severe chronic pain (albeit 
through different pathways), various studies indicate that both agents have a 
facilitatory rather than an inhibitory effect on central modulation of pain.4,12,13 
For example, Niesters et al.4 recently showed that ketamine treatment causes the 
shift of pain inhibition towards pain facilitation when testing DNIC with two 
heterotopic stimuli (heat pain as test stimulus and cold water pain as condition-
ing stimulus). However, the effect of morphine and ketamine on the central mod-
ulation of pain was assessed only in healthy volunteers. No knowledge is avail-
able on the effect of these agents on central modulation of pain in NP patients.
The main aims of our study are to (1) describe and compare OA in healthy volun-
teers and patients with chronic NP, and (2) assess whether age and sex differenc-
es exist in OA. The null hypotheses were that (1) there are no differences in OA in 
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Methods
Participants: volunteers, patients and controls
Three groups of subjects were recruited to participate in the study: volunteers, 
NP patients and control subjects who were age- and sex-matched to the pain 
patients. The study was approved by the Human Ethics Committee of the Leiden 
University Medical Center (Leiden, The Netherlands), and oral or written in-
formed consent, as outlined by the Declaration of Helsinki, was obtained from 
all participants. For participants who were minors, consent was obtained from 
participants and their parents. 
One hundred ten male and female volunteers were enrolled in the study after 
being selected from a convenience population (i.e. a convenience sample) and 
were in the age-range of 6 to 80 years. Ten patients with chronic NP were recruit-
ed. The patients had the diagnosis of isolated small-fiber neuropathy (SFN) and 
a pain score of at least 5 on an 11-point scale (0-10). Diagnosis was made when 
at least two of the following symptoms were present in legs and/or arms (in 
a stocking-glove distribution): (i) symmetrical dysesthesias or paresthesias; (ii) 
burning or painful feet with nighttime worsening of burning or pain; or (iii) tac-
tile allodynia.14,15 In addition, SFN had to be confirmed by neurological examina-
tion with normal tendon reflexes and absence of muscle weakness, and abnormal 
temperature thresholds had to be confirmed according to previously published 
criteria.14 Exclusion criteria (for patients and controls) were: age younger than 
18 years; presence or history of a severe medical disease (e.g. renal, liver, car-
diac, vascular (incl. hypertension) or infectious disease); presence or history of 
a neurological and psychiatric disease (e.g. increased cranial pressure, epilepsy, 
psychosis); glaucoma; pregnancy; obesity (body mass index more than 30 kg/
m2), and use of strong opioid medication. Patients were allowed to continue 
the following pain medication: acetaminophen, non-steroidal anti-inflammato-
ry drugs, tramadol, amitriptyline, gabapentin and pregabalin. Pain medication 
dosages were kept constant during the whole study period. Ten healthy male or 
female subjects who were not taking medication were enrolled in the study to 
serve as age and sex-matched controls to the patients. The control subjects were 
not recruited from the volunteer sample. A total of 130 subjects participated in 
the study.
Pain assessment and offset analgesia
The heat stimulus was applied on skin of the forearm where no painful sensa-
tions were present and the heat pain threshold was unaffected. Heat pain was 
induced with a 3 x 3 cm thermal probe positioned on the skin of the volar side of 
the non-dominant arm of the subject, using the Pathway Neurosensory Analyzer 
(Medoc Ltd., Ramat Yishai, Israel). A preset and computer-controlled tempera-
ture paradigm was used to generate a specific temperature pattern (Fig. 1). The 
subjects quantified the pain intensity of the heat pain stimulation using a slider 
on an electrical potentiometer connected to a computer. This allows continuous 




(no pain) to 100 (worst pain imaginable). To overcome adaptation or sensitiza-
tion, the volar side of the arm was divided into three zones. The thermode was 
moved from zone to zone between stimuli. The baseline temperature was set 
at 32 ℃. Before testing, the thermode was tested and calibrated using a surface 
thermometer (K-Thermocouple thermometer, Hanna Instruments, Woonsocket, 
RI). 
Offset analgesia was studied by applying a three-temperature paradigm as de-
scribed by Grill and Coghill.1 In NP patients and their matched controls, the 
study temperatures were individualized. To that end, a series of heat stimuli was 
applied; the stimulus duration was 10 seconds and there was 5-10 minutes be-
tween stimuli. The temperature of the first test stimulus was set at 42 ℃. At 1 
℃ increments the lowest temperature that evoked an eVAS of 50 mm was iden-
tified and used in the study (i.e. the individual’s test temperature). To test OA 
the temperature was ramped at 1.5 ℃/s from baseline temperature to the indi-
vidual’s test temperature. The test temperature was kept constant for 5 seconds 
after which it was increased by 1 ℃ for 5 seconds and next decreased by 1 ℃ 
to the test temperature and kept constant for 20 seconds. Next, the temperature 
quickly returned (6 ℃/s) to baseline. This temperature paradigm was applied 
three times with a 3-minute rest period between tests. For the volunteers from 
the convenience sample, the three-temperature paradigm was preset at 45 ℃ (for 
5 seconds) – 46 ℃ (for 5 seconds) – 45 ℃ (for 20 seconds). 
Study design
The study was registered in the Dutch trial register (www.trialregister.nl) as 
number NTR2005. In patients, the effect of S-ketamine and morphine on OA was 
tested using a single blind, placebo-controlled, randomized, crossover study de-
sign. Patients were randomized to receive a 1-hour placebo infusion (0.9% NaCl), 
a 1-hour infusion with S(+)-ketamine (total dose = 0.57 mg/kg; Ketanest-S, Pfiz-
er BV, Capelle a/d IJssel, The Netherlands) or a 1-hour infusion with morphine 
(bolus of 0.05 mg/kg followed by 0.015 mg/kg for 1 hour; Morphine HCl, Phar-
machemie BV, Haarlem, The Netherlands) on three separate occasions with 2-4 
weeks between sessions. Each patient participated in all three sessions. Before 
treatment, the test temperature was determined after which three OA tests were 
performed (pretreatment or baseline studies). Then, treatment was given. After a 
20-minute washout period the OA tests were repeated. Spontaneous pain scores 
were assessed using an 11-point numerical scale ranging from 0 (no pain) to 10 
(most severe pain) before and after the infusion period. Controls and volunteers 
were studied on one occasion. In controls, after determination of the individ-
ual test temperature, three OA tests were obtained. In volunteers, after a brief 
explanation of the test, one OA test was performed, although in some this was 
preceded by a test experiment to familiarize the subject with the test procedure. 
In patients, during ketamine, morphine and placebo treatment, the occurrence 
of nausea and vomiting (yes/no) and the occurrence of drug high was scored on 
an 11-point numerical scale ranging from 0 (no effect) to 10 (most severe effect).
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Data and statistical analyses
The eVAS data were averaged over 1-second periods. To quantify OA, the de-
crease in eVAS from peak eVAS value to the eVAS nadir after the 1 ℃ decrease 
of the test stimulus was measured (ΔeVAS), corrected for the value of the peak 
eVAS (ΔeVASc = (ΔeVAS/[peak eVAS])*100) (i.e. correction for the variation in 
the peak response among participants as explained in figure 1).4 
In volunteers, five age cohorts were created: 6-12, 13-19, 20-39, 40-59 and 60-80 
years. The effect of age (by cohort) and sex on ΔeVASc (ΔeVAS corrected for peak 
effect) was tested by one-way analysis of variance (ANOVA) and unpaired two-
tailed t-test, respectively. To compare the ΔeVASc of patients with the responses 
of their age matched controls, the predrug patient data were compared with the 
control data using an unpaired two-tailed t-test. Treatment effect (placebo, ket-
amine and morphine) on ΔeVASc and spontaneous pain reporting was tested 
using a one-way ANOVA and post-hoc Bonferroni or t-tests. A receiver operating 
characteristic curve was calculated to get an indication of the cutoff value for a 
healthy value of ΔeVASc versus a value observed in NP patients. Statistical anal-
ysis was performed in SigmaPlot version 11 for Windows (Systat Software Inc., 
Chicago ILL). p-values < 0.05 were considered significant. Data are presented as 
mean ± SEM and 95% confidence intervals (CI) unless otherwise stated. 
Results
OA in volunteers
The eVAS responses varied among the participants irrespective of age and sex. 
Using the preset temperature paradigm, eVAS-responses greater than 0 were 
present in 78 of 110 (70%) healthy volunteers. Eighteen of the 65 men (28%) and 
Figure 1. Calculation of the magnitude of offset analgesia (OA) relative to peak effect (ΔeVASc), 
where eVAS = electronic visual analogue score, ΔeVAS = the decrease in eVAS from peak eVAS val-
ue to the eVAS nadir after the 1 ℃ decrease of the test stimulus, and ΔeVASc  = ΔeVAS corrected 
for the value of the peak eVAS (ΔeVASc = (ΔeVAS/[peak eVAS])*100). A. Peak eVAS = a; reduction 
in eVAS after the 1 ℃ decrease in noxious heat stimulation (ΔeVAS) = b; ΔeVASc = (b/a)*100% 
= 100% because a = b. B. Peak eVAS = a; ΔeVAS = c; ΔeVASc = (c/a)*100% = 75% because c = 




14 of the women (31%) had no pain response to the fixed heat stimulus train. 
These individuals were distributed equally among the different age cohorts, and 
their data were not included in the analysis. For presentation purposes only, the 
data relative to peak eVAS responses (eVAS/[peak eVAS]*100%) are presented 
per age cohort in figure 2. To get an impression of the variability in the data, 
ΔeVAS (not corrected for peak value) per age cohort are plotted in figure 3A. It 
shows a trend towards a decrease in the ΔeVAS with increasing age and notice-
ably large variability in the response in the oldest cohort: 6-12 years: ΔeVAS = 
66.1 ± 6.9 mm (95% CI: 51.6 – 80.7 mm); 13-19 years: 47.6 ± 7.7 mm (31.2 – 64.0 
mm); 20-39 years: 45.3 ± 7.1 mm (29.9 – 60.8 mm); 40-59 years: 51.8 ± 4.5 mm 
(42.6 – 61.0 mm); and 60-80 years: 34.1 ± 9.0 mm (12.0 – 56.2 mm) (ANOVA main 
effect p = 0.054). The mean ΔeVASc of the total population that displayed a pain 
response greater than zero (n = 78) was 97 ± 1% (95% CI: 95-99%). No difference 
was observed in ΔeVASc scores between the age cohorts (Fig. 3B): 6-12 years: 92 
± 4% (85 – 100%; n = 17), 13-19 years: 98 ± 1% (96 – 100%; n = 17), 20-39 years: 96 
± 2% (92 – 100%; n = 14), 40-59 years: 99 ± 1% (96 – 100%; n = 23) and 60-80 years: 
97 ± 3% (89 – 100%; n = 7) (ANOVA main effect p = 0.54). The larger variability 
observed in the age cohort 60-80 years is related to the small number of partici-
pants in this group rather than to an age effect. Male (n = 47) and female volun-
teers (n = 31) showed similar eVAS responses, with no difference in peak eVAS 
values: men 51.5 ± 4.0 mm (43.3 – 59.6 mm) and women 55.8 ± 5.2 mm (45.1 – 66.6 
Figure 2. Offset analgesia (OA) responses to a heat stimulus paradigm (black line) in a random 
study population of healthy volunteers of different age categories (A-E). In panel F the effect of 
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mm; p = 0.57; Fig. 2). However, a small but significant difference in difference in 
ΔeVASc was observed: male 98% ± 1  (97 – 100%) and female 94 ± 2% (90 – 98%; p 
= 0.007). This sex effect was age-dependent with absence of a difference in young 
volunteers (age group 6-19 years: male ΔeVASc 98 ± 1% versus female 93 ± 2%; p = 
0.185) but persistent differences in the 20+ cohorts (20-80 years: male ΔeVASc 99 
± 1% versus female 95 ± 2%; p = 0.002; Fig. 4).
Figure 4. A. Offset analgesia (OA) responses in male versus female volunteers in the age category 
of 6-19 years. B. OA responses in male versus female volunteers in the age category of 20-80 years. 
Responses are percentage of peak response. All value are mean ± SEM. eVAS = electronic visual 
analogue score.
Figure 3. A. Absolute magnitude of offset analgesia (OA) in mm (ΔeVAS) of the different age 
categories. The age effect was not significant (p = 0.054). B. OA response relative to peak effect 
(ΔeVASc) of the different age categories. ΔeVASc scores range from 92 to 99% among age cohorts 
(not significant). In addition, the data from healthy controls (CON) and neuropathic pain patients 
(NPP) are added. Values are mean ± SEM. eVAS = electronic visual analogue score; ΔeVAS = 
the decrease in eVAS from peak eVAS value to the eVAS nadir after the 1 ℃ decrease of the test 





OA in neuropathic pain patients versus age-matched healthy controls
Baseline characteristics of NP patients and age- and sex-matched controls are 
listed in table 1. The underlying disease causing NP varied, with four patients 
having neuropathic pain related to diabetes mellitus type 2, two related to sar-
coidosis, one to Sjögren disease and three with NP of unknown origin. The ex-
tremities affected by the SFN were the two lower extremities in four patients and 
feet or legs together with hands in six patients. The patients used the following 
co-medication during the study: acetominophen, non-steroidal anti-inflamma-
tory drugs, tramadol, gabapentin, pregabalin and amitriptyline. All participants 
Figure 5. Example of the offset analgesia (OA) response in a A. healthy control and a B. neuro-
pathic pain (NP) patient. The healthy control shows OA with a ΔeVASc of 100%. The NP patient 
clearly shows an aberrant response to the heat stimulus paradigm (black line) with a delayed onset 
and offset in eVAS response. ΔeVASc was approximately 25%. eVAS = electronic visual analogue 
score; ΔeVAS = the decrease in eVAS from peak eVAS value to the eVAS nadir after the 1 ℃ de-
crease of the test stimulus; ΔeVASc  = ΔeVAS corrected for the value of the peak eVAS (ΔeVASc = 
(ΔeVAS/[peak eVAS])*100).
Table 1. Characteristics of healthy controls and neuropathic pain patients
Healthy controls Neuropathic pain patients p-value
n (M/F) 10 (2/8) 10 (2/8) 0.957
Age (year) 48.3 ± 3.3 54.4 ± 4.2 0.268
Underlying disease Diabetes mellitus n = 4
Sarcoidosis n = 2
Sjögren’s disease n = 1
Unknown cause n = 3
Test temperature (℃) 44.9 ± 0.7 45.0 ± 0.5 0.908
    Ketamine 45.2 ± 0.5
    Morphine 45.1 ± 0.4 0.888
    Placebo 44.8 ± 0.6
Values are mean ± SEM.
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(patients and controls) completed the protocol without unexpected side effects 
with no measurements lost to observation or analysis. Between groups no sig-
nificant differences were observed in test temperatures on the volar side of the 
arm to reach eVAS values of 50 mm: 45.0 ± 0.5 ℃ (43.7 – 46.3 ℃) and 44.9 ± 0.7 ℃ 
(43.0 – 46.8 ℃) for NP patients and age-matched healthy controls, respectively 
(p = 0.91). 
Examples of eVAS responses to the OA temperature paradigm are given in figure 
5. It shows that a healthy control displays a rapid increase in eVAS in response to 
increasing heat stimulation, followed by a rapid decline to an eVAS of zero when 
the temperature is decreased by 1 ℃ from 48 to 47 ℃. In contrast, a ‘typical’ NP 
patient shows a delayed increase in eVAS with increasing heat stimulation and a 
delayed and relatively small decline in eVAS when the temperature is decreased 
by 1 ℃ from 48 to 47 ℃. The eVAS response remains approximately 50% of peak 
eVAS at the end of the 30-second heat stimulation period. The mean eVAS re-
sponses for the two groups are given in figure 6, showing the distinct differences 
in response to the three-temperature paradigm. No difference was observed in 
mean peak eVAS: patients 47.9 ± 4.5 mm (95% CI: 37.7 – 58.2 mm) and controls 
53.6 ± 5.4 mm (41.3 – 65.8 mm; p = 0.44). Most striking is the delayed and smaller 
decrease in eVAS upon the 1 ℃ decrease in test temperature in patients com-
pared to controls. In control subjects ΔeVASc was significantly greater than in 
patients with pain; the ΔeVASc averaged to 98 ± 1%  (96 – 100%) in controls ver-
sus 56 ± 9% (38 – 73%) in NP patients (Fig. 6, p < 0.001). Individual values of the 
eVASc of patients and controls are given in table 2.




ΔeVASc (%) Age- and sex-
matched controls
ΔeVASc (%)
id P001 33 id C011 93
id P002 85 id C012 93
id P003 26 id C013 92
id P004 42 id C014 100
id P005 0 id C015 100
id P006 76 id C016 100
id P007 88 id C017 100
id P008 98 id C018 100
id P009 34 id C019 100
id P010 75 id C020 100
Mean (95% CI) 56 (38-73) Mean (95% CI) 98 (96-100)
CI = confidence interval; ΔeVASc = the corrected decrease in electronic visual analogue score from 




A receiver-operating characteristic curve was constructed to determine a ΔeVASc 
cutoff value between healthy subjects (volunteers and controls, n = 88) and pa-
tients with SFN (Fig. 7). A cutoff value of 0.88 (88%) yields a sensitivity of 90% 
(95% CI: 56 – 99%) and specificity of 91% (83 – 96%). The area-under-the-receiv-
er-operating characteristic curve is 0.96 ± 0.02 (± SE; 95% CI: 0.91 – 0.99, p < 0.001).
Treatment effects in NP patients
All neuropathic pain patients received a 1-hour intravenous infusion with ket-
amine, morphine and placebo. Nausea occurred in four patients receiving ket-
amine, two of whom vomited. After morphine nausea occurred in seven patients, 
Figure 6. eVAS responses to 
the three-temperature par-
adigm (black line) in neu-
ropathic pain patients (n = 
10, orange line) and age-
matched healthy controls 
(n = 10, blue line). Values 
are mean ± SEM. eVAS = 
electronic visual analogue 
score.
Figure 7. Receiver operating char-
acteristic (ROC) curve constructed 
to determine a ΔeVASc cutoff value 
between healthy subjects (volun-
teers and controls, n = 88) and pa-
tients with neuropathic pain. eVAS 
= electronic visual analogue scale.
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of whom four vomited. No nausea or vomiting was seen in patients receiving 
placebo. At the end of infusion, the mean drug high scores were 7.2 ± 0.6 (6.0 – 
8.4), 2.4 ± 0.5 (1.4 – 3.4) and 0.4 ± 0.2 (0 – 0.8) for ketamine, morphine and placebo, 
respectively. The NP spontaneous pain scores were 5.5 ± 0.6 (4.3 – 6.8) before 
and 0.3 ± 0.3 (-0.3 – 0.8) after ketamine treatment (p < 0.001), 6.2 ± 0.6 (5.0 – 7.4) 
before and 1.8 ± 0.66 (0.5 – 3.1) after morphine treatment (p = 0.002) and 6.5 ± 0.4 
(5.7 – 7.3) before and 3.2 ± 0.75 (1.7 – 4.7) after placebo treatment (p = 0.004). All 
spontaneous pain scores were significantly reduced after the infusion, irrespec-
tive of the treatment; however, the greatest pain relief was seen after ketamine 
treatment (Fig. 8). None of the treatments influenced the eVAS responses to the 
three-temperature paradigm (Fig. 9). Mean ΔeVASc scores were 51 ± 1% (49 – 
53%), 55 ± 1% (53 – 57%) and 34 ± 1% (32 – 36%) for placebo, ketamine and mor-
phine treatment, respectively (p = 0.51).
Figure 8. Effect of placebo, ket-
amine and morphine treatment 
on spontaneous pain scores in 
neuropathic pain patients. The 
blue bars represent the pain 
scores before treatment, the  or-
ange bars represent the scores 
directly after treatment. All 
three treatments produced sig-
nificant pain relief (p < 0.01). 
Values are mean ± SEM. VAS = 
visual analogue scale.
Figure 9. Effect of A. placebo, B. ketamine and morphine C. treatment on the eVAS responses in 
neuropathic pain patients. ΔeVASc scores were not different among treatments (p = 0.51). Values 
are mean ± SEM. eVAS = electronic visual analogue score; ΔeVAS = the decrease in eVAS from 
peak eVAS value to the eVAS nadir after the 1 ℃ decrease of the test stimulus; ΔeVASc  = ΔeVAS 






Offset analgesia, first described in 2002, is the phenomenon where a dispropor-
tionally large amount of analgesia is demonstrated during a slight decrease in 
noxious heat stimulation.1-3 The large reduction in pain experience and short du-
ration of effect distinguishes OA from simple stimulus adaptation. OA is consid-
ered a mechanism of endogenous pain modulation, akin DNIC (which is charac-
terized by central inhibition of a focal pain stimulus by administering a second 
noxious stimulus at a remote area).4,7 The phenomenon of OA was recently re-
lated to supraspinal modulatory mechanisms. Functional magnetic resonance 
imaging studies in healthy volunteers showed activation of periaqueductal gray 
and rostral ventromedial medulla during offset analgesia.5,6 Spinal mechanisms 
also may be involved (e.g. a process related to the intrinsic response properties 
of primary afferent neurons within the dorsal horn). For example, Darian-Smith 
et al.16 measured the response of warm fibers during a 39 ℃ stimulus to cooling 
pulses of graded intensity. They observed that cooling pulses greater than 1 ℃ 
suppressed discharge of the warmth-sensitive fibers. A similar mechanism may 
be involved in the OA experiments in addition to the central mechanisms in-
volved. Additional studies examining the behavior of the primary afferent neu-
rons are needed to increase the understanding of the mechanisms of OA.
Healthy volunteers
Offset analgesia was tested in volunteers from age 6 years on. The youngest age 
cohort (6-12 years) showed robust OA, with ΔeVASc mean scores of 92%, which 
is not different from values observed in other age cohorts. This suggests that OA 
is fully developed at the age of 6 years and does not undergo further maturation. 
Testing OA at an even younger age is not possible because the full cooperation 
of the subject is required. Absolute changes in VAS score were variable (Fig. 3A). 
We relate this to the well-known large variability in VAS responses to a stan-
dardized heat stimulus that we observed in our population of volunteers. In fact, 
about 29% of participants felt the stimulus train but experienced no pain at any 
point of the test (VAS remained 0 during the 30-second test period). An approach 
to reduce variability would have been to assess individual test temperatures (as 
was performed in controls and SFN patients). This was considered but rejected 
due to the time burden and consequently the possibly reduced compliance of the 
participants. 
A trend in decreasing ΔeVAS scores was observed with increasing age (Fig. 3A). 
This was related predominantly to a smaller peak eVAS score in the oldest age 
cohort. In contrast, no effect of age was observed on ΔeVASc (Fig. 3B). Age effects 
have been described for DNIC with a decrease in inhibition with increasing age, 
an effect that starts at middle age.17,18 It seems from our data that OA is more 
robust than DNIC over the years; however, one needs to consider that although 
a large number of volunteers was tested, some age cohorts were relatively small 
and we cannot exclude that this small sample size influenced the outcome of the 
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study at some level.
We observed no sex differences in peak eVAS in response to the fixed tempera-
ture stimuli (VAS: men 51.5, women 55.8 mm, p = 0.57) but did observe a small 
but significant greater OA in men (ΔeVASc: men 98%, women 94%, p < 0.01). This 
small difference cannot be explained by difference in peak eVAS and seems to be 
of limited clinical or mechanistic relevance. A systemic review on sex differences 
in DNIC describes a significantly more efficient DNIC in men than in women 
with a mean female-to-male ratio of 0.54, much smaller than observed here (OA 
female/male ratio = 0.96).
NP patients
Our patients were affected by SFN, which affects myelinated Aδ and unmyelin-
ated C-fibers that innervate the skin and mediate pain and thermal sensations.14,15 
Patients experience NP in the limbs in a distal-to-proximal gradient. SFN occurs 
in a variety of conditions including diabetes, sarcoidosis and Sjögren disease,15 
as was diagnosed in seven patients in the current study. Three patients had SFN 
without an underlying diagnosis. We were careful not to test the OA responses 
on ‘diseased’ skin areas. Indeed, the observation that eVAS responses of 50 mm 
were obtained at temperatures not different from those in age and sex-matched 
controls (table 1) is an indication that nociceptive perception was not affected 
in the test areas chosen. Still, we cannot exclude that we may have overlooked 
some ‘preclinical’ changes of the nociceptive fibers in the skin of the test areas. 
OA responses were reduced or absent with delayed offset and relatively small 
decreases in VAS scores after the minor decrease in temperature (Figs. 5 and 6). 
Pain was scored as would be expected from the decrease in temperature, instead 
of a disproportionally large decrease in pain scores, as was observed in healthy 
controls. On average, the ΔeVASc was 56% in patients versus 98% in controls. The 
receiver-operating characteristic analysis yielded a ΔeVASc cutoff of 0.88 (88%, 
Fig. 7) with a sensitivity and specificity of 90%, indicating that OA is reliably 
discernable between NP patients and healthy volunteers. The alterations in the 
OA responses observed in the patients indicate the inability to modulate changes 
in pain stimulation with perseverance of pain perception where healthy subjects 
display strong analgesia. 
The study included a rather small number of patients, so we cannot exclude a 
type I statistical error. However, of the 90 OA control tests performed in the pa-
tients, OA was reduced or absent in 90%. In addition, in a distinct set of patients 
with complex regional pain syndrome type 1, similar reduced OA responses 
were observed (oral communication June 6, 2011; Marieke Niesters MD MSc, 
Department of Anesthesiology, Leiden University Medical Center, Leiden, The 
Netherlands), suggestive of a common defect in OA responses in patients with 
chronic pain. We cannot exclude the possibility that this OA response was an 
effect of the medications used by our patients. Although no systematic effect of 
any medication was observed (data not shown), the numbers are small and no 




effect of medication (including those used in the current study) on the magni-
tude and development of OA responses. Moreover, in line with our study, most 
published data on quantitative sensory testing in NP patients is with patients re-
ceiving medication. Additional studies are required to assess the effect of drugs 
such as pregabalin, gabapentin, antidepressants and anticonvulsants on OA re-
sponses.
The mechanism of the differences in OA responses between NP patients and 
healthy controls was not addressed in our study. OA in our study may have 
been affected at peripheral (due to ‘preclinical’ peripheral nerve damage) and/
or central sites (e.g. spinal cord and supraspinal sites). There is evidence that var-
ious chronic pain states are linked to dysfunctional endogenous pain control, as 
tested by DNIC (such as complex regional pain syndrome type 1, irritable bow-
el syndrome, fibromyalgia, temperomandibular disorder, rheumatoid arthritis 
and chronic pancreatitis).8-11 It is currently unknown whether DNIC and OA are 
both dysfunctional in NP patients. The large placebo effect that we observed is 
of interest here (Fig. 7), since top-down modulatory pathways underlie the phe-
nomenon of placebo-induced analgesia.8 Neuroimaging techniques established 
that the placebo response is mediated via cortical and subcortical regions also 
involved in endogenous pain control.20 This suggests that central pain pathways 
common to OA and placebo responses remained intact in our set of SFN pa-
tients. This then implies a peripheral rather than a central mechanism involved 
in the altered OA responses in chronic pain and SFN. In contrast, the altered 
OA responses were obtained at (clinically) normal skin with normal nociceptive 
sensations, suggesting a more generalized and central origin of the altered OA 
responses in our patients. Additional studies are required to assess the location 
of the altered OA responses in NP patients.
Treatment effects
All treatments caused an analgesic effect on spontaneous pain scores with the 
largest effect observed for ketamine followed by morphine and placebo (Fig. 8). 
The analgesic effect from ketamine persisted for at least 24 hours, whereas those 
of morphine and ketamine effect lasted approximately 2 hours (data not shown). 
A prolonged analgesic effect of ketamine in NP states has been described be-
fore and is related to blockade of sensitized N-methyl-D-aspartate-receptors by 
ketamine.21,22 In contrast to spontaneous pain, no effect was observed on OA re-
sponses from treatment with ketamine, morphine or placebo (Fig. 9). In healthy 
volunteers OA is similarly unaffected by ketamine.4 These data indicate that the 
N-methyl-D-aspartate and μ-opioid receptors are less likely to be involved in OA 
mechanisms at central or peripheral sites. Alternatively, OA restoration may re-
quire long-term drug treatment. 
Conclusions
In conclusion, we showed the presence of OA in a large healthy study population. 
OA was reduced or absent in patients with chronic NP with SFN that remained 
unaffected by treatment with ketamine, morphine or placebo. The abnormal 
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OA responses in patients with chronic pain indicate their inability to modulate 
changes in pain stimulation with perseverance of pain perception where healthy 
subjects display strong analgesia. Whether the altered OA responses contribute 
to the pain being chronic or are a consequence of the chronic pain process re-
mains unknown and requires additional study.  
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Normal pain processing involves the modulation of pain signals in the central 
nervous system by activation of endogenous inhibitory (analgesic) or facilitatory 
(algesic) mechanisms.1-3 These modulatory mechanisms allow optimal function-
ality in response to an acute painful insult.4 For example, activation of endoge-
nous inhibition of pain allows for an evolutionary well-preserved fight or flight 
response;5,6 facilitation of pain responses puts the emphasis on tissue damage 
and forces an individual to seek rest and/or medical attention.6 In recent years, 
various experimental (surrogate) expressions of endogenous modulation of pain 
gained increasing interest in chronic pain research. Conditioned pain modulation 
(CPM, formerly known as diffuse noxious inhibitory controls or DNIC) has been 
investigated most intensively and induces central inhibition of a focal pain stim-
ulus by administering a second noxious stimulus at a remote area.7,8 In contrast 
to animals, where endogenous inhibition involves activation of a spinal-medul-
lary-spinal feedback loops (i.e. DNIC),9 in humans more complex supraspinal 
mechanisms also plays an important role (i.e. CPM).7,10 Absent or impaired CPM 
responses have been observed in several chronic pain states.8,11-13 Defects in CPM 
possibly reflect the inability to engage descending inhibition, either causing the 
perseverance of pain symptoms or possibly even leading to the development of 
chronic pain. For example, recent animal data show that less efficient descending 
inhibition is associated with a high probability of chronic pain development fol-
lowing peripheral nerve injury.14,15 
Few studies address the effect of analgesic medication on CPM responses in 
chronic pain patients. It can be hypothesized that chronic pain patients may ben-
efit from analgesics that enhance descending inhibition as measured by CPM.14,16 
A recent study showed that duloxetine-induced improvement of CPM respons-
es correlated with drug efficacy in patients with painful diabetic neuropathy.16 
Hence, the positive effect of analgesics on CPM might have a predictive effect on 
their ability to cause (long-term) analgesia. In the current study, we assessed the 
effect of morphine and ketamine on CPM responses in a group of patients with 
chronic painful peripheral neuropathy. Both treatments are effective in chronic 
pain patients, but their effects on CPM responses have only been tested in volun-
teers but not in chronic pain patients. We hypothesized that both drugs enhance 
CPM responses and that the magnitude of these responses correlates positively 
with the magnitude and duration of spontaneous pain relief.
Methods 
Approval of the study was obtained from the local human ethics committee, 
and written informed consent was obtained from all subjects. The study was 




Influence of morphine and ketamine on CPM in chronic pain patients
Subjects
Ten patients with chronic pain were recruited to participate in the study. They 
were diagnosed with chronic peripheral neuropathic pain and included on the 
basis of their symptoms, the results of quantitative sensory testing (QST) and a 
neurological examination.17-19 Subjects were required to have at least two of the 
following symptoms in legs, arms or both (in a stocking-glove distribution): (i) 
symmetrical dysesthesias or paresthesias; (ii) burning or painful feet with night-
time worsening; or (iii) peripheral tactile allodynia. With respect to the QST the 
patients were included if they had an abnormal warm and cold detection thresh-
old, an abnormal warm and cold pain threshold, or allodynia. 
Before participation, all subjects underwent a physical examination. Exclusion 
criteria for the study were: age < 18 years or > 80 years; presence or history of 
a medical disease such as renal, cardiac, vascular (including hypertension) or 
infectious disease; presence or history of a neurological and psychiatric disease 
such as increased cranial pressure, epilepsy or psychosis; glaucoma; pregnancy; 
obesity (body mass index > 30 kg/m2); or the use of strong opioid medication. 
Subjects were allowed to continue the following pain medications as long as they 
used a constant dose for at least 3 months before the start of the study and could 
be kept constant during the whole study period: acetaminophen, non-steroidal 
anti-inflammatory drugs, amitriptyline, gabapentin and pregabalin. 
Pain assessment and CPM
As examined by Pud and collegues,7 noxious cold water is the most used pain 
modality as a conditioning stimulus combined with different pain modalities as 
test stimulus. We applied a heat pain stimulus as test stimulus and cold water as 
conditioning stimulus, in agreement with earlier studies from our laboratory and 
from King and colleagues.8,20 The test stimulus was a noxious thermal stimulus 
applied to clinically normal skin of the volar side of the non-dominant forearm 
(with normal warm and cold thresholds). The skin was stimulated with a 3 × 3 
cm thermal probe of the Pathway Neurosensory Analyzer (Medoc Ltd., Ramat 
Yishai, Israel). During the heat pain stimulus, subjects continuously quantified 
the pain intensity level of the stimulus using a slider on a computerized poten-
tiometer that ranged from 0 (no pain) to 100 (worst pain imaginable), which al-
lowed continuous, electronic monitoring of the visual analogue scale (eVAS). 
To overcome sensitization, a 3-minute interval was incorporated between tests 
and the volar side of the arm was divided into three zones.8 The thermode was 
moved from zone to zone between stimuli. The test stimulus was obtained by 
gradually increasing the thermode temperature from baseline (32 ℃) to the test 
temperature (at 1.5 ℃/s). When the test temperature was reached it remained 
constant for 30 seconds. Next, the temperature rapidly decreased (at 6 ℃/s) to 
baseline.
Before the test, individual test and conditioning temperatures were determined. 
For the test stimulus, a series of heat stimuli was applied. Baseline temperature 




tures ranging from 42 ℃ to 49 ℃ for 10 seconds. The temperature evoking an 
eVAS of at least 50 mm was set as test temperature and used during the remain-
der of the study for the experimental stimulus. Before testing, the thermode was 
calibrated using a surface thermometer (K-Thermocouple thermometer, Hanna 
Instruments, Woonsocket, RI).
The conditioning stimulus was cold water immersion in a cold-water bath which 
was filled and temperature adjusted using a rapid-water cooling system (IcyDip, 
IcySolutions BV, Delft, The Netherlands).20 The subject’s foot and lower leg was 
immersed into the cold water reservoir, which could be set at different tempera-
tures ranging from 6 ℃ to 18 ℃. The temperature that produced an eVAS of at 
least 30 mm was used in the study for the conditioning stimulus. After exposure 
to cold water, the subject’s extremity was immediately warmed to normal tem-
perature using the warm water reservoir of the IcyDip system.
To measure CPM, eVAS responses to the test stimulus were obtained without (n 
= 3) and with the conditioning stimulus (n = 3).8,20 The conditioning stimulus was 
applied 25 seconds before the start of the test stimulus and ended simultaneous-
ly with the end of the test stimulus. The subject was instructed to only rate the 
pain intensity level of the test stimulus with the eVAS slider. 
Study design
Each subject visited the laboratory on three days, at least 2 weeks apart, in which 
placebo, morphine and ketamine were tested using a double-blind, randomized 
cross-over study design. Initially, CPM was measured without treatment (base-
line values). After a break, intravenous treatment was given (infusion duration 1 
hour), and 20 minutes later, the CPM responses were repeated. Treatments were 
as follows: (A) a 1-hour intravenous infusion of 0.57 mg/kg S(+)-ketamine (Ke-
tanest-S, Pfizer BV, Capelle a/d IJssel, The Netherlands); (B) morphine bolus of 
0.05 mg/kg followed by 0.015 mg/kg per hour for 1 hour (Morphine HCl, Phar-
machemie BV, Haarlem, The Netherlands); and (C) a 1-hour placebo (0.9% NaCl) 
infusion. 
Disease-related pain
The effect of treatment on disease-related pain or spontaneous pain scores was 
measured after treatment on a 0 – 10 numerical rating scale (NRS). Subjects were 
contacted after their treatment to determine the duration of pain relief. An arbi-
trary distinction was made between pain relief lasting 0 – 6 hours post treatment, 
6 – 12 hours post treatment and 12 – 24 hours post treatment. 
Data and statistical analyses
The difference between the eVAS response to the test stimulus without and with 
conditioning stimulus is the generated CPM. The eVAS data were averaged over 
1-second periods. To quantify CPM, the area under the curve (AUC) of each 
eVAS response was calculated. For analysis of the relative amount of CPM, the 
mean of the three AUC responses per condition was calculated (i.e. the mean of 
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the 3 AUCs without conditioning stimulus and the 3 AUCs with the conditioning 
stimulus). The percentage of CPM (CPM%) was calculated as: CPM% = [(mean 
AUC without CS stimulus – mean AUC with CS)/(mean AUC without CS)] × 100 
(i.e. corrected for the variation in the magnitude of the peak response between 
sessions and between subjects). The drug study was powered to detect a sig-
nificant difference between treatment effects on CPM%. Assuming a difference 
between groups of 20% (derived from previous data)20 with SD 10%, α = 0.05 and 
power = 0.9, we estimated a groups size of 10 (SigmaPlot v12, Systat Software 
Inc., Chicago IL, USA). A linear mixed model was used to compare the AUCs of 
the eVAS responses with and without conditioning stimulus within each exper-
imental session. The effect of treatment on CPM% and spontaneous pain scores 
was tested by one-way analysis of variance with post-hoc Bonferroni correction. 
Statistical analysis was performed in SigmaPlot version 12.0 for Windows (Systat 
Software Inc., Chicago IL). p-values < 0.05 were considered significant. Data are 
presented as mean ± SEM unless otherwise stated.
Results
Subjects
All 10 subjects completed the protocol without major side effects. The study pop-
ulation included two men, eight women, and had a mean age of 54.4 ± 4.2 years 
Figure 1. Quantitative sensory testing. The test site was the site most affected by pain (either hand 
or foot; orange symbols), the control site was the face (blue symbols). Data are the population mean 
z-scores ± SEM. Z-scores were calculated in relation to a population of healthy subjects as deter-
mined by Rolke and collegues.39 The horizontal broken lines indicate the +2 and -2 z-score bound-
aries. A specific QST test is considered abnormal if the test value lies above the upper or below the 
lower boundary. CDT: cold detection threshold; WDT: warm detection threshold; TSL: thermal 
sensory limen; PHS: paradoxal heat sensation; CPT: cold pain threshold; HPT: heat pain threshold; 
MDT: mechanical detection threshold; MPT: mechanical pain threshold; MPS: mechanical pain 
sensitivity; ALL: dynamic mechanical allodynia; WUR: windup ratio; VDT: vibration detection 




and mean weight of 83.6 ± 7.6 kg. All suffered from chronic neuropathy with 
signs of mixed small and large fiber neuropathy on the QST (significant abnor-
malities in cold detection threshold, warm detection threshold, paradoxal heat 
sensation and vibration detection threshold (Fig. 1). The patients were diagnosed 
with diabetes mellitus (n = 4), sarcoidosis (n = 2) and Sjögren’s syndrome (n = 
1). In three subjects the origin of the pain was unknown. Feet were affected in all 
subjects; in four subjects the hands were affected as well. Subjects used the fol-
lowing medication during the study: acetaminophen, non-steroidal anti-inflam-
matory drugs, gabapentin, pregabalin and amitriptyline.
CPM responses
Average test and conditioning stimulus temperatures were 45.1 ± 0.1 ℃ and 9.8 
± 1.0 ℃, respectively. At baseline, the average eVAS scores were 43.0 ± 2.4 mm 
and after treatment 49.0 ± 3.4 mm, 50.1 ± 2.9 mm and 51.1 ± 2.9 mm for ketamine, 
morphine and placebo, respectively. No significant CPM responses were detect-
ed before treatment: AUC without conditioning stimulus 1180 ± 71 mm·sec com-
pared with AUC with conditioning stimulus 1080 ± 79 mm·sec (p > 0.05). After 
all three treatments, significant CPM was detected indicating an inhibitory effect 
of the cold water conditioning stimulus on the experimental heat pain stimulus. 
Placebo AUCs were reduced by the conditioning stimulus from 1241 ± 209 to 862 
± 135 mm·sec (p = 0.001); morphine AUCs were reduced from 1503 ± 224 to 1049 
± 185 mm·sec (p < 0.001); ketamine reduced the AUCs from 1352 ± 118 to 809 ± 
159 mm·sec (p = 0.000) (Fig. 2A). Ketamine caused the largest increase in CPM: 
mean CPM% after placebo 22.1 ± 12.0% (95% confidence interval (95% CI): -5.1 – 
Figure 2. A. AUC values of the eVAS-time responses without conditioning stimulus (–) and with 
conditioning stimulus (+).  The conditioning stimulus had no effect on baseline responses, but de-
creased eVAS responses after treatment with placebo, morphine and ketamine. * p < 0.001 vs AUC 
of eVAS-time responses without conditioning stimulus. AUCs of responses without the condition-
ing stimulus were similar for baseline, placebo, morphine and ketamine. NS = not significant. B. 
Magnitude of conditioned pain modulation (CPM%) responses after treatment with placebo (Plc), 
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49.3), after morphine 28.5 ± 7.0% (95% CI: 12.8 – 44.3) and after ketamine 40.2 ± 
10.9% (95% CI: 15.6 – 64.6); however no difference in CPM enhancement could be 
detected between the three treatment groups (p > 0.05, see also Fig. 2B).
Pain relief and magnitude of CPM
The mean NRS at baseline was 6.2 ± 0.5. In terms of magnitude, pain relief was 
greatest after ketamine (mean NRS after treatment: 0.3 ± 0.3, p < 0.01 vs. baseline), 
followed by morphine (1.8 ± 0.7) and placebo (3.2 ± 0.7). In terms of duration 
of effect, ketamine had effects lasting > 12 hours in eight of 10 subjects and > 
6 hours in the remaining two subjects. Morphine had effects lasting > 12 hours 
in zero of 10 subjects, > 6 hours in eight of 10 subjects and < 6 hours in the re-
maining two subjects. After placebo treatment all analgesic effects had dissipated 
within 6 hours of treatment. The magnitude of CPM correlated positively with 
the magnitude of pain relief (Fig. 3) and duration of spontaneous pain relief.
Side effects after analgesic treatment
Minor side effects occurred with nausea in four subjects (two of whom vomited) 
during ketamine infusion and in seven patients (four of whom vomited) during 
morphine infusion. No nausea or vomiting was observed during placebo infu-
sion. At the end of the infusion, the mean drug high scores were 7.2 ± 0.6 for 
ketamine, 2.4 ± 0.5 for morphine and 0.4 ± 0.2 for placebo. 
Discussion
We tested CPM responses in a relatively homogenous population (in terms of 
QST abnormalities) of subjects with chronic pain related to peripheral neuropa-
thy. The main findings of our explorative studies are that CPM responses were 
not detectable in this patient population, but that treatment with ketamine, mor-
phine and placebo caused activation of CPM responses (p < 0.001). The magni-
Figure 3. Conditioned pain 
modulation (CPM% respons-
es) versus spontaneous pain 
ratings in chronic pain pa-




tude of CPM responses correlated positively with the magnitude and duration of 
spontaneous pain relief.
Descending inhibitory and facilitatory pathways involved in the modulation of 
pain originate at higher sites in the CNS including the prefrontal cortex, rostral 
anterior cingulate cortex (rACC) and insula, which project to the periaquaductal 
gray and rostral ventromedial medulla (RVM) and modulate nociceptive input 
at the level of the dorsal horn.1-4,6 Activation of inhibitory pathways will reduce 
trafficking of nociceptive input to supraspinal sites involved in pain processing 
and perception. Activation of facilitatory pathways will have the reverse effect. A 
shift in the balance between inhibition and facilitation has been suggested as an 
underlying mechanism in the development or maintenance of pain.20 There are 
various expressions of descending inhibitory pain modulation, including place-
bo and stress-induced analgesia and CPM.3,21,22 CPM is considered to be a central 
mechanism with activation of specific brain regions involved in descending in-
hibition.23,24 
Dysfunctional endogenous pain modulation (as tested by CPM or CPM-like par-
adigms) has been observed in several chronic pain states.8,11-13,25 In our current 
study we included patients with chronic (poly)neuropathic pain (from mixed 
small and large fiber neuropathy who all displayed abnormal CPM responses. 
Previous studies in healthy volunteers showed that females have less efficient 
CPM responses compared to males and that CPM efficiency decreases with in-
creasing age (starting at middle-age).26-29 Indeed, in a separate set of healthy peo-
ple of similar age and sex as our current study population, we did not observe 
significant CPM responses (M. Niesters, unpublished observation). Since the pa-
tient population in this study was predominantly middle-aged and female, CPM 
responses were a priori not expected or were at least assumed to be small. Our 
data and those of others indicate that patients of 40 years and older (especially 
females) have absent of less activated pain modulation mechanisms (compared 
to younger patients) and are therefore at a disadvantage in situations where a 
functional descending inhibitory mechanism is necessary for normal pain per-
ception. Consequently, in response to a noxious insult, pain may be more severe 
and persistence of pain may occur, which possibly is one of the factors involved 
in the development of chronic pain. There is indeed evidence from animal stud-
ies for a link between chronic pain development and efficacy of descending in-
hibitory pain pathways. Animals with more efficient engagement of descending 
inhibition show a reduced probability of peripheral nerve injury-induced chron-
ic allodynia compared with animals with less efficient descending inhibition.14,15
A novel observation in our study is that CPM responses in neuropathic pain pa-
tients could be re(activated) after pharmacological treatment and that ketamine, 
morphine and placebo were equally effective in this respect. The large effect of a 
1-hour intravenous treatment with placebo was not unexpected. There is ample 
evidence that activation of descending pain control underlies placebo-analge-
sia, via central opioidergic mechanisms.22,30 For example Levine and collegues30 
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showed that placebo analgesia is abolished by the opioid receptor antagonist 
naloxone. Furthermore, animal research demonstrated that remifentanil and pla-
cebo analgesia both activate brain areas involved in descending inhibition in-
cluding the rACC.31
An important finding in our study is that there was a significant correlation be-
tween the magnitude of CPM responses and the magnitude (and duration) of 
spontaneous pain relief (Fig. 3). As stated by De Felice and collegues,14 such find-
ings provide a mechanistic explanation for medications that engage descending 
inhibitory control or mimic its consequences and cause efficient and long-term 
pain relief, such as we observed after treatment with ketamine. To the best of our 
knowledge our study is the first to show that morphine enhances CPM responses 
in chronic neuropathic pain patients. Recently, Arendt-Nielsen and collegues32 
tested the effect of two opioid analgesics (fentanyl and buprenorphine transder-
mal patches) on CPM in healthy volunteers and showed enhanced responses af-
ter treatment. In contrast to these and our data, others observed that morphine 
reduces rather than increases CPM responses in healthy volunteers (after an in-
travenous infusion of 0.05 mg/kg) and non-neuropathic chronic pain patients 
(after prolonged opioid treatment).33,34 We have no conclusive explanation for 
these differences in the effect of opioid treatment on CPM engagement. Involve-
ment of endogenous opioids in CPM engagement is inferred from studies show-
ing that naloxone reduces CPM.35 Furthermore, opioid receptors are expressed 
on neurons involved in pathways of descending pain modulation both at spinal 
and supraspinal sites.1-3
Similar to morphine, ketamine enhanced CPM responses in our patient popula-
tion. Ketamine has gained a position in the treatment of chronic pain, especially 
of therapy-resistant neuropathic pain.36 Ketamine treatment results in prolonged 
analgesia, with persistence of effect beyond the treatment period. For example, 
we showed previously that a 100-hour ketamine infusion (20-30 mg/h) results 
in pain relief up to 3 months after intravenous treatment in patients with com-
plex regional pain syndrome type 1.37 The mechanisms through which ketamine 
exerts these prolonged effects remain unknown. Possibly one of the factors that 
contribute to ketamine’s prolonged analgesic effect is desensitization of upreg-
ulated N-methyl-D-aspartate receptors within the spinal cord.37 Another mecha-
nism might be that ketamine activates endogenous pain modulatory pathways. 
The observation that ketamine produced greater analgesia than morphine (or 
placebo) in our patient population correlated with a greater ability to engage de-
scending inhibition as tested by CPM (Fig. 3). Recently, we assessed the effect of 
ketamine on brain function using the technique of resting-state functional mag-
netic resonance imaging. Ketamine altered connectivity in brain regions respon-
sible for pain sensing and the affective processing of pain, and also in regions 
involved in activation of descending inhibitory pain pathways, including the 
rACC, insula, orbitofrontal cortex and brain stem.38 These findings corroborate 




The effects of ketamine on CPM responses in chronic patients differ from results 
in volunteers.20 In a population of healthy young volunteers, ketamine shifted 
the balance between pain inhibition and pain facilitation towards pain facilita-
tion. Major differences between study populations (i.e. age and underlying dis-
ease) could be responsible for the difference in study outcomes. For example, 
in healthy volunteers, CPM responses may be at maximum strength such that 
treatment leads to activation of interfering pathways (facilitatory pathways). 
This may also explain the effect of morphine on CPM in healthy volunteers and 
possibly also in chronic non-neuropathic pain patients.33,34 We can also not ex-
clude that treatment at maximum CPM activates noise sources resulting in in-
consistencies in the data. 
Critique of methods
One might contend that no population of healthy age- and sex-matched controls 
was included to make a comparison of treatment effects between groups possi-
ble. However, as discussed above, healthy volunteers lack underlying disease, 
that is a primary hit (i.e. peripheral nerve damage) and possibly also secondary 
damage (i.e. a defect in the descending inhibitory control system) of their pain 
pathways. Although we believe that knowledge on the effect of treatment on 
CPM responses in volunteers is valuable on its own, we argue that a direct com-
parison between populations is of limited value, as treatment induced changes in 
CPM responses in volunteers may differ mechanistically from those in patients.
Subjects were allowed to continue their pain medication as long as they had used 
these drugs for at least 3 months and dosages were constant during the study 
period. Subjects that used pain medication did not have a larger (or smaller) en-
hancement of CPM responses compared with those that did not. Therefore, we 
do not believe that continuation of analgesics during the study period affected 
our outcome.
Finally, we tested a small group of predominant middle-aged female pain pa-
tients. While this reflects the majority of chronic pain patients in clinical practice, 
our study needs replication in younger patients (including males) with neuro-
pathic pain. This will further clarify the link between sex, age, defective CPM 
responses and chronic pain.
Conclusions
In chronic neuropathic pain patients with similar QST abnormalities, treatment 
with placebo, morphine and ketamine activated prior absent CPM responses, 
suggesting a role of engagement of descending pain inhibition in their analge-
sic efficacy. We suggest that in clinical practice, drugs that cause enlargement 
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Chapter 5
Tapentadol potentiates Descending Pain 
Modulation in Chronic Pain Patients 
with Diabetic Polyneuropathy
M. Niesters, P. Proto, L.P.H.J. Aarts, E.Y. Sarton, A.M. Drewes, A. Dahan





Endogenous pain modulatory pathways are important regulators of human pain 
perception. Both inhibitory and facilitatory descending pathways, originating at 
higher centers, modulate the activity of nociceptive neurons at the level of the 
spinal dorsal horn, enhancing or inhibiting noxious signal propagation to the 
brain.1 A shift in the balance between pain inhibition and facilitation has been 
suggested to underlie the development or maintenance of many chronic pain 
syndromes, such as fibromyalgia, irritable bowel syndrome, chronic pancreatitis 
and neuropathic pain syndromes.2-5 Animal studies show that effective engage-
ment of descending inhibition protects against chronic neuropathic pain devel-
opment.9 Various neurotransmitter systems are involved in the descending pain 
pathways including endogenous opioid peptides, noradrenaline (NA) and sero-
tonin. Release of endogenous opioids and noradrenaline underlie pain inhibi-
tion, whereas the serotonergic pathway has both pain inhibitory and facilitatory 
properties.7,8 The new analgesic tapentadol is a centrally acting drug with a dual 
mechanism of action. Tapentadol is a weak μ-opioid receptor (MOR) agonist (its 
affinity for the MOR is 50 times less than that of morphine) and inhibits neuro-
nal reuptake of noradrenaline.9,10 Both mechanisms act synergistically to produce 
analgesia.11 Animal studies indicate that the opioidergic component is more im-
portant in the treatment of acute pain, whereas the noradrenergic component is 
largely involved in the treatment of chronic neuropathic pain.8 
As tapentadol modulates opioidergic and noradrenergic pathways simultane-
ously, the analgesic effect of tapentadol is thought to rely on the enhancement of 
descending pain inhibitory activity.12 However, up to know, no studies have been 
conducted to confirm the presence of such an effect in humans. In the current 
study the effects of tapentadol on two experimental paradigms, conditioned pain 
modulation (CPM) and offset analgesia (OA) were tested in chronic pain patients 
with diabetic polyneuropathy (DPN). CPM is an experimental measure of en-
dogenous pain modulation that gates incoming pain signaling as consequence of 
a preceding or simultaneous tonic painful stimulation.13-18 OA is a test in which 
a disproportionally large amount of analgesia becomes apparent upon a slight 
decrease in noxious heat stimulation.19,20 Both tests have been used previously to 
evaluate the engagement of pain modulatory pathways.4,15,20 
We performed a randomized, parallel-design, placebo-controlled study in chron-
ic pain patients with diabetic polyneuropathy on the effect of a 4-week tapen-
tadol treatment on CPM, OA and pain relief. We hypothesize that tapentadol’s 
analgesic efficacy relies, in part, on the engagement of endogenous pain inhibi-
tory pathways.
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Methods
Chronic pain patients were recruited to participate in the study performed at 
Leiden University Medical Center over the period January 2012 to October 
2012, after approval of the protocol was obtained from the local Medical Ethics 
Committee and the Central Committee on Research involving Human Subjects 
(CCMO, The Hague, The Netherlands). The study was registered at the Dutch 
trialregister under number NTR2716 and has EudraCT number 2010-012175-26. 
The study was registered as an addendum to an earlier trial on the effects of a 
single dose of tapentadol and morphine on CPM. All participants gave written 
informed consent and underwent a physical examination before enrollment in 
the study. 
Patients were recruited via an advertisement in the journal of the national diabet-
ic society. All recruited patients had diabetes and chronic pain in hands and/or 
legs and feet. They were included in the study when they were 18-75 years, had a 
body mass index below ≤ 40 kg/m2 and had: (1) presence of at least two of the fol-
lowing symptoms in legs and/or arms (in a stocking-glove distribution): (i) sym-
metrical dysesthesias or paresthesias, (ii) burning or painful feet with nighttime 
worsening or (iii) peripheral tactile allodynia; and (2) an abnormal warm or cold 
detection threshold, an abnormal warm or cold pain threshold, or allodynia ob-
served with quantitative sensory testing. Exclusion criteria included: indication 
of the presence of severe medical diseases (e.g. liver function elevation); allergy 
to opioids; current use of benzodiazepines and/or other sedatives; present or 
past use of illicit/recreational substances; present or past alcohol abuse; history 
of mental illness or epilepsy; pregnancy and/or lactation; current use of strong 
opioids; and inability to understand the purpose and instructions of the study. 
The patients were allowed to continue the following pain medications as long as 
they used a constant dose for the 8 weeks prior to the study and the dosage could 
be kept constant during the whole study period: acetaminophen, non-steroidal 
anti-inflammatory drugs, amitriptyline, gabapentin and pregabalin. Patients that 
had been using opioids previously (and terminated treatment due to absence of 
efficacy or side effects) were eligible for inclusion. 
Study design
This randomized, double blind, placebo-controlled study was performed in 24 
DPN patients (see Consort flow chart, Fig. 1). Twelve patients were treated orally 
for 4 weeks with tapentadol slow release (SR), twelve others with placebo. The 
dose of tapentadol SR was titrated to effect starting with 100 mg twice daily in 
week 1, followed by 200 mg twice daily in week 2 and 250 mg twice daily in 
week 3 and 4. In case of the presence of side effects unacceptable to the patient, 
the tapentadol dose was decreased to a dose were side effects were absent or 
acceptable. All patients were tested twice, once 1 day before the treatment period 
and once on the last day of treatment. On each study day, the subjects were famil-
iarized with the test procedures. Next the CPM and OA responses were obtained. 




(corresponding with no pain) to 10 (corresponding with most imaginable pain)) 
and side effects (presence of nausea, vomiting, drowsiness, dizziness and dry 
mouth, using a dichotomous scale (yes/no)) were monitored on a weekly basis.
To get an indication of the nerve-fiber involvement in the patient population, 
quantitative sensory testing (QST) was performed according to the standardized 
protocol of the German Research Network on Neuropathic Pain.21 In short, this 
protocol assesses cold, heat and mechanical detection and pain thresholds; par-
adoxical heat sensations; mechanical pain sensitivity; allodynia; wind-up and 
vibration and pressure pain thresholds. Sensory testing was performed on the 
hand and foot of all pain patients included in the study. 
Application of nociceptive stimuli for CPM and OA testing
Heat pain was induced on the lower part of the non-dominant arm with a 3 x 
3 cm thermal probe connected to the Pathway Neurosensory Analyzer (Medoc 
Ltd., Ramat Yishai, Israel). The probe was calibrated according to the specifica-
tions of the manufacturer. During the heat pain stimulation, subjects continuous-
ly quantified the pain intensity level of the stimulus using a slider on a computer-
ized potentiometer that ranged from 0 (no pain) to 100 (worst pain imaginable). 
This allowed for continuous monitoring of the visual analogue scale (eVAS). To 
overcome sensitization, the thermode was moved between different zones on 
the forearm and ample time was incorporated between the different heat stim-
uli. On each of the two study days (that is before treatment and at 4-weeks of 
treatment), the individual test temperature was determined by applying a series 
Figure 1.  Consort study flow chart.
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of heat stimuli. First the temperature was increased from 32 ℃ (baseline tem-
perature) by 1.5 ℃/s to a target temperature of 42 ℃ and kept constant for 10 
seconds. If the eVAS was less then 50 mm a next test was performed increasing 
the target temperature in steps of 1 ℃. The cut-off temperature for these series 
was 49 ℃. The temperature evoking an eVAS of at least 50 mm was used during 
the remainder of the study.
Cold pain was induced using a cold-water reservoir produced by a rapid wa-
ter-cooling system (IcyDip, IcySolutions BV, Delft, The Netherlands). The sub-
ject’s foot and lower leg was immersed into the cold water reservoir, which could 
be set at different temperatures ranging from 6 ℃ to 18 ℃. The temperature that 
produced an eVAS of at least 30 mm was used in the remainder of the study. 
After the exposure to cold water, the subject’s extremity was warmed to normal 
temperature using warm water collected from the counter-current outlet of the 
IcyDip system.
Conditioned pain modulation and offset analgesia
The method to induce CPM has been published previously.2,4,15 In short, to mea-
sure CPM two series of three pain tests were performed. One series included 
stimulation of the forearm with the experimental stimulus (heat pain). For this, 
the temperature of the heat probe gradually increased from baseline temperature 
(32 ℃) to the earlier set test temperature (at 1.5 ℃/s) and remained constant 
for 30 seconds. Next, the temperature rapidly returned (at 6 ℃/s) to baseline. 
The second series included stimulation with both the experimental stimulus and 
the conditioning stimulus (cold pain). The conditioning stimulus was applied 25 
seconds before the start of the experimental stimulus and ended simultaneously 
with the end of the experimental stimulus. In both sessions the subject’s only 
rated the pain intensity level of the experimental stimulus (heat pain on the arm). 
There were 3-minute intervals between single tests. 
OA was studied by applying a three-temperature paradigm as described by Grill 
et al.19 The temperature was ramped at 1.5 ℃/s from baseline temperature to the 
previously set test temperature. The test temperature was kept constant for 5 sec-
onds after which it was raised by 1 ℃ for 5 seconds and next decreased by 1 ℃ 
for 20 seconds. At the end of the test the temperature quickly returned (6 ℃/s) 
to baseline. This temperature paradigm was applied three times with a 3-min 
interval between tests. 
Randomization and blinding
Randomization and allocation was performed by the local pharmacy using a 
computer-generated randomization list. Placebo tablets were fabricated by the 
pharmacy and were identical to the tapentadol tablets in form, size and taste. 
The tablets were repackaged into unmarked containers and delivered to the re-
search team and subsequently by the research team to the patients. The research 






To quantify the magnitude of CPM, peak eVAS scores were used in the analyses. 
For each subject, the average peak eVAS without and with conditioning stimulus 
(CS) was calculated. Next, relative CPM responses were calculated to correct for 
variations in peak response between sessions and subjects using the formula: 
[(mean eVAS without CS stimulus – mean eVAS with CS)/(mean eVAS without 
CS)] × 100%.2,26,27 
OA responses were quantified as previously described.15,20 In short, the decrease 
in eVAS from the peak eVAS value to the eVAS nadir following the 1 ℃ decrease 
of the test stimulus was measured (ΔeVAS) and corrected for the value of the 
peak eVAS: ΔeVASc = [ΔeVAS/(peak eVAS)] x 100%. 
Sample size and statistical analysis
A sample size of 24 (12 per treatment level) was calculated by assuming an in-
crease in CPM of 20% (15%) (mean (SD)) with α = 0.05 and β > 0.95. An effect of 
20% was chosen as this constitutes the “average” value of CPM in healthy volun-
teers and is probably the maximum magnitude of CPM attainable in humans.15 
Table 1. Patient characteristics
Tapentadol Placebo
Men/Women (n) 7/5 7/5
Age (years; median (range)) 63 (54 - 75) 62 (53 - 71)
Weight (kg; median (range)) 95 (56 - 140) 97 (71 - 125)
Height (cm; median (range)) 177 (169 - 196) 178 (168 - 194)
Duration of disease
Diabetes mellitus (years; median (range)) 12 (3 - 35) 11 (2 - 45)
Neuropathic pain (years; median (range)) 6 (1 - 10) 6.5 (2 - 25)
Affected limbs
Legs (n) 8 8
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The effect of the conditioning stimulus on the relative eVAS responses was tested 
by two-tailed paired-t-test. Treatment effects were assessed by two-way repeated 
measures analysis of variance (factors: time and treatment). For all analyses, the 
software package SigmaPlot version 12.5 for Windows (Systat Software Inc., San 
Jose, CA) was used. Data are presented as mean ± SEM unless otherwise stated 
and p-values < 0.05 were considered significant.
Results
Eighty-seven patients responded to the advertisement (Fig. 1). Thirty-one decid-
ed not to participate after they were informed on the nature of the study. Thir-
ty-one others were excluded because of absence of pain, diabetes or neuropathy 
(as assessed by QST), not meeting age- or body mass index-related inclusion cri-
teria, the use of strong opioids or their inclusion in another trial. Twenty five 
subjects were enrolled in the study and randomized. One patient retracted her 
consent after randomization; she was replaced by another subject. The demo-
graphics of the participating patients are given in table 1. 
All patients completed the study without major side effects. QST measurements 
obtained from affected hands and feet are presented in figure 2. The patients 
presented with a mixed small- and large fiber neuropathy as evidenced by re-
Figure 2. Results of the quantitative sensory tests obtained on the affected skin areas (hand/feet). 
The data are the populations mean z-scores (SEM). Z-scores were calculated in relation to a popu-
lation of healthy subjects as determined by Rolke et al.21 Z-values above the broken line indicate a 
gain of function whereas values below this line are indicative for a loss of sensory function. CDT: 
cold detection threshold; WDT: warm detection threshold; TSL: thermal sensory limen; PHS: para-
doxal heat sensations; CPT: cold pain threshold; HPT: heat pain threshold; MDT: mechanical detec-
tion threshold; MPT: mechanical pain threshold; MPS: mechanical pain sensitivity; ALL: dynamic 





duced cold and warm detection thresholds and paradoxical heat sensation (signs 
of small fiber involvement) and a reduced vibration detection threshold (on the 
feet more than on the hands; a sign of large fiber involvement). Importantly, allo-
dynia was observed in 7 (of 24) patients. During the study period the daily drug 
dose was titrated to a level with sufficient analgesic effect and acceptable side 
effects to the patients. In the placebo group the maximum daily dose of 500 mg 
per day was reached in all subjects compared to an average of 433 ± 31 mg per 
day in the tapentadol SR group. Reported side effects were nausea (placebo: n = 
Figure 3. Relative CPM responses at baseline (before treatment), in patients receiving a 4-week 
placebo treatment and in patients receiving a 4-week tapentadol treatment. At baseline the effect of 
the conditioning stimulus was not significant (p = 0.09). After placebo and tapentadol treatment 
the effect of the conditioning stimulus was significant (placebo p = 0.04, tapentadol p < 0.01). A 
treatment effect was present with greater increase in CPM responses during tapentadol treatment 
than during placebo treatment (* p < 0.001 vs. placebo).
Figure 4. A. Average spontaneous pain scores of patients with painful diabetic neuropathy during 
the 4-week treatment period. There was a significant treatment effect with greater pain relief during 
tapentadol treatment (p = 0.03). B. Relative CPM responses versus pain scores. Values are mean 
± SEM.
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4; tapentadol: n = 3), vomiting (placebo: n = 0; tapentadol: n = 2), sedation (place-
bo: n = 2; tapentadol: n = 6), dizziness (placebo: n = 2; tapentadol: n = 6) and dry 
mouth (placebo: n = 1; tapentadol: n = 5).
Prior to treatment significant CPM responses were not detectable as the effect of 
the conditioning stimulus was not significant (CPM = 9.1 ± 5.4%, p = 0.09, Fig. 
3). Following both treatments CPM responses increased to significant levels (pla-
cebo: CPM = 14.3 ± 7.2%, p = 0.04; tapentadol SR: CPM = 24.2 ± 7.7%, p < 0.01). 
A clear treatment effect was present with tapentadol SR CPM responses being 
greater than placebo responses (p < 0.001, Fig. 3).
Weekly pain scores following tapentadol and placebo treatments are given in 
figure 4A. It shows a clear distinction in pain reduction in weeks 3 and 4 of treat-
ment with greater analgesia in patients treated with tapentadol SR (pain scores 
at baseline 6.5 ± 0.6 reduced to 4.8 ± 0.7 following placebo and 3.9 ± 0.6 follow-
ing tapentadol; 4-week treatment effect p = 0.03). Plotting pain relief versus CPM 
responses shows that greater pain relief from tapentadol SR coincided with en-
hanced CPM responses (Fig. 4B).
OA responses prior to tapentadol treatment and at week 4 of treatment are given 
in figure 5. As contrast, an example of an OA response in age and sex-matched 
healthy volunteer is added in figure 5A (data from ref. 20). ΔeVASc values in 
healthy volunteers in the age cohort 40-80 range between 90 and 100%, irrespec-
tive of sex.20 Prior to treatment ΔeVASc was 40.7 ± 7.4%. Neither placebo (change 
from baseline +2.6 ± 11.6%) nor tapentadol SR treatment (change from baseline 
-0.8 ± 3.7%) had an effect in the magnitude of OA (treatment effect p = 0.78).
Figure 5. Offset analgesia responses. A. An example of a healthy subject (female, 60 years). Data 
taken from ref. 20. B. Absence of tapentadol treatment on offset analgesia in painful diabetic neu-





Tapentadol is a new centrally acting analgesic agent for treatment of acute and 
chronic pain,12,22-25 that acts through MOR agonism and neuronal noradren-
aline reuptake inhibition (NRI).8-10,26 Through this dual mechanism of action it 
is thought that tapentadol engages and potentiates descending pain inhibitory 
pathways,12 although there are no human studies to substantiate this. We studied 
tapentadol’s effect on two experimental paradigms of endogenous pain modula-
tion (CPM and OA) in chronic pain patients with DPN. The main findings of our 
studies are that in DPN patients tapentadol SR caused significant pain relief that 
coincided with enhanced CPM responses. No effect of tapentadol was observed 
on OA responses. Taken these results we reason that relief of chronic pain in 
DPN patients by tapentadol is associated with engagement and potentiation of 
descending inhibitory pain pathways. 
Conditioned pain modulation
Modulation of pain in humans involves activation of higher cortical centers (pre-
frontal cortex, anterior cingulate cortex, insula), brainstem (periaquaductal gray, 
rostral ventromedial medulla) and descending pathways projecting to the dorsal 
horn of the spinal cord.1,27,28 These descending pathways may be inhibitory or ex-
citatory. Consequently, nociceptive input that enters the spinal dorsal horn will 
undergo some form of modulation, either facilitation or inhibition, which results 
in an amplified or inhibited pain sensation at central sites. Various chronic pain 
syndromes show loss of descending pain inhibition, including fibromyalgia, irri-
table bowel syndrome, chronic tension headache, temperomandibular disorder, 
complex regional pain syndrome and chronic pancreatitis.2-5 Of importance is the 
finding by De Felice et al. who showed in rodents that a genetic predisposition 
to activate descending inhibition protects against the development of chronic 
pain following peripheral nerve damage.6 In humans, examples of efficacious 
engagement of descending inhibitory pain modulation include placebo analge-
sia, stress-induced analgesia and CPM.16-18,29,30 CPM is an experimental and con-
sequently surrogate tool used to quantify descending pain inhibition in humans. 
Central inhibition of a focal noxious stimulus is induced by the administration 
of a noxious stimulus at a remote area (conditioning stimulus), thereby reducing 
the perception of the focal or test pain stimulus (“pain inhibits pain”).13,16 The 
central nature of CPM has been ascertained by the observation that specific brain 
regions involved in descending inhibition are activated during CPM-tests in vol-
unteers.31,32
Volunteer studies show that CPM engagement is less effective in women rela-
tive to men and that CPM efficacy is reduced in elderly people (starting at mid-
dle-age).33,35 Indeed in our middle-aged DPN patient population (mean age 59 
years) CPM was not present prior to the intake of study medication. Whether 
this is related to the underlying disease or an age-effect is unknown. Irrespective, 
individuals that are less able to activate CPM may have a higher probability of 
chronic pain development following a specific insult such as peripheral nerve 
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damage from diabetes (cf. De Felice et al.6) or surgery. Yarnitsky et al. showed that 
patients with less efficient CPM responses were at risk for development of chron-
ic post-thoracotomy pain.17 The method of induction of CPM has been validated 
previously by us in healthy volunteers and is applied and others in chronic pain 
patients.15,17 
Taken its mechanisms of action, tapentadol will interact within the descending 
modulatory system by activation of MORs and inhibition of neuronal noradren-
aline reuptake.7,8 Both neurotransmitter systems play an important role in the ac-
tivation of descending inhibitory pain pathways at supraspinal sites as well as in 
the spinal dorsal horn (at pre- and postsynaptic sites). See for an excellent review 
on this topic ref. 1. For example, animal studies show that activation of MORs 
on brainstem nociceptive “on-cells” will release the inhibition of brainstem noci-
ceptive “off-cells” that project to the spinal dorsal horn where nociceptive signal 
propagation is subsequently inhibited.1 Activation of spinal dorsal horn pre- and 
postsynaptic α2-adrenergic receptors will cause potent analgesic responses by 
inhibiting nociceptive afferent input. Such analgesic effects are observed after 
the intrathecal administration of the postsynaptic α2-adrenergic receptor ago-
nist clonidine.36 Although tapentadol displays weak MOP-receptor affinity, an-
imal studies show that its synergistic effect at MOP- and adrenergic-receptor 
systems will cause potent analgesic responses.9,10,26 Indeed, animal studies and 
clinical trials show that tapentadol is an effective analgesic in a variety of chron-
ic pain syndromes (for example osteoarthritis pain, low back pain, neuropathic 
pain).8,12,25,37,38 
We observed that the analgesic efficacy of analgesic treatment (tapentadol/pla-
cebo) was coupled to its effect on CPM (Fig. 4). A 4-week treatment with placebo 
caused small analgesic effects (ΔNRS = 1.7 cm) coupled to a modest increase in 
CPM (+14.3%), while tapentadol treatment caused a larger analgesic response 
(ΔNRS = 3.9) coupled to a large CPM response (+24.2%). This latter CPM value is 
similar to those observed in young healthy volunteers.14 These findings support 
a mechanistic role for the endogenous analgesia system in producing effective 
pain relief by tapentadol, possibly by its synergistic effect at MOP and α2-adren-
ergic receptors (see above). Yarnitsky et al.18 showed a coupling between drug 
efficacy and magnitude of CPM responses for duloxetine, a serotonin-noradren-
aline reuptake inhibitor (SNRI) in DPN patients with initially less effective CPM 
responses. While our small patient population, with initially minor or absent 
CPM responses benefited from the 4-week tapentadol SR treatment, we remain 
uninformed on the efficacy of tapentadol in chronic pain patients with “normal” 
CPM responses (i.e. responses of similar magnitude to those observed in young 
and healthy volunteers). Extrapolating the duloxetine data from Yarnitsky et al. 
would suggest that tapentadol is less effective in these patients. There is now am-
ple evidence to argue that in painful neuropathy patients with absent or reduced 
CPM, CPM responses may be reactivated or potentiated by analgesic treatment 





In chronic pain patients, the effect of tapentadol SR requires several weeks to 
develop (Fig. 3). Similar observations have been made for other S(N)RI-type of 
analgesics and tricyclic antidepressants.39 Hence, it is recommended to evalu-
ate the start of pain therapy with these agents not earlier than after 2 weeks of 
treatment.40 Taken the similarities of mechanisms of action among these analge-
sics, we argue that the slow accumulation of noradrenaline at its putative effector 
sites may be held responsible for its slow onset of action. Our findings stress the 
importance of the noradrenergic component in inducing tapentadol analgesia in 
chronic pain as was earlier observed in animal studies.8
Two patients in the tapentadol group used duloxetine (duration of treatment > 1 
year), a serotonin and noradrenaline reuptake inhibitor without opioidergic ac-
tivity. Theoretically, the use of this drug may have enhanced the CPM responses 
induced by tapentadol. However, prior to tapentadol treatment these patients 
had no detectable CPM response and the magnitude of their CPM response after 
the 4-week tapentadol treatment was well within the range observed in patients 
not on duloxetine. We argue that these two patients did not confound the results 
of our study. 
Offset analgesia
OA is a relatively novel model of endogenous analgesia that produces temporal 
alterations in pain processing. The phenomenon occurs when a small decrease 
(1 ℃) in temperature during noxious stimulation evokes a disproportionately 
large decrease in pain perception.19,20 We previously assessed OA responses in 
a large population of volunteers aged 6-88 years and observed response values 
ranging from 92-99%. It has been suggested that OA is of central origin as func-
tional imaging studies show that OA activation coincides with activation of brain 
regions involved in the central modulation of pain.41 However, it cannot be ex-
cluded that OA is initiated by dynamic responses of primary afferents or spinal 
processes. For example, Darian-Smith et al.42 reported that in monkeys the dis-
charge of heat-sensitive nerve fibers innervating the skin was nearly completely 
suppressed during a 10 second 1 ℃ cooling pulse from a baseline temperature 
of 39 ℃. A similar mechanism may occur during OA activation. A peripheral or-
igin of OA is further supported by the observation that central acting drugs such 
as opioids (tapentadol, morphine, remifentanil), opioid antagonists (naloxone) 
and NMDA receptor antagonists (ketamine) are unable to affect OA responses in 
volunteers and neuropathic pain patients.15,20,43 Finally, a recent observation that 
while offset analgesia is present on the forearm of healthy volunteers, it is absent 
on the palm of the hand further suggests that peripheral mechanisms are import-
ant in the development of offset analgesia.44
We reproduce our earlier observation that OA responses are absent or reduced in 
patients with peripheral neuropathy.20 The ΔeVASc values observed in the DPN 
patients were about 40% of those previously observed by us in healthy volun-
teers of the same age and sex.20 No improvement or alteration of OA responses 
was observed after the 4-week tapentadol treatment, which indicates that this 
69
Tapentadol potentiates CPM in patients with diabetic polyneuropathy
5
phenomenon of endogenous analgesia is without opioidergic or noradrenergic 
involvement. However, it may well be that the large and small nerve fiber dam-
age that was present in our current population prevented their ability to discern 
small changes in skin temperature and consequently prevented peripheral acti-
vation of OA. 
Conclusions
In conclusion, our results show that patients with DPN that display absent CPM 
responses benefit from tapentadol causing pain relief coupled to (re)-activation 
of descending inhibitory pain pathways.
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The noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ket-
amine has been used since the early 1960s as an anesthetic agent. It is the most 
potent NMDA receptor antagonist currently clinically available. At subanesthet-
ic concentrations, ketamine is a potent analgesic and is used in the treatment of 
acute and chronic pain.1 Ketamine use is hampered by central side effects, includ-
ing serious psychedelic effects.1 The influence of ketamine on central sites (i.e. 
within the central nervous system) has been investigated extensively with var-
ious imaging techniques, including positron emission tomography and task-re-
lated functional magnetic resonance imaging (fMRI).2-8 Several brain regions 
display ketamine-dependent activity changes. For example, during a short-term 
ketamine infusion, frontal and temporal brain regions are affected (these regions 
may be involved in the psychedelic effects of ketamine), as are several regions 
involved in pain processing, such as the anterior cingulate cortex, the insular 
cortex and the thalamus.3,4
Positron emission tomography and task-related fMRI studies have several dis-
advantages, including limited temporal and spatial resolution, radiation dose 
restrictions in positron emission tomography and the need to postulate an a 
priori hypothesis about the site of drug action for task-related fMRI. Further-
more, large-scale network interactions of brain regions on which central nervous 
system functions depend cannot be adequately captured with these techniques.9 
A new approach in central nervous system drug research is resting-state fMRI 
(RS-fMRI), which measures these intrinsic interactions at baseline activity of the 
brain (i.e. not task-related).10 This technique shows that spontaneous fluctuations 
in RS-fMRI signal form coherent networks (resting-state networks (RSNs)) that 
represent connections between brain areas of similar functionality.11,12 Studying 
drug effects on brain connectivity using RS-fMRI provides direct evidence of 
drug-induced changes in brain dynamics and consequently on brain function.
In the current study we test the effect of low-dose ketamine versus placebo in 
healthy volunteers using a crossover and randomized design. The effect of two 
doses of ketamine (or placebo) on RS-fMRI and on pain scores during noxious 
cutaneous heat stimulation is assessed. By incorporation of pain scores in the 
statistical model, we will be informed on the influence of both ketamine (i.e. 
intended effect and side effects) and pain processing on brain connectivity. We 
hypothesize that RS-fMRI is able to detect ketamine-induced alterations in large-
scale network patterns and will identify changes in connectivity for (1) brain ar-
eas involved in ketamine’s pharmacodynamic profile with respect to intended 
(analgesia) and side effects (most importantly psychedelic effects) and (2) areas 
involved in pain processing.
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Methods
Subjects
Twelve healthy male volunteers (age 19-36 years; body mass index: 21-27 kg/m2) 
were recruited to participate in the study after approval by the local ethics com-
mittee (Commissie Medische Ethiek, Leiden, The Netherlands). Oral and written 
informed consent was obtained from all participants and before participation 
all subjects received a physical examination. Exclusion criteria for participation 
were: age younger than 18 years or older than 45 years; a medical disease such 
as renal, liver, cardiac, vascular (including hypertension) or infectious disease; 
presence or history of a neurologic or psychiatric disease (e.g. increased cranial 
pressure, epilepsy, psychosis); glaucoma; obesity (body mass index greater than 
30 kg/m2); history of chronic alcohol or drug abuse; use of central-acting medi-
cation; presence of metal implants (e.g. pacemaker, hip/knee prosthesis, cochlear 
implants, vessel clips); claustrophobia. 
Study design
The effect of ketamine on resting-state brain function was assessed using a sin-
gle-blind, randomized, placebo-controlled cross-over study design with two oc-
casions (at least 1 week between sessions). Subjects received S(+)-ketamine (Ke-
tanest-S, Pfizer BV, Capelle a/d IJssel, The Netherlands) on one occasion and 
placebo (NaCl 0.9%) on the other. No details regarding treatment effects were 
given apart from the possibility of experiencing “drug high” during treatment.
Upon arrival subjects were given two intravenous lines (in separate arms), one 
for drug infusion and one for blood sampling. A baseline blood sample; base-
line measurements for heat pain, nausea, vomiting and psychedelic effects; and 
a baseline anatomical (T1) and RS-fMRI scan were obtained. Next, drug infu-
sion with either S(+)-ketamine or placebo was started at t = 0, at a low-dose (20 
mg/70 kg/h) for 1 hour, followed by a high dose (40 mg/70 kg/h) for another 
hour. During infusion heat pain rating, nausea, vomiting and psychedelic effects 
were scored at 15-minute intervals using visual analogue scales as described be-
low (sections “Subjective effects” and “Pain assessment”). RS-fMRI scans were 
obtained during the last 10 minutes of the low-dose and high-dose infusion peri-
od. After 2 hours, drug administration was terminated. Heat pain, nausea, vom-
iting and psychedelic effects were monitored at regular intervals for another 1.5 
hours, and two more RS-fMRI scans were performed during the drug elimina-
tion phase. The study was registered in the Dutch Trial Register under number 
NTR2717 (www.trialregister.nl).
Blood sampling and S(+)-ketamine and S(+)-norketamine analysis
Venous blood was collected from a venous line inserted into the arm of the sub-
ject. Blood samples were obtained at fixed time point (t = 0, 15, 30, 60, 75, 90, 
120, 130, 160 and 200 minutes) after the start of drug administration. Blood was 
centrifuged (3500 rotations per minute for 10 minutes) within 15 minutes after 




analysis. For the construction of S(+)-ketamine and S(+)-norketamine calibration 
lines, solid substances were obtained from Parke-Davis (Dallas, TX) and Tocris 
(St. Louis, MO), respectively. S(+)-ketamine and S(+)-norketamine concentra-
tions were determined by high-performance liquid chromatography on a Gemi-
ni C18 column (Phenomenex, Utrecht, The Netherlands) at 40 ℃. The detection 
of both analytes in the eluent was performed at 195 nm with a photodiode-ar-
ray-detector (PDA 100, Dionex, Amsterdam, The Netherlands). The lower limit 
of quantification was set at 10 ng/ml for both drugs.
Subjective effects
Psychedelic effects were scored at fixed time points (t = 0, 13, 28, 58, 73, 88, 118, 
128, 158 and 198 min) after the start of drug administration. Psychedelic effects 
were monitored using visual analogue scales ranging from 0 cm (no effect) to 10 
cm (maximum effect) of the Bowdle questionnaire.13 Three factors of psychedelic 
effects can be derived from this questionnaire: drug high, internal perception 
and external perception.14 Internal perception reflects inner feelings that do not 
correspond with the reality and is derived from questions regarding the hearing 
of unrealistic voices or sounds and having unrealistic thoughts and paranoid or 
anxious feelings. The external perception indicates a misperception of an external 
stimulus or change in the awareness of the subject’s surroundings and is derived 
from questions regarding the change of body parts, the change of surroundings, 
the altered passing of time, the difficulty of controlling thoughts and the change 
in color and sound intensity.
Pain assessment
Heat pain stimuli were applied between imaging sessions. Heat pain was in-
duced using the Pathway Neurosensory Analyzer (Medoc Ltd, Ramat Yishai, 
Israel) at fixed time point after the start of drug infusion (t = 0, 17, 32, 62, 77, 92, 
122, 132, 162, 202 minutes). A fixed location on the skin of the volar side of the 
nondominant arm was stimulated with a 3 x 3 cm thermal probe. To quantify the 
pain intensity of the noxious stimulus, subjects scored the perceived pain using 
a computer-connected slider on an electrical potentiometer that ranged from 0 
(no pain) to 100 mm (worst pain imaginable). This allows electronic monitoring 
of the visual analogue scale during heat pain stimulation. To induce heat pain, 
baseline temperature was set at 32 ℃. Next, the temperature of the probe grad-
ually increased (0.5 ℃/s) towards a preset peak temperature, after which the 
temperature rapidly (6 ℃/s) returned to baseline. A peak temperature causing 
a pain score between 60 and 70 mm was used during the study for evaluation of 
the analgesic effect of ketamine. Individual peak temperatures were determined 
on every experiment day before the start of drug administration.
Resting-state fMRI
Neuroimaging was performed on a 3-Tesla Achieva Scanner (Philips Medical 
System, Best, The Netherlands) at fixed time points (t = –30, 45, 105, 140, 170 
minutes), where drug infusion was started at time-point t = 0. The neuroimag-
ing protocol included a high resolution T1-weighted scan (repetition time = 9.7 
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ms, echo time = 4.6 ms, flip angle = 8 degrees, 256 x 256 x 140, isotropic reso-
lution 2 mm, 4 minutes) and 5 RS-fMRI series (each 220 T2*-weighted, whole-
brain volumes obtained with a gradient echo planar with repetition time = 2180 
ms, echo time = 30 ms, flip angle = 80 degrees; 64 x 64 x 38, isotropic resolution 
3.44 mm, 8 minutes). Because the subjects were taken out of the scanner between 
scans, and because only one anatomical T1-weighted image was acquired, each 
RS-fMRI was accompanied with a high resolution T2*-weighted echo planar (~ 
30 seconds) in order to facilitate registering the RS-fMRI data to the anatomical 
image. During scanning, heart rate was monitored with a magnetic resonance 
imaging-compatible pulse oximeter (INVIVO MRI 4500, Siemens Healthcare, Er-
langen, Germany). Respiratory rate was recorded and registered using a flexible 
pressure belt (Philips Medical System, Best, The Netherlands).
Data and statistical analysis
To assess the effect of ketamine versus placebo, a repeated measures analysis of 
variance was performed on pain scores, drug high effect, internal perception val-
ues and external perception with post-hoc t-testing with Bonferroni correction 
for multiple comparison. p-values < 0.05 were considered significant. Data are 
presented as mean ± SEM and 95% confidence interval (CI) unless otherwise stat-
ed. Statistical analysis was performed in SigmaPlot version 12.0 for Windows 
(Systat Software Inc., Chicago IL).
Each of the (12x5x2) RS-fMRI data series was preprocessed with motion correc-
tion, brain extraction, Gaussian smoothing, mean-based intensity normalization 
and high-pass temporal filtering with default software parameters. Then RS-fM-
RI data were normalized to a standard space by first registering the middle 
RS-fMRI volume to the high-resolution T2*-weighted image, which was regis-
tered to the subject’s anatomical T1-weighted image, which was registered to 
the MNI152 standard template. These registration parameters were combined to 
obtain the parameters to put the RS-fMRI data in standard space. This produced 
standardized RS-fMRI data sets that were further analyzed to estimate function-
al brain connectivity. We applied a technique that we have used previously in 
a placebo-controlled crossover study involving alcohol and morphine.10 In that 
study, we have shown that the proposed technique reveals drug-specific and re-
gional changes in functional brain connectivity. This method parcellates the brain 
into eight networks of interest (NOIs) that are consistently present in model-free 
analysis of the RS-fMRI data.15 These NOIs represent 80% of the total brain vol-
ume and include the medial (NOI1) and lateral (NOI2) visual network, the au-
ditory and somatosensory network (NOI3), the sensorimotor network (NOI4), 
the default mode network (NOI5), the executive salience network (NOI6), the 
visual-spatial network (NOI7) and the working memory network (NOI8). We 
then defined functional connectivity as a measure of the correspondence of the 
RS-fMRI fluctuations in each brain voxel in relation to characteristic fluctuations 
of the RS-fMRI signal in each NOI. This correspondence is expressed in terms 
of regional z-scores of fitting an average NOIs RS-fMRI fluctuation. We refer to 




To examine the effect of ketamine over time on functional connectivity, vox-
el-wise statistics were performed on RSN maps. The analysis involved a 
mixed-effects general linear model with subject as random and time and drug 
as fixed within-subject variables. Because subjects received a pain stimulus be-
tween each RS-fMRI session, the corresponding pain relief scores (obtained 10 
minutes before the RS-fMRI scan) were included as a regressor in the general 
linear model. This model accounts for possible confounding effects of pain per 
se on functional connectivity changes caused by ketamine. Voxel-wise statistical 
test runs the risk of false positive results because of the problem of multiple com-
parisons. However, true neuronal effects are likely to happen in adjacent voxels. 
For this reason, correction for multiple comparisons is conducted with a method 
that minimizes the chances of type I errors by examining both the magnitude 
and size of a cluster with effects in the same magnitude range.16 Within this cri-
terion, we set the corrected statistical significance to p < 0.05 after threshold-free 
cluster-estimation. In the post-hoc analysis, the highest value in the significant 
cluster (determined as explained above) was chosen to illustrate the connectivity 
change (z-score) over time for areas of interest. In all stages Functional Magnetic 




Ketamine and norketamine concentrations
Plasma ketamine and norketamine concentrations are shown in figure 1. Peak 
ketamine and norketamine concentrations at the end of the first infusion hour 
were 74.9 ± 4.5 ng/ml and 26.7 ± 2.3 ng/ml, respectively. At the end of the second 
hour, peak ketamine and norketamine concentrations were respectively 187.5 ± 
9.5 ng/ml and 93.0 ± 8.2 ng/ml. The relatively low variability in plasma concen-
trations indicates that the RS-fMRI data were obtained under stable ketamine 
and norketamine concentration conditions (between subjects).
Figure 1. The blood ketamine (blue 
circles) and norketamine (orange 
circles) concentrations in nanogram 
per milliliter. Ketamine was admin-
istered at 20 mg/70 kg in the first 
hour of infusion and at 40 mg/70 
kg during the second hour. A rapid 
increase in blood ketamine concen-
tration (peak 187.5 ± 9.5 ng/ml) and 
a slow increase in blood norketamine 




Effect of ketamine on intrinsic functional brain connectivity
Subjective effects
Psychedelic effects were observed in all subjects, and scores are shown in figure 
2. Mean drug high scores at 60 minutes after the start of drug infusion were 5.9 ± 
0.9 cm (-0.5 to 12.4 cm) for ketamine and 0.4 ± 0.2 cm (-0.8 to 1.6 cm) for placebo 
(p < 0.001). At 120 minutes after the start of drug infusion, mean drug high scores 
were 8.0 ± 0.9 cm (1.8 to 14.1 cm) for ketamine compared to 0.2 ± 0.08 cm (-0.4 
to 0.8 cm) for placebo (p = 0.003). Visual analogue scale scores for the outcome 
parameter internal perception for ketamine and placebo were, respectively, 1.6 ± 
0.4 cm (-1.0 to 4.3 cm) versus 0.2 ± 0.1 cm (-0.5 to 0.9 cm; p < 0.001) at time point t 
= 60 and 2.3 ± 0.6 cm (-1.1 to 6.0 cm) versus 0.2 ± 0.07 cm (-0.3 to 0.7 cm; p = 0.003) 
at time point t = 120. Mean external perception visual analogue scale scores were 
3.6 ± 0.8 cm (-1.3 to 8.5 cm) for ketamine and 0.3 ± 0.1 cm (-0.6 to 1.2 cm; p < 0.001) 
for placebo at time point t = 60 and 5.6 ± 1.0 cm (-1.0 to 12.1 cm) for ketamine and 
0.3 ± 0.1 cm (-0.4 to 1.0 cm) for placebo at time point t = 120 (p < 0.001). Psyche-
delic effects rapidly returned to baseline (within 30 minutes) after termination of 
the drug infusion.
RSN connectivity on drug effect
Resting-state network connectivity changes caused by ketamine administration 
were observed in relation to NOI1 (medial visual network) and NOI3 (auditory 
and somatosensory network). Figure 3A shows the statistical map (threshold-free 
cluster enhancement corrected p-value < 0.05 in yellow) of the areas where the 
connectivity in relation to NOI1 was increased. Affected areas include the frontal 
lobe, thalamus, primary and secondary somatosensory cortex, occipital cortex, 
optic radiation, cerebellum, and the supramarginal gyrus. The statistical map 
(threshold-free cluster enhancement corrected p-value < 0.05 in dark blue) of the 
areas involved in the cortical and subcortical connectivity decreases in relation to 
NOI3 is shown in figure 3B. The connectivity changes in the cortex in many ar-
eas, with the largest effects in the occipital cortex, the anterior and posterior cin-
gulate cortex, orbital frontal cortex and insular cortex. The connectivity changes 
in subcortical areas were observed in the basal ganglia and limbic areas. Details 
Figure 2. Psychedelic effects observed during ketamine (blue circles) and placebo (orange circles) 
infusion presented as A. drug high, B. internal perception, which reflects inner feelings that do not 
correspond with reality and C. external perception, which reflects a misperception of an external 
stimulus or change in the awareness of the surroundings. Concentration-dependent psychedelic 




regarding cluster size, t-value of the cluster peak and cluster peak location of 
the affected areas are provided in table 1. The ketamine effects over time on the 
primary somatosensory cortex and the cerebellum in relation to NOI1 are shown 
in figure 3C en 3D respectively; the effect over time for the occipital cortex in 
relation to NOI3 is shown in figure 3E. 
RSN connectivity on pain processing
Mean baseline pain scores are shown in figure 4A and were 63.9 ± 4.9 mm (30.6 
to 97.2 mm) for the ketamine study day versus 62.3 ± 4.9 mm (28.8 to 95.7 mm) 
for the placebo study day (p = 0.621). Corresponding testing temperatures were 
48.7 ± 0.6 ℃ (44.9 to 52.5 ℃) and 48.4 ± 0.7 ℃ (43.7 to 53.0 ℃) for ketamine 
and placebo respectively (p = 0.296). At the end of the first infusion hour (t = 60 
min), 20.1% ketamine-induced pain relief was observed with mean pain scores of 
Figure 3. Statistical maps of the ketamine induced A. increase in resting-state network (RSN) 
connectivity (yellow) in relation to network of interest 1 (NOI1; light blue) and B. decrease in RSN 
connectivity (dark blue) in relation to NOI3 (light blue; cluster P-value < 0.05). The ketamine 
effect (blue) on connectivity over time is shown for C. the primary somatosensory cortex, D. the 
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Effect of ketamine on intrinsic functional brain connectivity
51.0 ± 7.8 mm (9.6 to 92.4 mm) for ketamine compared to 69.2 ± 5.6 mm (31.2 to 
107.2 mm; p = 0.027) for placebo. Mean pain scores for ketamine and placebo at t 
= 120 (end of second infusion hour) were 33.9 ± 6.6 mm (-7.2 to 75.0 mm) and 64.7 
± 6.4 mm (21.5 to 107.8 mm; p = 0.001) respectively, with a pain relief of 46.9% 
by ketamine. During the drug elimination phase, ketamine pain scores rapidly 
returned to baseline (in approximately 20 minutes).
Since we included pain scores as a regressor in the general linear model, con-
nectivity maps were obtained that assist in separating brain areas affected by 
ketamine from regions involved in the processing of pain. Figure 4B illustrates 
the statistical map of regions where the amount of connectivity variations is ex-
plained by the drug effect (threshold-free cluster enhancement corrected p-value 
< 0.05 in yellow) and by the fluctuations in pain scores (threshold-free cluster 
enhancement corrected p-value < 0.05 in green). Using this model, an increase in 
RSN connectivity explained by pain processing was observed only in relation to 
NOI1 for the anterior cingulate cortex, insula, orbitofrontal cortex and the brain 
stem. No decrease in RSN connectivity was observed for any of the NOIs.
Figure 4. A. Pain scores to the fixed heat stimulus during and after ketamine (blue circles) and pla-
cebo (orange circles) infusion. Concentration dependent analgesia (46.9% at t = 120 minutes) was 
observed during ketamine infusion, which rapidly disappeared after termination of the infusion. No 
analgesia was observed during the placebo infusion. B. Statistical maps of the variations in con-
nectivity explained by the drug effect (yellow) and by pain relief (green). The network of interest is 
represented in light blue. A = anterior; ACC = anterior cingulate cortex; eVAS = electronical visual 





In the last decade, neuroimaging studies increasingly focused on the sponta-
neous RS-fMRI signal to study large-scale brain interactions within RSNs.11,12,18 
RS-fMRI can be used to evaluate the effect of psychoactive drugs on RSN connec-
tivity.10,19 In this study, we assessed the effect of low-dose S(+)-ketamine on brain 
connectivity. The use of low-dose (i.e. subanesthetic) ketamine has increased 
significantly since 1990, mainly for treatment of chronic neuropathic pain syn-
dromes (and since a few years for the treatment of therapy-resistant depression).1 
Thus, knowledge on the effect of low-dose ketamine on brain areas involved in 
pain processing is of importance, providing additional insight into the mecha-
nisms of action of this increasingly popular analgesic. 
Ketamine acts via antagonism of the excitatory glutamatergic NMDA receptor. 
The NMDA receptor has a high expression in the temporal cortex, hippocampus, 
basal ganglia, cerebellum and brain stem, all regions significantly affected by ket-
amine in our study.20,21 Ketamine most significantly affected the cerebellum (rela-
tive to NOI 1 and 3). The cerebellum has an important role in motor learning and 
coordination,22 and we showed previously in rats that ketamine produces motor 
dysfunction.23 Because of its connections with nonmotor cortical and subcortical 
areas, including the limbic system and prefrontal cortex, the cerebellum is also 
thought to play a role in emotional processing (mainly anxiety) and thought co-
ordination.22 Therefore, alterations in connectivity of the cerebellum (increases to 
NOI1 and decreases to NOI3) may be related to some of the psychedelic side 
effects observed during ketamine infusion. Large connectivity changes were also 
observed in the visual cortex and the optic radiation to NOI1, which may explain 
the visual hallucinations observed during ketamine infusion and perhaps the 
symptoms of blurry and double vision.5,24,25 Additional connectivity changes to 
NOI3 were observed in the (pre)frontal cortex, orbitofrontal cortex, temporal cor-
tex and gyrus, anterior and posterior cingulate cortex, thalamus and precuneus 
cortex. In agreement with our observations, task-related fMRIs, evaluating ket-
amine-induced psychedelic effects as model for schizophrenia, showed similar 
activity changes.3,5,24-30 Indeed, ketamine has long been recognized as a model for 
schizophrenia because many of the ketamine-induced psychedelic side effects 
show similarities with the positive (psychotic symptoms like hallucinations) and 
negative (emotional blunting, lack of initiation) symptoms of schizophrenia.26
Ketamine decreased resting-state connectivity in most of the known pain-pro-
cessing related structures to NOI3, including the thalamus, amygdala, insula, 
anterior and posterior cingulate cortex, orbitofrontal cortex and primary and 
secondary sensory cortices. The observed effect on the amygdala (which is part 
of the limbic system) may explain ketamine’s effect on the loss of the affective 
component of pain. Our findings are in close agreement with positron emission 
topography and task-related fMRI studies, which show the involvement of the 
brainstem, thalamus, amygdala, insula, anterior and posterior cingulate cortex, 
orbitofrontal cortex and the sensorimotor cortices in pain processing.31-33 Overall, 
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these data indicate that RS-fMRI is a reliable and relatively simple (more effi-
cient) method for identifying how drugs affect the brain. A single RS-fMRI study 
can recognize all pharmacologically affected regions in the brain simultaneously 
in contrast to task-related fMRI studies. 
Including pain scores as regressor in the statistical model for testing the ketamine 
versus placebo fingerprint on the brain revealed brain areas whose connectivity 
was explained by pain processing aside from drug effect. Pain relief scores were 
associated with increased connectivity in relation to NOI1 in the anterior cingu-
late cortex, orbitofrontal cortex, insula and brain stem, all of which are regions 
involved in pain sensing and processing.31-33 Various studies have demonstrated 
the involvement of these same brain areas in descending inhibition of pain.34-39 
Descending inhibition of pain is a modulatory system originating at spinal and 
supraspinal sites, modifying afferent pain signal propagation. Examples of this 
system are conditioned pain modulation (which is the central inhibition of a fo-
cal pain stimulus by administering a second noxious stimulus at a remote area), 
placebo analgesia and stress-induced analgesia.34,35 These top-down pain modu-
latory pathways dampen pain signal propagation at the level of the spinal cord 
dorsal horn and are thought to be defective in various chronic pain states.40,41 
The current study suggests a modulatory role for ketamine on descending pain 
inhibition. We previously tested the effect of ketamine treatment on endogenous 
pain modulation in patients with chronic pain and observed an increase in de-
scending inhibition as tested by conditioned pain modulation (unpublished ob-
servation by Marieke Niesters MD MSc, Leiden, The Netherlands; April 2011). 
Our current study corroborates the hypothesis that ketamine is able to influence 
endogenous pain modulation. 
An important potential of the current technique lies in the development of new 
NMDA receptor antagonists for treatment of chronic pain. By applying the cur-
rent RS-fMRI paradigm, new agents can be evaluated on their effects on the 
brain areas currently identified as involved in analgesia versus those involved in 
the side effects of ketamine, the most important, potent and prototypical NMDA 
receptor antagonist currently available. One such agent could be traxoprodil 
(Pfizer, NYC, NY), a selective NR2B NMDA receptor antagonist.21 In rats, we pre-
viously showed that this drug produces analgesic effects similar to that of ket-
amine but without significant side effects (such as absence of motor dysfunction 
and agitation). It would be of interest to assess whether this drug is effective in 
humans and whether the lack of side effects coincides with the absence of alter-
ations in activity (connectivity) in the cerebellum, frontal cortex and visual cor-
tex. The current study provides support for the use of the RS-fMRI technique to 
evaluate even newer NMDA receptor antagonists, which may allow prediction 
of the toxicity-efficacy balance prior to application in patients.
Only a limited number of drugs has been tested using RS-fMRI.10,19,42-44 Previ-
ously we assessed the effect of morphine and alcohol in healthy volunteers us-




resting-state connectivity in all NOIs, with the most extensive effects between 
NOI4 and NOI6 and the thalamus, brain stem, insula, putamen and cerebellum, 
some of which are areas involved in descending inhibition of pain. Alcohol ef-
fects were limited, with the most important changes relative to NOI1, NOI3 and 
NOI4 (areas: posterior parietal cortex, cerebellum, brain stem and visual cortex). 
Although some overlap in connectivity changes was present between morphine 
and alcohol versus ketamine, the overall connectivity change pattern observed 
after ketamine administration was different from that of morphine and alcohol. 
Further RS-fMRI studies include a study with psilocybin, a psychedelic found in 
mushrooms, which at a dose causing changes in consciousness (sedation) pro-
duced a decrease in connectivity between medial prefrontal cortex and posterior 
cingulate cortex. This may be related to its psychedelic effects.19 Anesthetic doses 
of propofol caused changes in corticocortical and thalamocortical connectivity 
relative to frontoparietal networks. These propofol changes correlated linearly 
with the level of consciousness.42-44 Although we do not know the biologic mean-
ing of the observed connectivity changes, the finding of drug and state-of-con-
sciousness specific changes in connectivity are plausibly related to drug-specific 
neuronal modulation (i.e. a drug-specific fingerprint of the brain). 
In the current study we applied two low (subanesthetic) doses of ketamine. In 
previous studies we showed that in volunteers and patients these doses had no 
effect on the level of consciousness.45-47 We cannot exclude that some (minor) sed-
ative effects did occur in our subjects that may have affected our results. Howev-
er, we did not find any changes in brain connectivity relative to the default- and 
executive-control networks. Connectivity changes relative to these frontoparietal 
networks play an important role in the generation of sedation and unconscious-
ness.45,46 Both respiratory stimulation and depression have been reported after 
ketamine administration.48-50 Changes in carbon dioxide concentration may affect 
the cerebral blood flow and possibly RS-fMRI connectivity globally in the brain. 
In our study, we observed no changes in cerebral blood flow in the areas of the 
brain where we report connectivity changes, as measured by arterial spin label-
ing (data not shown). Furthermore, we measured respiratory frequency during 
imaging and observed no changes during ketamine infusion relative to place-
bo. Finally, we incorporated breathing frequency as a regressor in our statistical 
model. This did not affect the ketamine-induced changes in RS-fMRI connectiv-
ity values.
Conclusions
In conclusion, RS-fMRI is a useful and efficient method for assessing drug effect 
on the brain. In the current study, this was exemplified by assessing the effect of 
the NMDA receptor antagonist ketamine on resting-state brain connectivity in 
healthy volunteers. Low-dose ketamine induced connectivity changes in brain 
areas involved in motor function, psychedelic effects and pain processing. With 
respect to pain processing, ketamine’s analgesic effect may arise from multiple 
pathways. We observed a decreased connectivity in regions of the pain matrix 
responsible for the perception of pain (pain sensing) and the affective processing 
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of pain. In addition, ketamine affected connectivity in brain areas involved in 
endogenous pain inhibition. 
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Deafferentation is the disruption of afferent and efferent signals between the cen-
tral and peripheral nervous system.1 Several experimental human and animal 
studies show that when peripheral sensory and motor input is removed (for ex-
ample by application of ischemia or local anesthetic-induced nerve blocks, cuta-
neous anesthesia or peripheral nerve damage) detectable functional changes in 
the cortex occur.1-6 Also subcortical areas, including the thalamus, show changes 
upon deafferentation.1,7-9 These changes are best described as reorganization of 
neuronal interactions due to a rebalancing of excitatory and inhibitory factors 
that mediate adaptation and neuronal plasticity.3 For example, the loss of sensory 
and motor input from the hand by peripheral nerve blockade is associated with 
supraspinal excitatory changes possibly mediated by disinhibition of unmasked 
(interhemispheric) cortical neuronal connections, and explains the enhanced 
functionality of the contralateral hand.4,5 These cortical changes coincide often 
with perceptueal changes.
One form of deafferentation that is performed yearly in millions of patients 
world-wide is spinal anesthesia where the sensory information from the lower 
part of the body is temporary removed to allow surgical intervention without 
the perception of pain. It is well known that spinal anesthesia may coincide with 
sensory distortions. For example, some patients report body image distortions 
(such as swelling of the legs, illusionary limb position and changes of the length 
of the limbs) during regional (including spinal) anesthesia.10-13 Additionally, the 
affected limbs are often perceived as warm upon the administration of the local 
anesthetic, while some patients perceive paradoxical heat sensations above the 
level of the anesthetic block (i.e. a cold stimulus is perceived as warm) during the 
assessment of the spread of the anesthetic.12,14 These observations are typically 
made during the initial rapid rise of the anesthetic level and are suggestive of 
changes in central sensory modulation, possibly related to the deafferentation 
from the spinal block. There is further the observation that epidural anesthesia 
(another form of deafferentation) can lead to occurrence of painful sensations in 
the deafferented area in an otherwise healthy individual.15 Existing evidence pre-
sented above suggests that deafferentation from spinal anesthesia would lead to 
a change in functional organization of cortical and subcortical networks involved 
in sensory motor perception and pain. Possibly the altered sensory perceptions 
during spinal anesthesia and functional changes in cortical and subcortical areas 
of the brain are causally related. Some evidence to that suggestion comes from 
data in patients where hyperexcitability of thalamic neurons coincides with neu-
ropathic deafferentation pain.13
A well-known paradigm to evaluate the efficacy of the endogenous pain mod-
ulatory system is “conditioned pain modulation” or CPM.17,18 The CPM par-
adigm assumes that adding afferent nociceptive input at a remote area of the 
body inhibits the intensity of primary focal pain stimulus (“pain inhibits pain”) 
through activation of supraspinal centers including the anterior cingulate cor-
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tex (ACC), the insula and the prefrontal cortex. Therefore, it would be plausible 
that blockade of afferent input would have the reverse effect on pain perception. 
This means that if afferent input becomes “disconnected”, then pain perception 
would become more intense. However, there are no human studies assessing the 
effect of pain perception on areas remote from deafferentation sites (such as pain 
perception on the arm during spinal anesthesia). We aim to use this model of 
acute deafferentation by spinal anesthesia in healthy participants to further un-
derstand the mechanisms involved in endogenous modulation of pain.
Our placebo (sham-spinal anesthesia), crossover, randomized study investigates 
(1) whether pain perception above the level of the anesthetic is altered by spi-
nal deafferentation, and (2) whether we can detect an coinciding change in rest-
ing-state functional connectivity of cortical and thalamic networks in healthy 
humans. The thalamus was chosen as region of interest as it is an important 
pain modulatory center that receives input from multiple ascending pain path-
ways and projects to various (sensory and affective) pain modulatory regions 
of the cortex and limbic system.19,20 In the current study we obtained repeated 
resting-state functional magnetic resonance images (RS-fMRI) in two sessions 
(spinal and sham-spinal peripheral anesthesia). It has been shown that this tech-
nique can be reliably used to evaluate alterations in intrinsic brain connectivi-




Twelve right-handed, healthy, male volunteers (age: 23.7 ± 3.4 years (mean ± SD); 
body mass index: 21.3 ± 2.4 kg/m2) were enrolled in the study after approval by 
the local ethics committee of the Leiden University Medical Center in Leiden, the 
Netherlands. All participants gave oral and written informed consent. The study 
was performed according to GCP guidelines and the ethical principles for med-
ical research involving human subjects of the International Association of the 
Study of Pain (http://www.iasp-pain.org/Education/Content.aspx?ItemNum-
ber=1213) and according to the Declaration of Helsinki, (http://www.wma.net/
en/30publications/10policies/b3/; amended in 2013). Before participation, all 
subjects were screened to exclude the presence or history of any disease or their 
inability to maintain a regular diurnal rhythm, the presence or history of alcohol 
or drug abuse, the presence of metal implants (e.g. pacemaker, hip or knee pros-
thesis, cochlear implants, vessel clips) and claustrophobia. Additional exclusion 
criteria included: < 18 or > 45 years of age and a body mass index > 30 kg/m2. 
The study was registered in the Netherlands' Trial Register (NTR at www.trial-





The study was performed using a randomized crossover design. Upon arriv-
al, an intravenous line was placed in the right hand to allow fast administra-
tion of emergency medication when necessary. Next, baseline anatomical MRI 
(T1-weighted) and baseline RS-fMRI scans were obtained followed by baseline 
heat pain measurements. After baseline measurements were complete, subjects 
received an intrathecal injection with a local anesthetic on one occasion and a 
sham procedure on the other as described below (time of injection is t = 0). Re-
sponses to heat pain and the height of the sensory block (measured by the re-
sponse to a cold 4 cm2 surface applied to the skin in the left and right mid-axil-
lary line) were measured at 15-minute intervals. Additional RS-fMRI scans were 
obtained 1 and 2 hours after the spinal injection or sham procedure. At the end 
of the study, subjects were monitored until fully recovered from the spinal anes-
thetic, as defined by return of motor functions and diuresis, and then allowed to 
go home.
Intrathecal injection and sham procedure
The intrathecal injection was performed at the interspace between vertebrae L3 
and L4 with 3 mL bupivacaine 5 mg/mL (AstraZeneca, Zoetermeer, the Neth-
erlands) after the skin was locally infiltrated with 1-2 mL lidocaine 10 mg/mL 
(AstraZeneca, Zoetermeer, the Netherlands). For the spinal puncture a 27 Gauge 
Whitacre needle (Vygon, Valkenswaard, the Netherlands) was used to minimize 
the risk of post-spinal headache. The sham procedure was performed by inser-
tion of a spinal needle at the interspace between vertebrae L3 and L4 through the 
skin, after the skin was locally infiltrated with 1-2 mL lidocaine 10 mg/mL. The 
dura mater was not punctured and no bupivacaine was injected. An indepen-
dent anesthesiologist, who was not involved in conducting or analyzing other 
measurements made during the study, performed the injections. The instructions 
to the subject were similar on both occasions so that the subject and the investi-
gators did not know which treatment was given at the moment of injection. 
Pain assessment
Heat pain was induced on the lower part of the non-dominant arm with a 3 x 
3 cm thermal probe of the Pathway Neurosensory Analyzer (Medoc Ltd., Ra-
mat Yishai, Israel). Baseline temperature was set at 32 ℃. During heat pain tests 
the temperature of the probe gradually increased (1.5 ℃/s) towards a pre-set 
destination temperature that was held constant for 30 seconds and then rapidly 
returned (6 ℃/s) to baseline temperature. To quantify pain intensity of the heat 
pain stimulus, subjects rated the perceived pain stimulus using a computer-con-
nected slider on an electrical potentiometer that ranged from 0 mm (no pain) to 
100 mm (worst pain imaginable). This allowed for continuous electrical mon-
itoring of the visual analogue scale during the noxious stimulation. The target 
temperature of the heat stimulus was determined at the start of each study day 
and was intended to evoke an electronic visual analogue scale (eVAS) of 40 mm. 
To evaluate pain responses after the intrathecal injection or sham procedures, 
pain tests were applied between imaging sessions at fixed time points: t = 15, 30, 
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45, 90, 105 and 150 minutes.
Resting-state functional magnetic resonance imaging acquisition
A 3-Tesla Achieva Scanner (Philips Medical System, Best, The Netherlands) was 
used to acquire functional data at fixed time points (baseline, t = 60 and t = 120 
min). The neuroimaging protocol included a high-resolution T1-weighted scan 
(repetition/echo time = 9.7/4.6 ms, flip angle = 8 degrees, 1 mm isotropic, 4 min) 
and 3 RS-fMRI series (each 220 T2*-weighted whole-brain volumes, obtained 
with a gradient echo planar with repetition/echo time = 2180/30 ms, flip angle 
80 degrees, 3.44 mm isotropic, duration 8 min; subjects were instructed to keep 
their eyes open and relax). A high resolution T2*-weighted scan (~ 30 seconds) 
was acquired at the end of each repeated RS-fMRI in order to facilitate register-
ing the functional data to the anatomical image.
RS-fMRI analysis
The following pre-statistics processing was applied using FSL software on all 
individual RS-fMRI scans: motion correction; registration to standard space by 
applying 6 rigid-body transformations between RS-fMRI and high-resolution 
T2*, and high resolution T1, followed by an affine registration to the MNI152 
template with 2 mm resampling;25 brain extraction; spatial smoothing using a 
5-mm full width at half-maximum Gaussian kernel; grand-mean intensity nor-
malization; and high-pass temporal filtering (Gaussian-weighted least-squares 
straight line fitting, with a 0.01 Hz cut-off).
Functional connectivity was assessed using two different approaches. First, to 
evaluate the general effects of deafferentation from spinal anesthesia on func-
tional brain connectivity, we used a model-free analysis of eight predefined net-
works of interest (NOIs) as previously described by Khalili-Mahani et al.22 These 
canonical networks represent 80% of the total brain volume and are described 
based on their general function as the medial and lateral visual network, the 
auditory and somatosensory network, the sensorimotor network, the default 
mode network, the executive salience network, the visual-spatial network and 
the working memory network.26 As we have previously shown for morphine, 
alcohol, δ(9)-tetrahydrocannabinol and ketamine, RS-fMRI data analysis using 
these networks reveals localized and drug-specific changes in functional brain 
connectivity.21-24
The second functional connectivity analysis focused on functional connectivity 
in relation to the thalamus. The thalamus was chosen as it receives projections 
from multiple ascending pain pathways, is involved in processing nociceptive 
information, and projects the information to various parts of the limbic and cor-
tical structures involved in sensory discriminative and the affective dimensions 
of pain perception.19 We used 7 thalamic subregions according to the Oxford tha-
lamic connectivity atlas.27 Our choice of this atlas is motivated by our principle 
to develop objective, easily reproducible and standardized procedures for rep-




based on probabilistic diffusion tractography that describes the probability of 
corticothalamic white matter fibers connection between thalamic subregions and 
cortical segments (prefrontal cortex, temporal cortex, pre-motor cortex, primary 
motor cortex, sensory cortex, posterior-parietal cortex and the occipital cortex). 
We refer to the resulting functional networks as the thalamo-prefrontal, thala-
mo-premotor, thalamo-primary motor, thalamo-sensory, thalamo-parietal, thal-
amo-occipital network, and thalamo-temporal network to indicate the reference 
region.
In both analyses, we used a dual regression analysis to define resting-state net-
works (RSNs) in relation to reference regions (the 8 canonical NOIs or the 7 
subthalamic segments).28 Briefly, dual regression involves multiple-regression 
of RS-fMRI time-series against several NOIs or thalamic subregions to estimate 
a representative vector of BOLD fluctuations within each reference region, and 
next regressing the RS-fMRI time-series against the time vector to identify spatial 
representations of RSNs, i.e. brain areas with similar fluctuations patterns as the 
reference regions. Nuisance variables corresponding to fluctuations in the deep 
white matter (measured from the center of the corpus callosum) and cerebrospi-
nal fluid (measured from the center of the lateral ventricles) were included in 
the dual regression analysis to account for non-specific and physiological varia-
tions.29 This resulted in statistical maps of z-scores, where each voxel of the brain 
represents the functional connectivity between that voxel and each of the NOIs 
or the thalamic subregions. These statistical maps were later used for voxel-wise 
inference testing of the spinal anesthesia on each network.
Data, power and statistical analyses
To quantify pain intensity, the area-under-the-curve (AUC) of each eVAS re-
sponse was calculated and presented relative to the baseline measurement.30 The 
study was powered to detect a 50% treatment difference in the eVAS AUC at 
peak spinal level (estimated SD 35%, alpha = 0.05, 1-beta = 0.9). The effect of 
spinal anesthesia on pain perception was tested by a repeated measures analy-
sis of variance with post-hoc Bonferroni correction on the AUC values relative to 
baseline. The statistical analysis was performed in SigmaPlot version 12.0 (Systat 
Software Inc., Chicago, IL) and p-values < 0.05 were considered significant. Data 
are presented as mean ± SEM unless otherwise stated.
To determine the effect of deafferentation from spinal anesthesia on resting-state 
functional connectivity a mixed-effects analysis was applied with subject as 
random and time and drug as fixed within-subject variables. Voxel-wise statis-
tical analysis on the z-score connectivity maps was performed using a permu-
tation-based statistical inference with 5000 permutations. Statistical significance 
was set at p-value < 0.05 after family wise error cluster-based correction (with 
cluster forming voxelwise thresholds set at p < 0.01).31 To further control for spu-
rious effects, we report clusters that included a minimum of 10 adjacent voxels. 
We also performed a stepwise regression (without and with pain score as regres-
sor in the model) to examine brain regions whose connectivity was modulated 
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by the subjective perception of pain. In all stages of MRI analyses the FMRIB 
Software Library was used (FSL 4.1, Oxford, United Kingdom).25
Results
Spinal anesthesia
All subjects completed the study without the occurrence of major side effects. 
Peak sensory blockade was achieved after 45 minutes with 17.5 ± 1.0 blocked 
segments corresponding to a sensory block level from dermatomes S5 to Th5. 
This sensory block persisted throughout the whole study period. The mean time 
of spinal anesthesia to full recovery of diuresis and motor function was 369 ± 11 
minutes. No sensory blockade was observed after the sham procedure in any 
of the subjects. The spinal anesthetic and sham procedure did not result in sig-
nificant cardiorespiratory changes. Blood pressure remained within 5% of con-
trol values. Due to the absence of spinal block following the sham procedure, 
blinding of the study was rapidly lost to both investigators and volunteers. 
Pain responses
The mean eVAS responses prior to treatment and at peak spinal anesthetic level 
and sham experiments are given in figure 1A and B. Spinal anesthesia signifi-
cantly increased pain sensitivity on the skin of the lower forearm. Mean AUC 
values at baseline were 844.7 ± 63.2 mm·sec on the study day with spinal injec-
tion and 898.6 ± 122.6 mm·sec on the day of the sham procedure (p = 0.644). Mean 
AUC values at peak spinal level were 1165.0 ± 71.0 mm·sec after spinal injection 
and 877.1 ± 105.8 mm·sec after the sham procedure (p = 0.005). Mean AUC values 
over time are shown in figure 1C showing that the hyperalgesic responses lasted 
for at least 3 hours (end of the study). There was no effect of study order on the 
pain AUC values (Fig. 1D).
Effect of spinal anesthesia on predefined general resting-state networks
Spinal anesthesia induced significant changes in functional connectivity in rela-
tion to three of the eight canonical NOIs: the medial visual network (increase), 
the somatosensory network (decrease) and the default mode network (increase). 
Regions that demonstrate functional connectivity changes in relation to these 
three networks are given in table 1 and include amongst others the thalamus, pri-
mary somatosensory cortex, primary motor cortex, premotor cortex, anterior cin-
gulate cortex, caudate nucleus and the cerebellum. Figure 2A demonstrates the 
statistical connectivity map (cluster corrected; p < 0.05) of the brain areas with 
a decrease in functional connectivity in relation to the somatosensory network. 
The effects of spinal anesthesia on functional connectivity over time for the pre-
motor cortex, primary somatosensory cortex and thalamus are shown in figure 
2B-D. Details regarding cluster size, z-score and location of the areas that show 
functional connectivity changes are provided in table 1. Adding treatment order 
(sham first vs. spinal first) as a covariate to the statistical model did not affect the 





Cortico-thalamic connectivity maps are shown in figure 3A. To evaluate wheth-
er anatomically distinguishable networks were produced by the dual regression 
analyses of the thalamic subregions, average functional connectivity maps were 
obtained for each thalamic resting-state network. This was done by first thresh-
olding and binarizing each functional connectivity map at a z-score > 4.0 and 
next computing a probability map (with probabilities of connectivity > 50%). 
Figure 3B represents the average functional connectivity probability maps of 
the RS-fMRI data acquired at baseline for all 7 thalamic subregions. With one 
exception, all thalamic subregions were functionally connected to cortical areas 
as expected according to the anatomical atlas. The exception was one thalamic 
subregion that instead of predominantly connecting to the premotor cortex (as 
expected from the atlas) demonstrated functional connectivity to the occipital 
cortex and cerebellum (Fig. 3B (yellow areas)). 
Figure 1. A. Pain responses upon thermal stimulation on the skin of the lower arm at baseline and 
B. at peak deafferentation effect (45 minutes). C. Pain presented as area-under-the-curve (AUC) 
relative to baseline over the whole study period. The orange circles represent the pain sensitivity 
during spinal anesthesia; the blue circles represent the pain perception after the sham procedure. 
Spinal anesthesia induced a significant increase in pain sensitivity (p < 0.001). D. Pain responses 
in subjects receiving sham (placebo) treatment on visit 1 or spinal treatment on visit 1 (closed 
symbols), and the pain responses of the second visit for sham and placebo (open symbols). No order 
effect was observed. eVAS: electronic visual analogue scale.
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Effect of spinal anesthesia on thalamic resting-state networks
Spinal anesthesia induced a significant increase in functional connectivity in re-
lation to three of the seven thalamic networks: the thalamo-prefrontal, the thal-
amo-parietal and the thalamo-temporal network. These networks are involved 
in the sensory discriminative (i.e. pain intensity) and affective components of 
pain.19 Regions that show connectivity changes in relation to the three networks 
are given in table 2 and include (partly) similar regions observed in the general 
RSN analysis: thalamus, primary somatosensory cortex, primary motor cortex 
Figure 2. A. Statistical connectivity map (p < 0.05; cluster corrected) of the decrease in resting 
state network connectivity (dark blue) induced by spinal anesthesia in relation to the auditory 
and somatosensory network (light blue). The effect of spinal anesthesia on connectivity over time 
is shown for the B. premotor cortex, C. somatosensory cortex and D. the thalamus. A: anterior; I: 
inferior; L: left; P: posterior; R: right; S: superior.
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and ACC. Additional affected regions are the insula, precuneus cortex, the fron-
tal lobe and the posterior cingulate gyrus. The effect of deafferentation from spi-
nal anesthesia in relation to the thalamo-prefrontal network is presented in the 
statistical connectivity map of figure 4A, which shows a significant increase in 
thalamic connectivity (in red) overlapping the subregion of the thalamus that 
functionally and anatomically connects to the prefrontal cortex (in green). The 
main effect of treatment over time in this thalamic region is shown in figure 4B. 
Figure 3. A. Illustrative map of the 7 thalamic subregions used for connectivity analysis based on 
the oxford thalamic anatomic connectivity probability atlas. B. Probabilistic connectivity map of 
the seven thalamic resting-state networks at baseline (> 50% probability that a functional con-
nection between the thalamic subregion and the cortex was present at Z > 4.0). All thalamic sub-
regions (except for the region that anatomically connects to the premotor cortex) demonstrated 





The significant effect from deafferentation from spinal anesthesia in relation to 
the thalamo-posterior parietal network is presented in the statistical map of fig-
ure 5A. The main effect of treatment over time for the ACC, the posterior cin-
gulate gyrus and the insula is given in figure 5B-D, with significant treatment 
changes during the complete course of measurement. Details regarding cluster 
size, z-score and location of the affected areas are provided in table 2. Study or-
der did not affect the location and extent of these clusters.
Correlations between pain and functional resting-state connectivity
Table 2 lists brain areas whose connectivity was altered by including the abso-
lute AUC pain scores as a covariate in the permutation testing (i.e. connectivi-
ty changes increased with greater pain scores). Illustrative examples of signif-
icant correlations observed between functional connectivity changes and pain 
responses are given in figure 6 for the thalamus (in relation to the thalamo-pre-
frontal network, i.e. intra-thalamic), ACC and insula (both in relation to the thal-
amo-parietal network).
Discussion
Our hypothesis that spinal deafferentation would enhance pain sensitivity was 
confirmed by our finding that nociceptive stimuli applied to dermatomes above 
the level of spinal deafferentation were perceived as hyperalgesic. This observa-
Figure 4. A. Statistical connectivity map (P < 0.05; cluster corrected) of the spinal anesthesia 
induced increase in resting-state network connectivity in relation to the thalamo-prefrontal net-
work. It shows the subregion of the thalamus that functionally and anatomically connects to the 
prefrontal cortex (green) and the thalamic area with increased connectivity due to deafferentation 
(red). B. The effect of spinal anesthesia on connectivity over time is shown for the thalamic subre-
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tion is suggestive of transient central cortical and subcortical changes in neuro-
nal organization. Indeed, we observed spinal deafferentation-induced connectiv-
ity changes in brain networks involved in the sensory discriminative dimension 
(e.g. thalamus, insula and somatosensory cortex) and in the affective dimension 
(e.g. brainstem, thalamus, insula and ACC) of pain perception from two inde-
pendent analyses of canonical NOIs and thalamic networks.32,33 Furthermore, 
the increased pain sensitivity at non-deafferentated skin areas was correlated to 
Figure 5. A. Statistical connectivity map (P < 0.05; cluster corrected) of the spinal anesthesia in-
duced increase in resting-state network connectivity in relation to the thalamo-parietal network. B. 
The effect of spinal anesthesia on connectivity over time is shown for the anterior cingulate cortex, 
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thalamo-cortical connectivity changes within the thalamus, ACC and insula. Our 
findings are in agreement with earlier animal and human studies showing that 
deafferentation is associated with changes in neuronal organization in the cortex 
and subcortical areas. These changes are associated with warm and referred sen-
sations, perceptual illusions, neuropathic pain and enhanced sensorimotor func-
tion of non-deafferented areas.2,4-6,12-16,34-36
Effect of deafferentation on canonical resting state networks
In the current study, the RS-fMRI technique was successfully used to evaluate 
deafferentation-induced changes in brain connectivity in awake humans. The 
changes in RSN connectivity induced by the symmetric spinal deafferentation 
included areas involved in the sensory discriminative components of pain per-
ception (sensory cortex, (pre)motor cortex, brainstem, thalamus) and the affec-
tive dimension of pain (insula, caudate nucleus, frontal pole, ACC, thalamus, 
brainstem and cerebellum), in relation to the medial visual network (increase in 
RSN connectivity), the somatosensory network (decrease) and the default mode 
network (increase) (see Table 1).
In two previous studies in an anesthetized rat model the effects of traumatic pe-
ripheral nerve- or spinal cord injury-related deafferentation were studied using 
RS-fMRI.1,37 Both studies show changes in connectivity between the thalamus 
and cortical and subcortical areas of the brain (e.g. the primary somatosensory 
cortex). The authors argue that these changes are related to the loss of inhibitory 
influences within these brain neuronal networks. There is general agreement in 
the literature that deafferentation causes a rebalancing of excitatory and inhibito-
ry neuronal activity towards disinhibition exposing formerly masked excitatory 
connections.1-7,9,37 Krupa et al.8 further show that also feedback from cortex to 
thalamus plays an important role in plastic changes due to deafferentation (see 
also ref. 3). These deafferentation-related changes may be adaptive and due to 
alterations in neuronal activity, such as due to reduced GABAergic inhibitory 
activity and/or enhanced glutamatergic excitatory activity, or due to changes in 
Figure 6. Scatterplots of the pain response area-under-the-curve scores in relation to the absolute 
connectivity Z-scores for A. the thalamic subregion functionally connected to the prefrontal cortex, 




microcirculation, where reduced afferent input changes the neurovascular cou-
pling.1,38,39 Synaptic sprouting and development of structural changes between 
brain areas takes more time to develop and seems to play a role in chronic de-
afferentation (in SCI, peripheral nerve injury or amputation).1,35,36 Given the fact 
that we are unable to determine from the RS-fMRI analyses whether changes in 
connectivity coincide with increases or decreases in neuronal activity, attribution 
of the observed changes in RS-fMRI connectivity during spinal anesthesia to a 
shift from inhibitory towards excitatory nociceptive pathways is currently at best 
speculative.
We observed changes in connectivity relative to medial visual, somatosensory, 
and default mode networks. The reason for the selective association of spinal 
deafferentation with connectivity changes relative to these specific canonical 
networks cannot be deduced from our study. Possibly compared to the other 
networks, these networks are most sensitive to loss of peripheral afferent input. 
Irrespective of the mechanism, we argue that the observed changes may cause 
specific behaviors associated with neuraxial blockade. For example, epidural an-
esthesia is associated with block-height dependent sedation and reduced brain-
stem auditory evoked potentials.40 Further, several studies show that neuraxial 
blockade coincides with sedation and consequently reduced (volatile and intra-
venous) anesthetic requirements.41,42 These effects may be related to connectivity 
changes relative to the default mode and medial visual networks.43,44 Particular-
ly the default mode network seems important in altered states of consciousness 
(anesthesia, coma, vegetative state, epileptic loss of consciousness and somnam-
bulism).43,45 We did not measure the arousal state in our study. Due to this lim-
itation we cannot conclude whether in our population a change in arousal state 
occurred. Changes observed relative to the somatosensory network may be as-
sociated with nociceptive sensations (warm sensation/paradoxal heat sensation, 
and as observed here: hyperalgesia) and illusions of abnormal bodily position 
and recognition.12,13
Effect of deafferentation on pain responses and thalamic resting state networks 
An important observation of this study is that pain sensitivity increased during 
spinal deafferentation. Similar observations were made in rats following exper-
imental spinal cord injury (SCI) where allodynia is perceived at dermatomes 
above the transection level in a majority of animals.46,47 Gerke et al.47 further 
showed increased spontaneous firing of thalamic neurons in rats following SCI. 
Several other studies show spatio-temporal changes and neuronal hyperactivi-
ty in the thalamus upon deafferentation (either in experimental animal models 
or in patients with deafferentation pain), with augmented connections between 
the primary somatosensory cortex and the thalamus.37,48 Consistent with these 
findings, we observed changes in functional connectivity within the thalamus 
in our general RSN analysis (Fig. 2D). The more specific analysis of the thalamic 
subnetworks revealed significant increases in connectivity between the thalamus 
and regions of the brain involved in sensory and affective pain processing and 
perception (Figs. 4 and 5; Table 2). This indicates the importance of neuronal ac-
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tivity changes in the thalamus upon deafferentation. Importantly, the enhanced 
pain sensitivity was also correlated with the thalamic RSN connectivity (Table 2). 
Positive correlations were observed between pain scores and intrathalamic and 
thalamo-cortical (involving the ACC and insula) functional connectivity (Figs. 
6A-C), suggestive of a causal role for these networks in enhancement of pain 
sensitivity during acute deafferentation. 
Interestingly, several brain areas that we identified in the hyperalgesic responses 
to deafferentation (e.g. thalamus, insula and ACC) are involved in endogenous 
modulation of pain, where activation of these supraspinal brain areas causes 
either facilitation or inhibition of afferent nociceptive input at the level of the 
spinal cord dorsal horn.18,33 This suggest that spinal anesthesia-induced deaffer-
entation causes the shift of the endogenous pain system towards pain facilita-
tion. Our findings therefore support the CPM paradigm as we now observed that 
blockade of afferent inputs (i.e. the reverse of the CPM paradigm) enhances pain 
sensitivity.17,18 Of interest is that You et al.49 identified the medio-dorsal subregion 
of the thalamus of the rat in being involved in pain facilitation as part of the 
endogenous pain modulatory system. This region corresponds to the human tha-
lamic subregion anatomically connected to the prefrontal cortex (Fig. 4). Several 
studies on chronic (deafferentation) pain syndromes have also observed altered 
functionality in these same brain regions. For example, Apkarian et al.50 showed 
that chronic low back pain was associated with abnormalities (i.e. loss) of the 
thalamus (and prefrontal) gray matter density. Spinal cord injury in primates 
leads to a functional reduction of the GABAergic inhibitory circuitry of the thala-
mus, and in humans, abnormal thalamic bursting patterns and abnormal activity 
patterns in the ACC were observed following spinal cord injury.51-54 Knowledge 
on the mechanism of both afferent and efferent signaling pathways is important 
for our understanding of the (ab)normal perception of pain and may lead to new 
insights for the treatment of pathological pain syndromes. Speculating that the 
enhanced pain sensitivity we observed in dermatomes above the deafferenta-
tion level is associated with excitatory changes in thalamo-cortical connectivity, a 
therapy focused on inhibition of these excitatory networks may be indicated. For 
example, pain relief may occur by reconstituting GABAergic inhibitory activity, 
or inhibition of glutamatergic excitatory activity. Indeed, recent studies indicate 
that the N-methyl-D-aspartate receptor antagonist ketamine induces long-term 
relief of neuropathic pain by improving descending pain inhibition, possibly via 
a central inhibitory effect on excitatory pathways.24,55,56
Blinding
The inability of blinding the anesthetic treatment in both subjects and investi-
gators in our study is inevitable with the procedure and paradigm in question. 
Anticipation is a critical aspect of subjective pain perception and it is plausible 
that awareness of subjects of the nature of the effect of the spinal injection could 
have affected the study outcome. We controlled for possible experimental order 
effects and deblinding by including the order effect in our statistical model. In 




of pain intensity (Fig. 1D), nor did we find an effect on the RS-fMRI results. This, 
however, is not generalizable and some effect due to differences in the attention 
to the thermal pain in spinal vs. sham sessions cannot be excluded.57,58 Possibly 
such an interoceptive effect became visible in the insula signal at 2-h into the 
sham spinal (Fig. 5D).59
The insula
In this study we focused on the thalamus in relation to other brain areas to ex-
plain the observations of hyperalgesia following spinal analgesia. We are aware 
that other important pain areas of the brain were involved in the effect of spinal 
deafferentation on pain sensitivity, such as the insula and ACC. The insula is 
involved in the sensory and affective dimensions of pain perception as well as 
in the processing and modulation of interoceptive sensations.33,59,60 Although not 
part of our initial protocol, we performed a secondary analysis on the effect of 
spinal deafferentation on the functional connectivity in relation to the insula us-
ing a similar approach as presented for the thalamus network on the complete 
left and right insula (as a seed region). We observed that deafferentation changed 
connectivities between the insula and several brain areas including the ACC, 
frontal cortex and hippocampus (increased connectivity) and cerebellum, occip-
ital cortex and brainstem (decreased connectivity) (Fig. 7 and Table 3). Interest-
ingly, connectivity changes did increase when subjects had greater pain scores 
although the effect size was not as large as observed for the thalamus networks 
(data not shown). These data indicate that apart from an effect on pain intensity, 
deafferentation changes the pain affect and possibly also interoceptive sensations 
via changes in functional connectivities in the mentioned insula networks. Since 
the insula is topographically organized, further studies are needed to assess the 
deafferentation effect on networks relative to specific insula subregions.
Figure 7. Statistical connec-
tivity map (p < 0.05; cluster 
corrected) of the increase (red) 
and decrease (blue) in resting 
state network connectivity in-
duced by spinal anesthesia in 
relation to the insula.
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Deafferentation from spinal anesthesia is associated with connectivity changes in 
the brain involving both cortical and subcortical areas. Furthermore, spinal an-
esthesia enhanced pain sensitivity that was correlated to enhanced connectivity 
patterns of the thalamus, anterior cingulate cortex and insula, areas associated 
with endogenous modulation of pain and the sensory and affective dimensions 
of pain perception.
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Endogenous pain modulation is a complex phenomenon involved in the per-
ception of pain. It consists of top-down inhibitory and facilitatory pathways that 
originate at higher sites within the central nervous system and converge at dor-
sal horn neurons in the spinal cord, to modulate incoming afferent nociceptive 
information. Dysfunction of inhibitory pain pathways or a shift in the balance 
between pain facilitation and pain inhibition has been associated with the devel-
opment of chronic pain. This thesis describes the effect of several central-acting 
drugs on descending control of pain in both healthy volunteers and chronic pain 
patients to further understand the underlying mechanism of endogenous pain 
control in health and disease.
In chapter 2 the effect of the N-methyl-D-aspartate (NMDA) receptor antago-
nist ketamine on endogenous pain modulation was investigated in healthy vol-
unteers. Ten healthy subjects (4 men/6 women) received an 1-hour placebo or 
S(+)-ketamine (40 mg/70 kg) infusion on two separate occasions in random or-
der. Upon termination of the infusion the capacity to recruit descending pain in-
hibitory pathways was evaluated using two experimental or surrogate biomark-
ers for endogenous modulation of pain: conditioned pain modulation (CPM) 
and offset analgesia (OA). After placebo treatment significant inhibition of pain 
responses was present for CPM and OA. In contrast, after ketamine infusion no 
CPM response was observed, but rather a significant facilitatory pain response (p 
< 0.01); the OA response remained unchanged. These findings indicate that the 
balance between pain inhibition and pain facilitation was shifted by ketamine 
towards pain facilitation and suggest a modulatory involvement of the NMDA 
and/or other glutamatergic receptors at some level within the endogenous pain 
system. The absence of an effect of ketamine on OA indicates the presence of 
different mechanisms and neurotransmitter influences underlying OA and CPM 
and suggests that OA and CPM differ in their susceptibility for glutamatergic 
influences. 
In contrast to CPM, the relatively new phenomenon offset analgesia had only 
been described in young healthy volunteers. In chapter 3, we explored OA in 
a large population consisting of several age categories and in ten chronic neu-
ropathic pain patients. We defined OA by the reduction in electronic pain score 
upon the 1 ℃ decrease in noxious heat stimulus relative to the peak pain score. 
OA was present in healthy volunteers irrespective of age and sex (pain score de-
crease = 97 ± 1% (mean ± SEM), which suggests that OA is fully developed at the 
age of 6 years and does not undergo further maturation. In contrast, a reduced 
or absent offset analgesia response was observed in neuropathic pain patients 
(pain score decrease = 56 ± 9% vs. controls 98 ± 1%, p < 0.001). This indicates that 
chronic neuropathic pain patients are unable to modulate changes in pain stimu-
lation with perseverance of pain perception where healthy subjects display signs 
of strong analgesia. Whether the altered OA responses contribute to the chronifi-




and requires further study. Intravenous treatment with ketamine, morphine and 
placebo had no effect on OA responses in patients despite sharp reductions in 
spontaneous pain scores, which suggests that the NMDA and μ-opioid receptors 
are less likely to be involved in OA mechanisms. Possibly, not central but pe-
ripheral sites may be involved in the altered offset analgesia responses in these 
patients. 
Chapter 4 describes the effect of ketamine and morphine on CPM responses in 
chronic pain patients. CPM responses were obtained in 10 neuropathic pain pa-
tients (2 men/8 women), with peripheral neuropathy as defined by abnormal 
quantitative sensory testing. Patients were treated with S(+)-ketamine (0.57 mg/
kg/h for 1 hour) and morphine (0.065 mg/kg/h for 1 hour) in a randomized, pla-
cebo-controlled double-blinded study. CPM was measured at baseline and 100 
minutes after the start of treatment. Without treatment no CPM was detectable, 
which indicated that the descending pain inhibitory properties within this group 
of chronic pain patients were diminished. Treatment with ketamine, morphine 
and placebo produced significant CPM responses of respectively 40.2 ± 10.9%, 
28.5 ± 7.0% and 22.1 ± 12.0% with no statistical difference in magnitude of CPM 
among treatments. However, the magnitude of the CPM responses correlated 
positively with the magnitude and duration of spontaneous pain relief observed 
after treatment. This suggests a role for CPM engagement of descending pain 
inhibition in analgesic efficacy of ketamine, morphine and placebo treatment in 
chronic neuropathic pain patients.
In chapter 5 the effect of long-term treatment with the new analgesic tapentadol 
is described. Tapentadol is an analgesic agent for treatment of acute and chronic 
pain that activates the μ-opioid receptor combined with inhibition of neuronal 
noradrenaline reuptake. Both mechanisms are implicated in activation of de-
scending inhibitory pain pathways. Twenty-four patients with diabetic poly-
neuropathy were randomized to receive daily treatment with tapentadol sus-
tained-release (average daily dose 433 ± 31 mg) or placebo for 4 weeks. CPM 
and OA responses were measured before and on the last day of treatment. Prior 
to treatment none of the patients had significant CPM or OA responses. After 4 
weeks of treatment, CPM was significantly activated by tapentadol slow-release 
(SR) and coincided with significant analgesic responses. CPM increased from 9.1 
± 5.4% (baseline) to 14.3 ± 7.2% after placebo treatment and 24.2 ± 7.7% after 
tapentadol SR treatment (p < 0.001 vs. placebo). Relief of spontaneous pain was 
also greater in patients treated with tapentadol than placebo (p = 0.028). Neither 
placebo nor tapentadol SR treatment had an effect on the magnitude of the OA 
responses (p = 0.78). These results show that patients with painful diabetic poly-
neuropathy who display absent CPM responses benefit from tapentadol, which 
induces pain relief coupled to (re)-activation of descending inhibitory pain path-
ways.
A relatively new approach in central nervous system drug research is resting-state 




rest (i.e. not task-related). In chapter 6 the effect of low-dose S(+)-ketamine on 
intrinsic brain connectivity was investigated. We aimed to identify brain regions 
involved in ketamine’s pharmacodynamic profile with respect to intended (anal-
gesia) and side effects (most importantly psychedelic effects) and areas involved 
in pain processing. Twelve healthy, male volunteers received a 2-hour intrave-
nous S(+)-ketamine infusion (first hour 20 mg/70 kg, second hour 40 mg/70 
kg). Before, during and after S(+)-ketamine administration resting-state brain 
connectivity was measured. Additionally, heat pain tests were performed in-be-
tween imaging sessions to determine ketamine-induced analgesia. Ketamine in-
creased the connectivity in the cerebellum and visual cortex in relation to the 
medial visual network. A decrease in connectivity was observed in the auditory 
and somatosensory network in relation to regions responsible for pain sensing 
and the affective processing of pain, which included the amygdala, insula, and 
anterior cingulate cortex. Connectivity variations related to fluctuations in pain 
scores were observed in the anterior cingulate cortex, insula, orbitofrontal cortex 
and the brain stem, which are all regions involved in descending inhibition of 
pain. This study demonstrated that RS-fMRI is a useful and efficient method to 
assess drug effects on the brain. Low-dose ketamine induced connectivity chang-
es in brain areas involved in motor function, psychedelic effects and pain pro-
cessing. With respect to pain processing, ketamine’s analgesic effect may arise 
from multiple pathways. We observed a decreased connectivity in regions of the 
pain matrix responsible for the perception of pain (pain sensing) and the affec-
tive processing of pain. Additionally, ketamine affected connectivity in brain ar-
eas involved in endogenous pain inhibition. 
Descending (efferent) pain pathways are important for the normal perception 
of pain. However, little is known on the effect of afferent pain pathways on pain 
modulation. In chapter 7, the effect of spinal deafferentation on pain sensitivity 
was studied and linked to whole-brain functional connectivity as assessed by 
RS-fMRI. Deafferentation was induced by spinal or sham anesthesia (spinal: 15 
mg bupivacaine injected at L3-4; sham: no puncture of the dura mater) in 12 
male volunteers. Resting-state brain connectivity was determined in relation to 
8 predefined and 7 thalamic resting-state networks and measured before, and 1 
and 2 hours after spinal or sham injection in a cross-over study design. To mea-
sure the effect of deafferentation on pain sensitivity, responses to heat pain were 
measured at 15-minute intervals on non-deafferented skin and correlated to the 
RS-fMRI connectivity data. Spinal anesthesia altered functional brain connectivi-
ty within brain regions of the sensorimotor system and pain matrix in relation to 
somatosensory and thalamic resting-state networks. A significant enhancement 
of pain sensitivity on non-deafferented skin was observed after spinal anesthesia 
compared to sham (area-under-the-curve (mean ± SEM)): 190.4 ± 33.8 versus 13.7 
± 7.2; p < 0.001), which significantly correlated to functional connectivity changes 
observed within the thalamus in relation to the thalamo-prefrontal network, and 
in the anterior cingulate cortex and insula in relation to the thalamo-parietal net-
work. This study demonstrated that deafferentation from spinal anesthesia was 




and subcortical areas. These changes are best described as reorganization of neu-
ronal interactions due to a rebalancing of excitatory and inhibitory factors that 
mediate adaptation and neuronal plasticity. Furthermore, spinal anesthesia en-
hanced pain sensitivity that was correlated to enhanced connectivity patterns of 
the thalamus, anterior cingulate cortex and insula, which are all areas associated 
with endogenous modulation of pain. 
Comparison with the literature
In order to compare the results of this thesis to published data, a PubMed search 
was performed to identify studies evaluating the effect of central-acting drugs on 
CPM in healthy volunteers and chronic pain patients. From all relevant studies, 
on the condition that adequate quantitative data were presented, standardized 
effect sizes were calculated using the statistical program Comprehensive Meta 
Figure 1. Comparison of the literature on the effect of central-acting drugs on conditioned pain 
modulation (CPM) responses in healthy volunteers. Values are the standardized differences in 
mean ± 95% confidence interval (CI) calculated from CPM values relative to either placebo treat-
ment or control (baseline or pretreatment) values. The orange symbols depict treatment that in-
creased CPM, the blue symbols treatment that decreased CPM. The grey symbols depict treatment 
that caused CPM responses not different from control or placebo. The data collected from studies 
outside this thesis are from Le Bars et al.1 (morphine); Suzan et al.2 (oxycodon); Arendt-Nielsen 
et al.3 (buprenorphine and fentanyl); Baba et al.4 (dexmedetomidine); Kunz et al.6 (lorazepam); 
Vuilleumier et al.7 (clonazepam and clobazam); Treister et al.8 (apomorphine) and Meeus et al.5 




Analysis v2.2.064 (Biostat, Englewood, NJ, USA). The results for the healthy vol-
unteers are given in figure 1. Apart from morphine, all studied drugs were tested 
only once. Intravenous morphine administration decreased CPM responses in 
both studies (this thesis and ref. 1). Single dose oxycodone and tapentadol, giv-
en orally on a single occasion, had no effect on CPM (this thesis and ref. 2). In 
contrast, buprenorphine and fentanyl, both administered by a continuous drug 
delivery transdermal patch formulation, did produce a significant increase in 
CPM.3 CPM responses following treatment with non-opioid analgesics (single 
administration) such as ketamine and dexmedetomidine, are predominantly 
reduced with the exception of acetominophen.4,5 With regard to non-analgesic 
central-acting drugs, no effect on CPM was observed for the single administra-
tion of GABA-ergic agonists.6,7 The dopamine-agonist apomorphine did increase 
CPM responses in healthy volunteers.8 These data indicate that drugs acting on 
the μ-, α2 - and NMDA-receptor influence CPM responses in healthy volunteers. 
However, large dissimilarities in the methods used to study CPM are present be-
tween these studies. Hence a significant part of the variability observed in study 
outcomes may be related to methodological issues.
The results for the chronic pain patients are given in figure 2. All studied drugs 
were tested only once. A significant decrease in CPM responses was observed in 
Figure 2. Comparison of the literature on the effect of central acting drugs on conditioned pain 
modulation (CPM) responses in chronic pain patients. Values are the standardized differences in 
mean ± 95% confidence interval (CI) calculated from CPM values relative to either placebo treat-
ment or control (baseline or pretreatment) values. The orange symbols depict treatment that in-
creased CPM, the blue symbols treatment that decreased CPM. The grey symbols depict treatment 
that caused CPM responses not different from control or placebo. The data collected from studies 
outside this thesis are from Ram et al.9 (opioids); Yarnitsky et al.10 (duloxetine); Bouwense et al.11 




a group of chronic pain patients (either cancer or non-cancer related) who were 
treated with opioids compared to patients who were not on opioid treatment.9 An 
increase in CPM response was observed in patients with chronic painful diabetic 
neuropathy after tapentadol treatment (this thesis) and in patients with rheuma-
toid arthritis after treatment with acetominophen (this effect was not observed 
in fibromyalgia patients).5 And although no significant effect on CPM responses 
was observed after treatment with morphine, ketamine (this thesis), duloxetine 
and pregabalin,10,11 a (linear) relationship was observed between the magnitude 
of increase in CPM and magnitude of pain relief induced by ketamine, morphine 
and tapentadol (this thesis). These data indicate that also in patients opioidergic 
and noradrenergic pathways influence CPM. The different responses between 
healthy volunteers and pain patients observed after treatment with morphine, 
tapentadol and ketamine may be related to central pathological alterations ob-
served in pain patients (i.e. central sensitization and inflammation), and hence 
comparison of treatment effects between patients and volunteers should be done 
with caution. Again a large variability in study methods was present, which may 
have influenced the outcome of the meta-analysis.
Conclusions
From the data presented in this thesis several conclusions may be drawn:
1. In healthy volunteers, short-term ketamine treatment induces a shift in the 
balance between pain inhibition and pain facilitation towards pain facilita-
tion (as measured by CPM responses). In contrast, in chronic neuropathic 
pain patients, in whom descending control of pain is dysfunctional, ketamine 
restores pain inhibitory pathways.
2. Short-term morphine treatment significantly restores CPM responses in 
chronic neuropathic pain patients who display dysfunctional descending in-
hibitory pain control prior to treatment.
3. Long-term (4-week) tapentadol treatment significantly enhances CPM re-
sponses compared to placebo in patients with chronic painful diabetic neu-
ropathy.
4. Chronic neuropathic pain patients show an absent or diminished OA re-
sponse compared to healthy volunteers. None of the central-acting drugs de-
scribed in this thesis (ketamine, morphine and tapentadol) alters or restores 
OA responses in healthy volunteers or chronic pain patients. Whether this 
is because there is no central origin for OA or that other central receptors 
or neurotransmitter systems (which are not influenced by these drugs) are 




5. Resting-state fMRI is a valuable, reliable and efficient method to assess phar-
macological effects on the brain.
6. Ketamine treatment and deafferentation by spinal anesthesia induce alter-
ations in functional brain connectivity in cortical and subcortical areas. Fur-
thermore, they both alter pain sensitivity, where ketamine induces analgesia 
and deafferentation induces hyperalgesia, which is correlated to alterations 
in functional brain connectivity in brain areas involved in descending control 
of pain.
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Endogene pijnmodulatie is een complex fenomeen dat betrokken is bij de per-
ceptie van pijn. Efferente inhiberende en facilitatoire zenuwbanen die hun oor-
sprong vinden in het brein en afdalen naar de dorsale hoorn van het ruggen-
merg, moduleren afferente pijnprikkels en hiermee de pijnperceptie. Dysfunctie 
van deze inhiberende zenuwbanen of een verschuiving in de balans tussen pijn- 
inhibitie en pijn-facilitatie wordt geassocieerd met de ontwikkeling van chroni-
sche pijn. Dit proefschrift beschrijft het effect van een aantal centraal werkende 
geneesmiddelen op endogene pijnmodulatie in gezonde vrijwilligers en chroni-
sche pijnpatiënten om zo het onderliggende werkingsmechanisme van endoge-
ne pijnstilling beter te leren begrijpen.
In hoofdstuk 2 is het effect van de N-methyl-D-aspartaat (NMDA) receptor an-
tagonist ketamine op de endogene pijnmodulatie bestudeerd in gezonde vrijwil-
ligers. Tien gezonde personen (4 mannen/6 vrouwen) kregen een 1-uur durende 
infusie met placebo of S(+)-ketamine (40 mg/70 kg) op twee verschillende dagen 
in willekeurige volgorde. Na het beëindigen van de infusie werd de effectiviteit 
van het endogene pijnstillingssysteem onderzocht met behulp van twee expe-
rimentele testen: “conditioned pain modulation” (CPM) en “offset analgesia” 
(OA). Integenstelling tot placebo, kon na infusie met ketamine geen CPM res-
pons worden waargenomen, maar vond significante facilitatie van pijn plaats 
(p < 0.01); de OA respons was onveranderd. Deze bevindingen geven aan dat 
ketaminebehandeling de balans tussen pijn-inhibitie en pijn-facilitatie heeft ver-
schoven richting pijn-facilitatie en zijn suggestief voor een modulerende rol van 
NMDA en/of glutamaterge receptoren in de endogene pijnmodulatie. Het af-
wezig zijn van een effect van ketamine op OA impliceert dat er verschillen zijn 
tussen CPM en OA wat betreft het onderliggende mechanisme en de neurotrans-
mitters die hierbij betrokken zijn.  
In tegenstelling tot CPM was het relatieve nieuwe fenomeen OA alleen beschre-
ven in jonge, gezonde vrijwilligers. In hoofdstuk 3 hebben we de aanwezigheid 
van OA in een grote groep vrijwilligers van verschillende leeftijden onderzocht, 
alsmede in chronische pijnpatiënten. De OA respons werd in vrijwilligers (n = 
110) in de leeftijdscategorie 6-80 jaar onderzocht, evenals in tien neuropathische 
pijnpatiënten. OA werd gedefinieerd als een afname in pijnscore in reactie op 
een verlaging van een pijnlijke warmtestimulus met 1 ℃. OA was aanwezig 
in gezonde vrijwilligers onafhankelijk van leeftijd en geslacht met een afname 
in pijnscore van 97 ± 1% (gemiddelde ± standaard error), wat aangeeft dat OA 
volledig ontwikkeld is op de leeftijd van 6 jaar en geen verdere veranderingen 
doormaakt. Echter, in neuropathische pijnpatiënten werd een verminderde of 
afwezige OA waargenomen (afname in pijnscore = 56 ± 9% vs. 98 ± 1%, p < 0.001). 
Deze data duiden erop dat chronische neuropathische pijnpatiënten niet in staat 
zijn om hun pijnperceptie te moduleren tijdens veranderingen in pijnstimulatie 
op een moment waarop bij gezonde vrijwilligers sterke analgesie waarneem-




of een consequentie is van het chronische pijnproces is onduidelijk en vergt ver-
der onderzoek. Intraveneuze behandeling met ketamine, morfine en placebo had 
geen effect op de OA respons in patiënten ondanks sterke afname in spontane 
pijnscores, wat aangeeft dat de NMDA en μ-opioïd receptor waarschijnlijk niet 
betrokken zijn bij het mechanisme van OA. Mogelijk is niet het centraal zenuw-
stelsel maar een perifere lokatie betrokken bij de veranderde OA respons in pati-
enten. 
Hoofdstuk 4 beschrijft het effect van ketamine en morfine op de CPM respons 
in chronische pijnpatiënten. De CPM respons werd bepaald in 10 neuropathi-
sche pijnpatiënten (2 mannen/8 vrouwen) met perifere neuropathie. Patiënten 
werden behandeld met S(+)-ketamine (0.57 mg/kg per uur gedurende 1 uur) 
en morfine (0.065 mg/kg per uur gedurende 1 uur) in een gerandomiseerde, 
placebo-gecontroleerde dubbelblinde studie. CPM werd bepaald voor infusie en 
100 minuten na de start van de behandeling. Voor behandeling was geen CPM 
aantoonbaar, wat aangeeft dat de pijn-inhiberende mogelijkheden in deze groep 
patiënten sterk verminderd is. Na behandeling met ketamine, morfine en place-
bo werd een significante CPM respons waargenomen van respectievelijk 40.2 ± 
10.9%, 28.5 ± 7.0% en 22.1 ± 12.0%. De grootte van de CPM respons na behan-
deling was gecorreleerd aan de mate en duur van de afname van de spontane 
pijnscores. Dit suggereert dat endogene pijnmodulatie een rol speelt bij het anal-
getische effect van ketamine, morfine en placebo in de behandeling van chroni-
sche neuropathische pijn.
In hoofdstuk 5 wordt het effect van langdurige behandeling met de nieuwe 
pijnstiller tapentadol beschreven. Tapentadol is een pijnstiller geschikt voor de 
behandeling van acute en chronische pijn. Het werkingsmechanisme berust op 
activatie van de μ-opioïd receptor gecombineerd met inhibitie van neuronale no-
radrenaline heropname. Beide mechanismen zijn betrokken bij het activeren van 
efferente inhiberende pijnbanen. 24 patiënten met diabetische polyneuropathie 
werden gerandomiseerd voor behandeling met tapentadol (gemiddelde dage-
lijkse dosis 433 ± 31 mg) of placebo gedurende 4 weken. CPM en OA werden 
voor en aan het einde van de behandeling bepaald. Voor behandeling was geen 
significante CPM of OA aantoonbaar. Tapentadol behandeling activeerde de 
CPM respons significant en induceerde pijnstilling. CPM nam toe van 9.1 ± 5.4% 
(voor behandeling) naar 14.3 ± 7.2% na placebo behandeling en 24.2 ± 7.7% na 
tapentadol behandeling (p < 0.001 vs. placebo). Verlichting van spontane pijn was 
groter in patiënten behandeld met tapentadol dan met placebo (p = 0.028). Zowel 
behandeling met placebo als met tapentadol had geen invloed op de grootte van 
de OA respons (p = 0.78). Deze resultaten tonen aan dat patiënten met pijnlijke 
diabetische polyneuropathie en een afwezige CPM respons baat hebben bij be-
handeling met tapentadol. Tapentadol induceerde pijnstilling die gekoppeld was 
aan (re)-activatie van efferente inhiberende pijnbanen.
Een relatief nieuwe benadering van geneesmiddelenonderzoek in het centraal 




interacties in het brein in rust (niet taak-gerelateerd). In hoofdstuk 6 is het ef-
fect van een lage dosis S(+)-ketamine op de intrinsieke breinconnectiviteit on-
derzocht. Het doel was om breinregio’s te identificeren die betrokken zijn bij het 
farmacodynamische profiel van ketamine wat betreft analgesie en bijwerkingen 
(met name psychedelische effecten) en regio’s betrokken bij pijnperceptie. Twaalf 
gezonde, mannelijke vrijwilligers werden intraveneus behandeld met een 2 uur 
durende S(+)-ketamine infusie (1e uur 20 mg/70 kg, 2e uur 40 mg/70 kg). Voor, 
tijdens en na toediening van ketamine werd de resting-state breinconnectiviteit 
gemeten. Tussen de scansessies door werden hitte pijntesten uitgevoerd om het 
analgetische effect van ketamine te bepalen. Ketamine verhoogde de connecti-
viteit in het cerebellum en de visuele cortex in relatie tot het mediale visuele 
netwerk. Een verminderde connectiviteit werd waargenomen in het auditore en 
somatosensore netwerk in relatie tot regio’s betrokken bij pijnperceptie en de af-
fectieve component van pijn. Hiertoe behoren de amygdala, insula en de ante-
rieure cingulate cortex (ACC). Variaties in connectiviteit gerelateerd aan fluctu-
aties in pijnscores werden gezien in de ACC, insula, orbitofrontale cortex en de 
hersenstam, allen regio’s betrokken bij endogene modulatie van pijn. De resulta-
ten van deze studie geven weer dat RS-fMRI een bruikbare en efficiënte methode 
is om effecten van geneesmiddelen in het brein te onderzoeken. Een lage dosis 
ketamine induceerde connectiviteitsveranderingen in breinregio’s betrokken bij 
motorfunctie, psychedelische effecten en de verwerking van pijn. Wat betreft de 
pijnverwerking kan het analgetische effect van ketamine worden veroorzaakt 
door verschillende mechanismen. Enerzijds werd een verminderde connectivi-
teit waargenomen in regio’s van de pijnmatrix welke verantwoordelijk zijn voor 
de perceptie en de affectieve component van pijn. Anderzijds veranderde keta-
mine de connectiviteit in regio’s betrokken bij endogene pijn-inhibitie. 
Efferente zenuwbanen zijn belangrijk voor de normale perceptie van pijn. Er is 
echter weinig bekend over de rol van afferente zenuwbanen in de modulatie van 
pijn. In hoofdstuk 7 werd het effect van spinale deafferentiatie op pijnsensitivi-
teit onderzocht en gecorreleerd aan functionele breinconnectiviteit gemeten met 
RS-fMRI. Deafferentiatie werd geïnduceerd door spinale of sham anesthesie (spi-
naal: 15 mg bupivacaïne geïnjecteerd op niveau L3-4; sham: geen punctie van 
de dura mater) in 12 mannelijke vrijwilligers. Resting-state breinconnectiviteit 
werd bepaald in relatie tot 8 algemene netwerken en 7 thalamus netwerken en 
gemeten voor, 1 en 2 uur na de spinale- of sham-injectie in een cross-over stu-
diedesign. Om het effect van deafferentiatie op pijnsensitiviteit te beoordelen 
werd iedere 15 minuten de respons op een hitte pijnstimulus gemeten op niet-ge-
deafferentieerde huid en gecorreleerd aan de RS-fMRI connectiviteitswaarden. 
Spinale anesthesie veranderde de functionele breinconnectiviteit in regio’s van 
het sensorimotor systeem en de pijnmatrix in relatie tot de somatosensore- en 
thalamusnetwerken. Na spinale anesthesie werd een significante toename in 
pijnsensitiviteit gezien vergeleken met de shamprocedure (area-under-the-curve: 
190.4 ± 33.8 versus 13.7 ± 7.2; p < 0.001). Deze toename in pijnsensitiviteit was 
gecorreleerd aan de functionele connectiviteitsveranderingen in the thalamus 




tot het thalamo-parietale netwerk. Deze studie laat zien dat deafferentiatie door 
spinale anesthesie geassocieerd is met snelle connectiviteitsveranderingen in het 
brein van zowel corticale als subcorticale regio’s. Deze veranderingen zijn mo-
gelijk een gevolg van reorganisatie van neuronale interacties tussen excitatoire 
en inhiberende factoren betrokken bij adaptatie en neuronale plasticiteit. Verder 
verhoogde spinale anesthesie de pijnsensitiviteit welke kon worden gecorreleerd 
aan versterkte connectiviteitspatronen in de thalamus, ACC en insula, allen re-
gio’s betrokken bij endogene pijnmodulatie.
Vergelijking met de literatuur
Om de resultaten van dit proefschrift te kunnen vergelijken met eerder gepu-
bliceerde literatuur werd een zoekopdracht in PubMed uitgevoerd met als doel 
studies te identificeren die het effect van centraal werkende geneesmiddelen op 
Figuur 1. Vergelijking van de literatuur naar het effect van centraal werkende geneesmiddelen op 
CPM in gezonde vrijwilligers. De waarden zijn gestandaardiseerde verschillen van het gemiddelde 
± het 95% betrouwbaarheidsinterval (BI) berekend met relatieve CPM waarden ten opzichte van 
placebo behandeling of uitgangswaarden voorafgaand aan behandeling. De oranje symbolen geven 
behandelingen aan die CPM vergrootten, de blauwe symbolen behandelingen die CPM verklein-
den. De grijze symbolen geven behandelingen aan die geen verandering in CPM induceerden. De 
gepresenteerde data die niet afkomstig zijn uit dit proefschrift komen van: Le Bars et al.1 (morfine); 
Suzan et al.2 (oxycodon); Arendt-Nielsen et al.3 (buprenorfine and fentanyl); Baba et al.4 (dexme-
detomidine); Kunz et al.6 (lorazepam); Vuilleumier et al.7 (clonazepam and clobazam); Treister et 





CPM hebben onderzocht in gezonde vrijwilligers en chronische pijnpatiënten. 
Van alle relevante studies werden gestandaardiseerde effect groottes berekend 
met het statistische programma “Comprehensive Meta Analysis" v2.2.064 (Bio-
stat, Englewood, VS). De resultaten van deze vergelijking voor de gezonde vrij-
willigers staan in figuur 1. Voor alle geneesmiddelen geldt dat het effect op CPM 
in slechts één studie was onderzocht, met uitzondering van morfine waarvoor 
twee studies beschikbaar waren. In beide studies was een afname van CPM aan-
toonbaar na intraveneuze toediening van morfine (dit proefschrift en ref. 1). Een 
eenmalige toediening van oxycodon en tapentadol had geen effect op CPM (dit 
proefschrift en ref. 2). Echter, na een continue toediening van buprenorfine en 
fentanyl via een transdermale pleister werd een significante toename in CPM 
waargenomen.3 Niet-opioïd gerelateerde analgetica zoals ketamine en dexme-
detomidine verkleinde CPM, met uitzondering van paracetamol (allen na een-
malige toediening).4,5 Centraal werkende geneesmiddelen zonder analgetische 
werking, zoals de GABA-erge stoffen, lieten geen effect op CPM zien.6,7 De do-
pamine agonist apomorfine, daarentegen, gaf wel een toename van CPM.8 Deze 
data geven aan dat geneesmiddelen met werking op de μ-, α2 - en NMDA-re-
ceptor een invloed hebben op CPM in gezonde vrijwilligers. Echter, de studies 
Figuur 2. Vergelijking van de literatuur naar het effect van centraal werkende geneesmiddelen 
op CPM in chronische pijnpatiënten. De waarden zijn gestandaardiseerde verschillen van het 
gemiddelde ± het 95% betrouwbaarheidsinterval (BI) berekend met relatieve CPM waarden ten 
opzichte van placebo behandeling of uitgangswaarden voorafgaand aan behandeling. De oranje 
symbolen geven behandeling aan die de CPM vergrootten, de blauwe symbolen behandeling die 
CPM verkleinden. De grijze symbolen geven behandelingen aan die geen verandering in CPM 
induceerden. De gepresenteerde data die niet afkomstig zijn uit dit proefschrift komen van: Ram 
et al.9 (opioïden); Yarnitsky et al.10 (duloxetine); Bouwense et al.11 (pregabaline) en Meeus et al.5 




vertoonden grote verschillen in de gebruikte methode om CPM te onderzoeken. 
Dit bemoeilijkt de interpretatie van de resultaten en verklaart mogelijk voor een 
groot deel de variabiliteit tussen de verschillende studies.
De resultaten voor de chronische pijnpatiënten zijn weergegeven in figuur 2. Alle 
geneesmiddelen werden voor een langere periode toegediend en zijn onderzocht 
in één studie. Terwijl in kankerpatienten een afname van CPM werd gezien tij-
dens behandeling met morfine, werd in neuropathische pijnpatiënten en patiën-
ten met reumatoïde artritis een toename gezien na behandeling met respectieve-
lijk tapentadol en paracetamol (dit proefschrift en refs. 5 en 9). Ondanks dat er 
geen significant effect op CPM werd waargenomen na behandeling met morfine, 
ketamine (dit proefschrift), duloxetine en pregabaline,10,11 kon een (lineaire) re-
latie worden aangetoond tussen de grootte van CPM toename en de mate van 
pijnstilling geïnduceerd door ketamine, morfine en tapentadol (dit proefschrift). 
Deze data geven aan dat ook in patiënten opioïderge en noradrenerge effecten 
CPM beïnvloeden. Het verschil in farmacologisch effect op CPM tussen gezonde 
vrijwilligers en patiënten wordt mogelijk verklaard door plastische veranderin-
gen in het centraal zenuwstelsel die ontstaan in chronische pijnpatiënten (zoals 
centrale sensitisatie en inflammatie). Hierdoor is terughoudendheid geboden 
bij het vergelijken van behandelingseffecten tussen patiënten en vrijwilligers. 
Wederom was er een grote variabiliteit aanwezig in de studiemethoden tussen 
de verschillende onderzoeken wat mogelijk de uitkomst van deze meta-analyse 
heeft beïnvloed.
Conclusies
Uit de data gepresenteerd in dit proefschrift kunnen de volgende conclusies 
worden getrokken:
1. In gezonde vrijwilligers leidt een kortdurende behandeling met ketamine 
tot een verschuiving in de balans tussen pijn-inhibitie en pijn-facilitatie met 
als netto effect een toename van pijn-facilitatie (gemeten met CPM). Daaren-
tegen wordt in chronische neuropathische pijnpatiënten, waarbij endogene 
pijnstilling aanvankelijk afwezig of gereduceerd is, een herstel of toename 
van pijn-inhibitie waargenomen na behandeling met ketamine.
2. Kortdurende behandeling met morfine herstelt de CPM respons in chroni-
sche neuropathische pijnpatiënten die voor behandeling een afwijkende en-
dogene inhibitie van pijn lieten zien.
3. Langdurige (4-weken) behandeling met tapentadol vergroot de CPM res-
pons in patiënten met chronische diabetische neuropathie.
4. Chronische neuropathische pijnpatiënten vertonen een afwezige of vermin-




ven in dit proefschrift (ketamine, morfine of tapentadol) zijn in staat om de 
OA respons te herstellen. Het is onbekend of dit wordt veroorzaakt door het 
afwezig zijn van een centraal substraat voor OA of dat andere receptoren of 
neurotransmitters (die niet worden beïnvloed door deze geneesmiddelen) in 
het centraal zenuwstelsel hierbij betrokken zijn.
5. Resting-state fMRI is een betrouwbare en efficiënte methode om farmacologi-
sche effecten in het brein te onderzoeken.
6. Ketamine behandeling en deafferentiatie door spinale anesthesie veroorza-
ken beide veranderingen in functionele connectiviteit in corticale en subcor-
ticale breinregio’s. Beide beïnvloeden de pijnsensitiviteit, waarbij ketamine 
analgesie induceert en deafferentiatie hyperalgesie. Beide effecten zijn ge-
correleerd aan de veranderingen in functionele connectiviteit in breinregio’s 
betrokken bij endogene pijnmodulatie.
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